Drug, bio-affecting and body treating compositions inventions 07/06

20060165591 - Metal complex-containing pharmaceutical agents: Improved metal complex-containing pharmaceutical agents are described which, as an additive, contain one or more complexing agents and/or one or more weak metal complex(es) or mixtures thereof....

20060165590 - Method for the use of [11c] carbon monoxide in labeling synthesis of 11c-labelled esters by photo-induced free radical carbonylation: Methods and reagents for photo-initiated carbonylation with carbon-isotope labeled carbon monoxide using alkyl/aryl iodides with alcohols pretreated by a base are provided. The resultant carbon-isotope labeled esters are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits for PET studies are also provided....

20060165592 - Nk cell receptor conjugates for treating malignancies: The present invention relates generally to compositions useful in therapies involving the selective destruction of tumor cells in vivo. In particular, this invention relates to a conjugate which comprises a target recognition segment and an active cytotoxic segment. The target recognition segment comprises a receptor specific to NK cells, wherein...

20060165593 - Tc and re labeler radioactive glycosylated octreotide derivatives: Improved sst-receptor binding peptidic ligands for diagnostic and therapeutic applications in nuclear medicine are provided. The improved ligands contain either natural or unnatural amino acids or peptidomimetic structures that are modified at either the N-terminal or the C-terminal end or at both termini, a carbohydrate unit and a chelator or...

20060165594 - Preparation of m(co)3-complexes by solid phase techniques via metal assisted cleavage from the solid support: The present invention relates to a process for generating a water soluble metal complexed agent, comprising contacting a solid phase bound organic conjugate represented by the formula I with [M(H2O)3(CO)3]n+, under suitable conditions to cause the formation of a coordinate bond between [M(H2O)3(CO)3]n+ and the tertiary amine nitrogen atom of...

20060165595 - In vivo angiogenesis assay: A method for evaluating in vivo a test substance for angiogenesis modulation activity, including the steps of providing a rodent pup having a pupillary membrane system in a first eye, injecting transcorneally proximate to the pupillary membrane a test substance; and examining the pupillary membrane to determine whether new vascular...

20060165596 - Method and apparatus for noninvasively evaluating endothelial function: The present invention relates to assessing and measuring endothelial functions. A vasodilating stimulant is provided to a patient to stimulate hemodynamic activity in a selected region of the patient's body. In an embodiment, endothelial function may then be assessed by monitoring a change in a hemodynamic parameter at the selected...

20060165600 - Backbone-substituted bifunctional dota ligands, complexes and compositions thereof, and methods of using same: Backbone-substituted 1,4,7,10-tetraaza cyclododecane-N,N′,N″,N′″-tetraacetic acid compounds, metal complexes thereof, compositions thereof, conjugates thereof, and methods of use in diagnostic imaging and treatment of a cellular disorder....

20060165601 - Dendritic compound and use thereof: A dendritic compound of the following structure: PDn-Z-L is disclosed. In the structure above, P is X—(CH2CH2—O)r—, r is an integer ranging from 1000 to 4000, X is OH, NH2, or OR, R is C1 to C10alkyl, Dn is a residue of branched C3 to C30 polyol compounds, n is...

20060165598 - In-vivo diagnostic method by near infrared radiation: This invention relates to an in-vivo diagnostic method based on near infrared radiation (NIR radiation) that uses water-soluble dyes and their biomolecule adducts, each having specific photophysical and pharmaco-chemical properties, as a contrast medium for fluorescence and transillumination diagnostics in the NIR range, to new dyes and pharmaceuticals containing such...

20060165597 - Methods for cancer imaging: Methods are provided for cancer and pre-cancer detection by increased uptake of fluorophore glucose or deoxyglucose conjugates in cancerous and pre-cancerous cells relative to normal cells....

20060165599 - Near infrared imaging agent: This invention relates to an in-vivo diagnostic method based on near infrared radiation (NIR radiation) that uses water-soluble dyes and their biomolecule adducts, each having specific photophysical and pharmaco-chemical properties, as a contrast medium for fluorescence and transillumination diagnostics in the NIR range, to new dyes and pharmaceuticals containing such...

20060165602 - Method for deterring abuse of opioids by combination with non-release formulation of emetic: The present invention pertains to a pharmaceutical dosage form comprising an opioid and a sequestered emetic. When abuse is attempted by crushing, chewing, or otherwise compromising the sequestration, sufficient emetic is released to cause emesis....

20060165604 - Buccal, polar and non-polar spray containing sumatriptan: Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide sumatriptan for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, sumatriptan, and optional flavoring agent; formulation II:...

20060165603 - Solubilisation of drugs in hfa propellant by means of emulsions: Emulsion and microemulsion aerosol formulations in a HFA propellant system include a medicament, one or more surfactant, optionally a cosolvent and water. Emulsion formulations are based on 0.1-% w/w surfactant and 1-10% w/w water. Microemulsion formulations are based on 1-20% w/w surfactant, 1-30% w/w cosolvent and 1-10% w/w water. Preferred...

20060165605 - Process to regenerate fcc spent catalyst: A process to supply solid particles to a fluidized bed via a riser which has a substantially vertical upper part terminating at an outlet opening in the fluidized bed and wherein the solid particles are transported towards the fluidized bed in the riser with a lift gas, which lift gas...

20060165606 - Pulmonary delivery particles comprising water insoluble or crystalline active agents: A pulmonary delivery medicament comprises a plurality of particulates, the particulates comprising a structural matrix and a water insoluble and/or crystalline active agent. The particulates have a geometric diameter of 0.5 to 50 μm. The water insoluble active agent can be a fungicide, antibiotic, budesonide. A method of making the...

20060165607 - Carbon dioxide external preparation and material for formation of carbon dioxide external preparation: A material for formation of carbon dioxide external preparation of the present invention comprises a base agent and a reactant. The base agent comprises a polymeric three-dimensional network structure impregnated with a viscous material containing at least an acid and water, and is made to contact with the skin in...

20060165608 - Ethyl 3-mercaptobutyrate as a flavoring or fragrance agent and methods for preparing and using same: This invention pertains to a method for flavoring an ingestible composition with a flavoring agent in organoleptically purified form, unaccompanied by substances of natural origin present in mango. The flavoring agent may be used in a wide variety of ingestible vehicles such as chewing gum compositions, hard and soft confections,...

20060165610 - Composition for treating and preventing periodontal disease and method of use: The present invention is a mixture for treating and preventing periodontal disease comprising tea tree oil and a hydrated dialkali monometal polycarboxylate 1:1 molar ratio of metal-to-complexing agent, such that the antibacterial activity is synergistically increased....

20060165611 - Composition for treating and preventing periodontal disease and method of use: The present invention is a mixture for treating and preventing periodontal disease comprising acemannan, an immuno-stimulant with tissue repair activity and a hydrated dialkali monometal polycarboxylate 1:1 molar ratio of metal-to-complexing agent, such that lysyl oxidase for collagen formation and subsequent tissue repair is activated....

20060165612 - Compositions for hygienic hand disinfection and disinfectant handwashing: The invention relates to disinfectant compositions which include one or more 1- or 2-(C1- to C24-alkyl)glycerol ethers (glycerol monoalkyl ethers), one or more bispyridiniumalkanes and where appropriate one or more polyols and/or one or more surfactants selected from the group of c1) nonionic surfactant and c2) quaternary ammonium compound, and...

20060165609 - Periodontal ligament-protecting agent: e

20060165613 - Detergent compositions comprising bacillus subtilis pectate lyases: Detergent composition comprising a surfactant and a pectate lyase (EC 4.2.2.2) enzyme en-coded by a DNA sequence endogeneous to a strain of Bacillus subtilis or a stabilized variant thereof provides superior cleaning and stain removal....

20060165615 - Non-oxidative tooth whiteners for dentifrice application: The present invention relates to a non-oxidative approach for removing or reducing stains, which is based on reactive modification and complexation of porphyrins. This approach was found to be suitable for removing stains from hydroxyapatite, and the whiteness that was achieved using this formulation was found to be superior as...

20060165614 - Palatable micro-capsules: A formulation comprising at least one active or at least one ingredient, and a plurality of micro-capsules formed from a plurality of micro-organisms and having at least one flavouring encapsulated and passively retained within said micro-capsules, said flavouring not being a natural constituent of said micro-organisms, said micro-capsules having: (a)...

20060165617 - Cosmetic composition and method: A cosmetic topical formulation and method are directed toward diminishing skin wrinkling and fine lines and improving skin tone. It contains a matrix metalloproteinase inhibitor, MMPI, e.g. batimastat or marimastat, and a natural estrogen, e.g., a true estrogen compound, such as 17-beta estradiol, or an estrogen-like steroid (such as various...

20060165616 - Microemulsion containing anti-uv filters and/or anti-dandruff agents: This invention relates to microemulsions containing alkanolammonium salts of alkylsulfates and/or alkylpolyalkyleneglycolethersulfates, UV filters and/or antidandruff substances. The invention also relates to the use of said emulsions for cosmetic and/or medicinal-dermatologic applications....

20060165618 - Photoactivatable composition and uses thereof: The invention relates to a cosmetic composition including a photoactivatable compound having a support molecule chosen from carbon-containing and/or sulfur-containing and/or nitrogen-containing and/or phosphorus-containing nonpolymer compounds, polymers and oligomers and to which are covalently bonded at least two species containing chemical groups which, after irradiation between 200 et 450 nm,...

20060165619 - Cosmetic composition for skin whitening comprising senkyunolide a as active ingredient: The present invention relates to cosmetic compositions and more particularly to skin-whitening cosmetic compositions comprising senkyunolide A as an active ingredient. The present invention discloses the novel inhibitory function of senkyunolide A isolated from Cnidium officinale and Ligusticum chuanxiong on the melanocyte-stimulating hormone (MSH), and provides MSH-inhibitory compositions and skin-whitening...

20060165620 - Coloured gloss pigments having at least one coating of siox, with x=0.03 to 0.95 for use in cosmetic and personal care formulations: The present invention relates to a cosmetic and personal care preparation or formulation comprising (a) from 0.0001 to 90% by weight of a gloss pigment comprising (a1) a core consisting of a substantially transparent or metallically reflecting material, and (a2) at least one coating substantially consisting of one or more...

20060165621 - Cosmetic composition comprising fluorescent nanoparticles as pigments: The invention concerns a make-up composition comprising as pigment cosmetically acceptable fluorescent semi-conductive nanoparticles in a cosmetic support....

20060165622 - Deodorant composition: It is intended to provide a novel deodorant composition which is excellent in the deodorizing effect, is capable of affording a deodorant composition by a convenient method, and shows no decrease in the deodorizing performance even after a long period of time, once the deodorant being prepared. Specifically, there is...

20060165623 - Natural deodorant composition: The present invention relates to a natural deodorant system and a natural system for topical and systemic delivery of active ingredients, both systems being primarily free of, preferably substantially free of, more preferably essentially free of, and most preferably completely free of ethoxylates or other petrochemical derivatives, and comprising: (a)...

20060165626 - Cosmetic composition comprising at least one ester of alkoxylated alcohol and at least one film-forming polymer: Disclosed herein is a composition comprising at least one ester of an alkoxylated alcohol and of a carboxylic acid and at least one solid noncrystalline film-forming polymer. The ester of an alkoxylated alcohol may, for example, be Octyidodecyl PPG-3 Myristyl Ether Dimer Dilinoleate. In one embodiment, this composition may be...

20060165624 - Cosmetic hair preparation: A leave-on hair cosmetic composition contains (a) malic acid or its salt, (b) lactic acid or its, and (c) an organic solvent selected from the group consisting of aromatic alcohols, N-alkylpyrrolidones, alkylene carbonates, polypropylene glycol, lactones and cyclic ketones. This hair cosmetic composition is excellent in the effect of substantially...

20060165627 - Polyglycerol partial esters of polyricinoleic acid and polyfunctional carboxylic acids and the use thereof for producing emulsions and dispersions: The invention relates to polyglycerol partial esters of polyricinoleic acid and polyfunctional carboxylic acids, obtainable by esterification of a a) polyglycerol mixture with b) at least one polyricinoleic acid and c) at least one di- and/or tricarboxylic acid and optionally d) at least one fatty acid having 6 to 22...

20060165625 - Water-soluble film article having salt layer, and method of making the same: Water-soluble articles such as films, which can be made resistant to contact with small amounts of water, and methods of making the same are disclosed. The water-soluble article is formed from a water-soluble film-forming composition, such as polyvinyl alcohol, and includes a salt that is distributed more closely to at...

20060165628 - Hair care product: c: number-average polymerization degree of from 3 to 7 The hair cosmetic composition of the invention is excellent in spreadability, has a slick and smooth feel, and a soft touch upon application of it to the wet hair, can impart the hair with a sleek touch without harsh friction upon...

20060165629 - Powder composition, a dispersion of powder in oil, and a cosmetic comprising the same: wherein R1 may be same with or different from each other and is an organic group selected from the group consisting of C1-30 alkyl groups, aryl groups, aralkyl groups, fluorinated alkyl groups, amino-substituted alkyl groups, carboxyl substituted alkyl groups, or polyoxyalkylene groups, R2 is a group derived from polyglycerin, and...

20060165633 - Process for the parmanent reshaping of keratin substances without intermediate rinsing: The invention concerns a method for the permanent setting of keratin fibres and in particular hair, characterised in that it consists in: applying on the keratin fibres a composition reducing keratin, with adhesive capacity less than 15 g and a viscosity ranging between 0 and 2500 mpa's at a laminar...

20060165630 - Use of amide or ester of sugar and of fatty acid, for treating and/or preventing dry skin: The present invention relates to the use of at least one amide, a mono- or polyester of suger and of fatty acid, especially linoleic acid, for the preparation of a cosmetic of pharmaceutical composition intented for treating and/or preventing dry skin. It also relates to the use of at least...

20060165632 - Use of carbohydrates to improve skin barrier function: The present invention concerns compositions containing carbohydrate derivatives for enhancing the skin barrier function. The invention further concerns a cosmetic treatment method for enhancing the skin barrier function by applying on the skin compositions comprising carbohydrate derivatives....

20060165631 - Use of oligoglucosamines in cosmetic or dermatological preparations: Disclosed is the use of low molecular weight oligoglucosamines or chitosans in cosmetic or dermatological preparations for stimulating the metabolism of the human skin....

20060165634 - Advanced cell-transducing transport domain-target protein-transport domain fusion protein and uses thereof: The present invention provides a fusion protein which delivers a functional protein or peptide into a cell at enhanced efficiency. The fusion protein of the present invention is a transduction domain-target protein-transduction domain fusion protein, wherein the transduction domain, which comprises 6-12 amino acid residues whose more than ¾ consist...

20060165636 - Hair treatment composition and hair cosmetic for damaged hair: The present invention intends to provide a composition for hair treatment containing γ-polyglutamic acid or a salt thereof, a hair cosmetic for damaged hair containing such a composition, and their uses. The composition for hair treatment containing γ-polyglutamic acid or a salt thereof and the hair cosmetic for damaged hair...

20060165635 - Personal care formulations containing keratin: A range of personal care products that include a keratin protein fraction. The fraction may be intact or hydrolysed. It is preferably S-sulfonated. The content of the fraction may range from 0.001% to 50%. In most formulations its content will be less than 1% although in certain products such as...

20060165637 - Topical agent containing phytanic acid or a derivative thereof: The invention relates to agents for topical administration of a compound of formula (I): (CH3)2CH—(CH2)3—CH(CH3)—(CH2)3—CH(CH3)—(CH2)3—C(A)(CH3)—C(B)2—C(O)—R, wherein R represents hydrogen, OR1, N(OH)R1 or NR2R3; R1, R2 and R3 independently represent hydrogen C1-C22-alkyl, C1-C22-alkenyl, C7-C12-arylalkyl (particularly benzyl, phenethyl and phenylpropyl), retinyl, tocopheryl, ascorbyl or a radical stemming from an amino acid or...

20060165638 - Compositions comprising at least one copolymer (a) and at least one copolymer (b) and use thereof in cosmetic preparations: Disclosed is a composition comprising (A) copolymer made up of (A-1) at least one ethylenically unsaturated, radically copolymerizable monomer of general formula Y—NR1—C(V)—NHR2, wherein the substituents have the following meaning: Y represents a radically polymerizable ethylenically unsaturated radical; V represents O, S, or NH; R1, R2 independently represent H or...

20060165639 - Use of cross-linked cationic polymers in cosmetics: The invention relates to the use of a cationic crosslinked polymer which is preparable by free-radical polymerization in the presence of salts and of protective colloids in cosmetics....

20060165640 - Cosmetic composition comprising at least one alkoxylated alcohol ester and at least one apolar oil: The present disclosure relates to a composition comprising at least one ester derived from at least one alkoxylated alcohol and at least one carboxylic acid; and at least one apolar oil, wherein when the composition forms a deposit, the deposit has a mean gloss measured at 600 of greater than...

20060165641 - Cosmetic compositions containing combinations of hydroxamate derivatives and antioxidants in a liposomal delivery system: A cosmetic skin care composition includes salicylhydroxamate or one or more other hydroxamate derivatives in an amount of about 0.001% to about 10.0% by weight, and nordihydroguaiaretic acid or one or more other antioxidants in an amount of about 0.00001% to about 10% by weight. The composition can be optionally...

20060165642 - Hair treatment compositions: The invention provides a hair treatment composition such as a shampoo or conditioner suitable for topical application to hair for the repair and prevention of damage, comprising a molecule having the following formula (I) in which R1, R2 and R3 are independently selected from a methyl, ethyl, propyl group or...

20060165643 - Cosmetic or dermopharmaceutical compositions containing kombucha: Cosmetic or dermopharmaceutical compositions which contain kombucha are disclosed. The present invention further relates to the use of kombucha and cosmetic or dermopharmaceutical compositions containing the same, alone or in combination, for the care of the skin, mucosae and skin appendages, and in particular for preventing the signs of endogenous...

20060165644 - Cosmetics: Cosmetics containing humectants, cell activators, antiinflammatory agents, antioxidants and an Epilobium argustifolium extract, optionally together with jojova leaf, rosemary, extracts thereof and so on. These cosmetics contain C4-7 diols. Antibacterial compositions containing orchid, Eriobotrya japonica, hop, rosemary, Filipendula multijuga, hawthorn, Persicae semen, Althaea officinalis, jojoba leaf, Epilobium argustifolium, extracts thereof...

20060165645 - Lipid preparation, particularly cosmetic preparation: A lipid-bearing preparation and method for preparing same in particular in the form of a stick or a workable paste, which is suitable for cosmetic uses, in particular in the field of decorative cosmetics for coloring and improving the appearance of the skin, the lips and the eyelids. The lipid-bearing...

20060165646 - Method for the treatment of nucleic acid damage: The present invention features a composition for regulating the firmness, tone, or texture of skin, or for regulating wrinkles, or for the treatment of external aggression in skin containing a safe and effective amount of a Feverfew extract and a cosmetically-acceptable topical carrier, and the use thereof....

20060165648 - Compounds, compositions, and methods for controlling biofilms: The present invention provides nitrogen heterocyclic compounds, compositions, and methods for controlling biofilms, i.e., disrupting biofilms, preventing biofilm formation, enhancing biofilms, or modifying biofilms. Methods for screening test compounds for control of biofilms and devices for use therein are also provided....

20060165647 - Immunosuppressive substance adsorbent, extracorporeal cicrulation column and method of treating cancer: An object of this invention is to provide an adsorbent for immunosuppressive substance, which adsorbent can highly efficiently and selectively adsorb an excessive immunosuppressive substance directly from the body fluid, can carry out extracorporeal perfusion safely and can be utilized in treatment of cancer. Such an excessive immunosuppressive substance may...

20060165651 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention....

20060165649 - Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases: Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells....

20060165650 - Rantes-derived peptides with anti-hiv activity: RANTES-derived peptides and the use thereof in the treatment of diseases in which RANTES receptor is involved, such as viral infections, particularly HIV infections, and inflammatory, allergic, degenerative, neoplastic or metastatic diseases....

20060165652 - Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy: A method of promoting the regression of a cancer in a mammal comprising: (i) administering to the mammal nonmyeloablative lymphodepleting chemotherapy, and (ii) subsequently administering: (a) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to...

20060165653 - Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders: Methods for the use of Fc gamma receptor (FcγR) polymorphisms as a diagnostic for intervention with interleukin-2 (IL-2) immunotherapy are provided. The methods comprise detecting the allelic pattern of an FcγRIIIA gene or FcγRIIA gene of an individual, and determining whether the allelic pattern is predictive of a positive therapeutic...

20060165654 - Peptides and recombinant proteins mimicking interferons: The present invention provides peptide and recombinant protein mimetics specifically representing the antiviral and antiproliferative activities of interferons with avoiding interferons' undesirable side effects during treatment of a variety of diseases. The basic embodiment of the present invention was to link together, through a short artificial spacer, two primary protein...

20060165655 - Therapeutic furopyrimidines and thienopyrimidines: The invention provides compounds of formula I, II, and III as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of formula I, II, and III are useful as anti-viral agents and/or as anti-cancer agents....

20060165658 - Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof: Adenovirus vectors replication specific for cells expressing α-fetoprotein (AFP) and their methods of use are provided. By providing for a transcriptional initiating regulation dependent upon AFP expression, virus replication is restricted to target cells expressing AFP, particularly hepatocellular carcinoma cells. The adenovirus vectors can be used to detect and monitor...

20060165659 - Compositions and methods for cancer diagnosis and therapy: The miR15 and miR16 micro RNA genes are located at 13q14 within a 30 kb region of loss characteristic of cells from certain cancers, such as cells from chronic lymphocytic leukemia or prostate cancer. Chronic lymphocytic leukemia or prostate cancer can be diagnosed by detecting a reduction in miR15 or...

20060165656 - Medicinal preparation having chemotherapeutic encapsulated therein: An apparatus and a method of remote control which can enable real time operation of a device in home from a terminal device at remote location through a network are provided. A first server communicates with a terminal device through the Internet and generates device control data for controlling the...

20060165657 - Method for delivery of cosmetic by topical application: The present invention relates to compositions comprising a baculovirus vector and a pharmaceutically acceptable carrier to deliver the baculovirus vector onto or into the skin of a mammal to achieve a cosmetic effect. The present invention also provides methods of producing various cosmetic effects by administering the compositions of this...

20060165660 - Process for preparing purified nucleic acid and the use thereof: The invention relates to a nucleic acid preparation with a content of below 1% protein, preferably below 0.1% protein, free of ethidium bromide, phenol, cesium chloride and detergents based on octyl phenol poly(ethylene glycol ether)n and with a content of below 1 EU/mg DNA of endotoxins. Said preparation is suitable...

20060165668 - Genetically modified tumor cells as cancer vaccines: The present invention provides methods and compositions for electroporation-mediated gene transfer to cancer cells. The transfected cancer cells are genetically modified to express one or more therapeutic proteins. In certain embodiments, the cancer cells are modified to express one or more cytokines capable of enhancing the immunogenicity of the transfected...

20060165666 - Hemangioblast progenitor cells: The invention relates to isolated hemangioblast cells. Hematopoietic and endothelial cells are postulated to be derived from a common progenitor, hemangioblast. While hemangioblast has been isolated retrospectively during embryonic stem cell differentiation, it has not been isolated from embryos or from bone marrow. Prospectively stable clonal cell lines have been...

20060165665 - Immunomodulation using altered dendritic cells: The invention relates to altered immune cells and their use in methods and compositions to alter the immune system in a mammal. More specifically, the invention is directed to the alteration of gene expression in antigen presenting cells such as dendritic cells (DC) and their use in various methods and...

20060165664 - Method of inducing an enhanced immune response against hiv: An efficient means of inducing an immune response against human immunodeficiency virus (HIV) utilizing specific prime-boost regimes is disclosed. The specific prime-boost regimes employ a heterologous prime-boost protocol employing recombinant adenoviral vectors of alternative and distinct serotypes comprising exogenous genetic material encoding a common HIV antigen. Vaccines administered into living...

20060165667 - Novel methods, compositions and devices for inducing neovascularization: The invention provides methods of inducing neovascularization in a subject in need thereof. The invention further provides compositions, devices and implantable products generated from conditioned media, and in particular, from conditioned media from cultured umbilical cord populations. These compositions are useful for inducing neovascularization. The invention also provides methods of...

20060165661 - Pediocin-producing pediococci: There are provided pediocin-producing pediococci that have an enhanced survival property in the small intestine. The pediococci comprise in particular Pediococcus acidilactici isolated from human faeces. The pediococci are suitable for use in the gastrointestinal tract of humans to provide a health-promoting action, in particular against infection by multi-resistant pathogens....

20060165669 - Lactobacillus iners for the enhancement of urogenital health: The present invention provides methods and compositions for administration of Lactobacillus iners alone or together with at least one other probiotic organism such as Bifordobacterium, or another Lactobacillus for reduction of the risk of urogenital infection and concomitant restoration and/or maintenance of a healthy urogenital flora. A method of treatment...

20060165670 - Synbiotic combination: The invention concerns a composition comprising a Lactobacillus strain and a non-digestible oligosaccaride....

20060165662 - Isolation of target cells, capillaries and microorgans: An isolation method for target cells, capillaries and microorgans comprises perfusion of an organism with a solution containing magnetic beads, removal of a selected tissue or region of the organism, digestion of the portion removed and isolation of the target cells, capillaries or microorgans using a magnet. Filtration may be...

20060165663 - Scaffold material for regeneration of hard tissue/soft tissue interface: This invention relates to a scaffold consisting of a biodegradable polymeric material with a composition gradient of calcium phosphate that is capable of effectively regenerating the hard/soft tissue interface and an implant for hard/soft tissue filling with the utilization of such scaffold....

20060165672 - Fatigue reducing agent: To maintain physical fitness and health of middle-aged and older persons living in the threshold of the aging society, the present invention provides a fatigue reducing agent which is highly effective for preventing and reducing fatigue, wherein the agent is made of a composition of substances that are very safe...

20060165671 - Novel nutraceutical compositions comprising epigallocatechin gallate: The invention relates to nutraceutical compositions comprising at least two ingredients from the groups of EGCG, pantethine or a metabolite thereof, phytanic acid, lipoic acid, policosanol and coenzyme Q-10 and their use in the treatment or prevention of diabetes or obesity....

20060165674 - Granular composition and process for producing the same: The present invention intends to provide a granular composition which is stable at high temperature and high humidity and to provide a simple method of efficiently producing such a granular composition. According to the present invention, there is provided a granular composition containing a core material and a layer that...

20060165673 - Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same: 3-OST-5 proteins, and nucleic acid molecules encoding the same. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed, along with methods of producing each. Isolated and purified antibodies to 3-OST-5 homologs, and methods of producing the same, are also disclosed. 3OST-5 gene products have biological activity in...

20060165677 - Deletion forms of ige-dependent histamine releasing factor having histamine releasing activity, hrf-binding peptides and the uses thereof: The present invention relates to IgE-dependent histamine releasing factor (HRF) and HRF-binding peptides, more precisely, deletion forms of HRF which are able to be formed as dimers containing amino acid sequence represented by SEQ ID NO:3, genes encoding thereof and novel HRF-binding peptides having an activity of inhibiting HRF. The...

20060165676 - Identification of tsh receptor autoantibodies using affinity-purified antibodies: The present invention relates to the use of affinity-purified polyclonal human autoantibodies against the TSH receptor (TSHR-Auto-Ab), obtained from the serum of Graves' disease patients and which have been purified to obtain biochemical homogeneity and comprise a specific activity of at least 1 IU/mg protein (human immunoglobulin). Also disclosed is...

20060165675 - Modulation of mesenchymal cells via iga-receptors: IgA receptors, including a polymeric immunoglobulin receptor (pIgR) and a FcαR, have been found on smooth muscle cells, synovial fibroblast cells and on both synovial and endothelial cells in synovial tissues from patients with arthritis. Incubation of smooth muscle cells or tissue with pIgA increases cytosolic calcium and alters the...

20060165678 - Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof: The present invention is directed to cell surface antigens found on myeloma cells and on ovarian cancer cells, and monoclonal antibodies, and antibody binding fragments thereof, capable of being used for therapeutic, diagnostic, detection and cell purification purposes. An exemplified monoclonal antibody of the present invention recognizes and binds to...

20060165681 - Antibodies: Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative....

20060165679 - Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 2 (vpac2): The invention provides a human VPAC2 which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, genitourinary diseases, inflammation. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous...

20060165680 - Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors: The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the...

20060165682 - Humanized antibodies that recognize beta amyloid peptide: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include antibodies, e.g., humanized antibodies....

20060165685 - Bispecific anti-erb-b antibodies and their use in tumor therapy: The invention relates to novel bispecific antibodies and their use in tumor therapy. The novel antibodies have the ability to bind to ErbB receptors, preferably ErbB1 receptors, which are overexpressed on many cancer tissues. Since the different specificities of the antigen-binding sites are directed to different epitopes within the binding...

20060165686 - Combining therapies targeting multiple toll-like receptors and use thereof: The invention relates generally to compositions that contain multiple antibodies, e.g., multiple neutralizing antibodies, that immunospecifically bind to one or more toll-like receptors, e.g., two or more toll-like receptors, and methods of using these compositions in the treatment of inflammatory disorders....

20060165683 - Methods and compositions for control of bone formation via modulation of sympathetic tone: This invention relates to methods for treatment, diagnosis and prevention of bone disease and comprises methods including measurement and modulation of sympathetic tone and leptin activity. Alteration of sympathetic tone in bone disease can be accomplished by decreasing or increasing leptin synthesis, leptin receptor synthesis, leptin binding to the leptin...

20060165684 - Therapeutic anti-tirc7 antibodies for use in immune related and other diseases: Provided are specific antibodies against T-cell immune response cDNA7 (TIRC7) costimulatory molecule, which are capable of inhibiting proliferation of peripheral blood mononuclear cells (PBMCs). In particular, high affinity monoclonal and chimeric anti-TIRC7 antibodies are described. Compositions comprising such antibodies and their use for the treatment of immune diseases are provided....

20060165687 - Vaccine adjuvant: The present invention relates, in general, to a method of enhancing an immune response in a mammal and, in particular, to a method of enhancing an immune response to a vaccine comprising suppressing the number and/or function of regulatory T cells. The invention further relates to compounds and compositions suitable...

20060165689 - Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7: Provided are compositions and methods for the prevention and treatment of mammalian disorders that are ameliorated by modulation of effects on phagocyte and lymphoid cell populations and T-cell immune response cDNA 7 (TIRC7) activity in certain cells. Furthermore, improved methods for the production of immunoglobulins to a desired antigen are...

20060165691 - Humanized anti-cd3 specific antibodies: Novel aglycosylated antibodies having a binding affinity for the Cd3 antigen complex are of value for use in therapy, particularly in immunosuppression....

20060165692 - Humanized anti-cd3 specific antibodies: Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression....

20060165693 - Humanized anti-cd3 specific antibodies: Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression....

20060165694 - Polypeptides capable of forming antigen binding structures with specificity for the rhesus d antigens, the dna encoding them and the process for their preparation and use: Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1a to 16b. The obtained polypeptides, being Fab fragments, MAY be used directly as an active ingredient in pharmaceutical and diagnostic compositions. The Fab and their DNA sequences can also be...

20060165688 - Remedies for pemphigus containing cd40l antogonist as the active ingredient: The present invention concerns developing a remedy for treating pemphigus by administering a CD40L antagonist to patients with pemphigus such as pemphigus vulgaris or pemphigus foliaceus, and a preventive agent for preventing the development of pemphigus by preventively administering a CD40L antagonist. Antagonists such as an anti-CD40L antibody that inhibit...

20060165690 - Vaccine comprising an antigen conjugated to low valency anti-cd40 or anti-cd28 antibodies: We describe a conjugate comprising an anti-CD40 or anti-CD28 antibody and antigen wherein said conjugate has low antibody valency and including methods to prepare said conjugate....

20060165695 - Antibody against human insulin-like growth factor: For the effective treatment of diseases such as cancer in which hIGF participates, there have been desired to be developed antibodies which strongly bind to both factors hIGF-I and hIGF-II and inhibit their functions and fragments of these antibodies. The present invention provides antibodies which have the ability to specifically...

20060165696 - Remedy for spinal injury containing interleukin-6 antagonist: A therapeutic agent for spinal cord injury, a modulator of differentiation of neural stem cells and an inhibitor of differentiation into glia cells comprising an interleukin-6 antagonist as an active ingredient....

20060165698 - L-amino acid oxidase with cytotoxic activity from aplysia punctata: The present invention relates to a cytotoxic polypeptide which is an L-amino acid oxidase isolated from the ink of the sea hare Aplysia punctata....

20060165697 - Medicinal agent and method for curing erectile dysfunction: A medicament based on antibodies contains an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to endothelial nitric oxide synthase (NO synthase), the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably according to the homeopathic technology. A method of treating erectile...

20060165701 - Agents for the diagnosis and treatment of tumors that expose alerted proteins on the cell surface: The present invention relates to agents for the diagnosis and treatment of tumours that expose altered proteins on the cell surface....

20060165700 - Cancer therapy using whole glucan particles and antibodies: The present invention relates to methods of using whole glucan particles and complement activating antibodies for antitumor therapy. Whole glucan particles enhance the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. This binding enhances innate immune system cytotoxicity, as well as stimulating...

20060165702 - Fixed dosing of her antibodies: The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab....

20060165703 - Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis: The present invention describes methods for inhibiting angiogenesis in tissues using vitronectin αvβ5 antagonists. The αvβ5-mediated angiogenesis is correlated with exposure to cytokines including vascular endothelial growth factor, transforming growth factor-α and epidermal growth factor. Inhibition of αvβ5-mediated angiogenesis is particularly preferred in vascular endothelial ocular neovascular diseases, in tumor...

20060165699 - Use of specified tcf target genes to identify drugs for the treatment of cancer in particular colorectal cancer in which tcf/ss-cateini/wnt signalling plays a central role: The present invention relates to the use of inhibitors of the expressed proteins of TCF target genes whose expression is regulated by TCF/β-catenin complexes for the preparation of a therapeutical composition for the treatment of cancers in which TCF/β-catenin signalling is deregulated. Such inhibitors can be antibodies, small molecules, antisense...

20060165704 - Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody: The present invention relates to methods for the control of virulence of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. Derivatives of cell signalling molecules are conjugated to suitable carrier proteins and used to isolate high affinity receptors recognising the native signal molecule(s). By binding to...

20060165706 - Antibodies against ctla4 and uses therefor: The invention provides an antibody-toxic moiety conjugates comprising an antibody that specifically recognizes a molecule expressed on the surface of a T cell which is expressed only on T cells and is only expressed transiently on T cells upon T cell activation. Preferably, the T cell molecule is CTLA4. The...

20060165705 - Immunoselective targeting agents and methods of use thereof: The present invention provides immunoselective targeting agents that bind to transporters that are transiently accessible on the surface of neuronal cells, and that deliver compounds selectively to such cells. The invention provides methods of selectively killing, as well as methods of selectively promoting survival of, a neuronal cell....

20060165708 - Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes: A cancer vaccine comprising a cancer antigen which comprises, as an active ingredient, the product of a tumor suppressor gene WT1, a partial peptide or a modified version thereof, and a cationic liposome....

20060165709 - Cancer vaccines containing epitopes of oncofetal antigen: Disclosed are fragments of oncofetal antigen, otherwise known as immature laminin receptor protein that specifically stimulate one T cell subclass. The fragments may be formulated into compositions for potentiating T cell-mediated response in mammalian cancer patients. They also have therapeutic uses in vitro....

20060165712 - Catalytically active peptides: A catalytically active peptide comprising an imidazole function in position i flanked by at least one functional group to be amidated in position i+3+4k, where k is an integer equal to or higher than −1 or in position i−4−4n, wherein n is an integer equal to or higher than 0,...

20060165710 - Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes: The present invention relates to the use of alpha (2) macroglobulin complexes isolated from the serum of a mammal. The invention also relates to methods for making such complexes and compositions comprising alpha (2) macroglobulin complexes, isolated from the serum of a mammal, wherein such compositions are used in methods...

20060165711 - Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes: Embodiments relate to methods and compositions for eliciting, enhancing, and sustaining immune responses, preferably multivalent responses, preferably against MHC class I-restricted epitopes. The methods and compositions can be used for prophylactic or therapeutic purposes....

20060165707 - Substances: The present invention provides a multimers of class I Major Histocompatibility Complexes (MHCs) having a modified P2-microglobulin whose binding to CD8 is inhibited. Such MHCs are capable of inhibiting CD8+ T cell response, particularly by inducing apoptosis or anergy of the T cell. The invention also provides nucleic acids encoding...

20060165714 - Peptides for vaccination against human cmv: The present invention relates to peptides or pretide derivatives of the 65 kD lower matrix phosphoprotein of human cytomegalovirus. The peptides disclosed are useful for determining whether subjects have een exposed to human cytomegalovirus. Methods for using these peptides or derivatives thereof to determine the peptide-induced production of interferon-γ and/or...

20060165713 - Vaccine: The present invention relates to methods and compositions useful in the treatment and prevention of human papilloma virus infections. In particular the invention relates to nucleic acid molecules encoding E1 and/or E2 and vectors suitable for DNA vaccine delivery, and pharmaceutical compositions containing them. Methods for manufacturing said molecules, vectors...

20060165715 - Gp41 inhibitor: This invention provides a trimeric protein complex that presents an exposed N-terminal coiled-coil domain from the HIV gp41 protein. The preferred embodiment of the invention inhibits membrane fusion mediated by HIV virus. The invention also provides methods to use the trimeric protein complexes as a vaccines to prevent infection by...

20060165717 - Dcchol in newborns: The present invention involves the use of DCchol for preparing a vaccine composition intended to be administered to newborns....

20060165718 - Immunizing compositions and methods of use: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions....

20060165716 - Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae: The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group B Streptococcus serotypes and isolates. The adhesin islands are thought to encode surface proteins which are important in the bacteria's virulence. Thus, the adhesin island proteins of the invention may...

20060165719 - Plasmodium falciparum antigens and methods of use: the subject invention provides novel Plasmodium falciparum antigens and novel polynucleotides encoding these antigens. Also provided by the subject invention are methods of using these antigens and polynucleotides....

20060165721 - Cinnamomi and poria composition, method to prepare same and uses thereof: This invention provides a method for identifying a composition of Cinnamomi and Poria. This invention further provides a composition comprising: Ramulus Cinnamomi, Poria Cortex, Moutan Radicis, Radix Paeonize Alba, and Semen Persicae. This invention provides various uses of these compositions....

20060165720 - Drug product for diabetes: The present invention provides a drug product for the prevention, improvement in conditions relating to, and/or treatment of diabetes, comprising β (1→3) glucan derived from vegetable material and having a molecular weight of from about 5,000 to about 20,000. The drug product of the present invention can be widely employed...

20060165722 - Peptides for delivery of mucosal vaccines: The present invention is directed to a adjuvant peptide and uses to facilitate antigen absorption in the mucosa, particularly nasal tissue. Vaccine compositions for mucosal delivery include the adjuvant peptide and an antigen for inducing an immune response....

20060165724 - Method of producing infectious reovirus: A simple and efficient method of producing mammalian reovirus is developed using HEK 293 cells. The method provides for fast production of reovirus in high yield. Furthermore, this method provides for a simpler purification procedure of the produced reovirus....

20060165723 - Nucleic acid sequences encoding proteins capable of associating into a virus-like particle: The present invention relates to nucleic acids comprising: (a) sequences of a replication competent transmissible gastroenteritis virus (TGEV), which sequences encode a TGEV replicase under the control of expression regulatory sequences so that expression of the replicase in a cell containing the nucleic acid will initiate replication of the nucleic...

20060165725 - Hbv drug resistance drug resistance detection methods: New polymorphisms in the nucleic acid sequences of the DNA polymerase/reverse transcriptase open reading frame and viral surface antigen open reading frame of the hepatitis B virus are reported. In particular, the present invention relates to the mutation YMDD YSDD in the HBV reverse transcriptase domain and to the W196V...

20060165726 - Remedies with the use of hollow protein nanoparticles presenting growth factor or the like: The invention provides a disease-treating drug, specifically acting particular cells or tissues, which is based on protein hollow nanoparticles. The drug's therapeutic effects are confirmed through animal experiments. The invention also provides a treatment method using the drug. The disease-treating drug comprises a substance to be transferred into a cell...

20060165727 - Recombinant poxvirus expressing homologous genes inserted into the foxviral genome: The sent invention relates to a recombinant poxvirus vector capable of expressing two or more homologous, foreign sequences, which derive from different variants of a microorganism, and which have a homology of 50% or above. The invention further relates to a method for preparing such recombinant poxvirus and the use...

20060165728 - Campylobacter glycans and glycopeptides: Multiple strains and species of Campylobacter were found to share a common glycan moitie which is present in a plurality of surface-exposed glycoproteins. This glycan has the formula: GalNAc-a1,4-GalNAc-a1,4-[Glc-β1,3]GalNAc-a1,4-GalNAc-a1,4-GalNAc-a1,3-Bac, wherein Bac is 2,4-diacetamido-2,4,6-trideoxy-D-glucopyranose. This glycan and immunologically active fragments of it have use as vaccines against campylobacter infection in humans...

20060165729 - Protein from photobacterium damselae and use thereof: A derivative of a 55 kDa extracellular protein from Photobacterium damselae subsp. Piscicida is the basis for a vaccine against Photobacterium infection, and thereby protects fish from pasteurellosis....

20060165730 - Polysaccharide and glycoconjugate vaccines: The present invention concerns a conjugation process for coupling a endotoxin (LPS) free polyfunctional polysaccharide with a polyfunctional carrier protein with quantitative yields. The invention also provides for vaccine formulations comprising the glyconjugate antigen manufactured by the process....

20060165731 - Vaccines: Vaccines active against coccidiosis in domestic fowls contain attenuated precocious strains of Eimeria species....

20060165732 - Fungal antigens and eosinophil activity: The invention provides methods and materials related to T cell activation, eosinophil activation, and the ability of eosinophils to attack fungi. The invention also provides animals having a fungal antigen-induced eosinophilic response as well as methods of making such animals and method of using such animals to identify compounds that...

20060165733 - Liquid formulations with high concentration of hunan growth hormone (hgh) comprising phenol: The present invention relates to liquid formulations of human growth hormone (hGH, somatropin) which are storage stable, show reduced or no crystallization on storage and are suitable for administration to the human or animal body. More particularly, the invention relates to liquid formulations of human growth hormone which are stable...

20060165734 - Novel method of deodorization for fat odor and composition obtained by the same: The present invention provides a novel deodorizing composition and a novel deodorizing method. A composition is provided in which oily odors have been deodorized by containing a xanthophyll or other carotenoid in an oil such as a highly unsaturated fatty acid or compound containing a highly unsaturated fatty acid as...

20060165739 - Alcohol-free microemulsion composition: The present invention concerns compositions that comprise alcohol-free microemulsions and methods for their use that include a surfactant, a lipophilic linker, and/or a hydrophilic linker. These compositions can be used, for example, in cosmetic or hair applications. In certain aspects, compositions of the invention have the ability to microemulsify sebum...

20060165736 - Cosmetic composition: The invention provides an emulsified cosmetic composition having an anti-perspiring action. The invention relates to an emulsified cosmetic composition comprising surface-hydrophobated water-absorbing polymer particles and water, particularly an emulsified cosmetic composition as an antiperspirant....

20060165741 - Low ph skin care compositions containing dehydroacetic acid: Stable skin care compositions comprising dehydroacetic acid and a dermatologically acceptable carrier. The dermatologically acceptable carrier comprises at least one oil, said oil having a solubility in water of about 5% or less and a solubility parameter of from about 7 to about 15, and the dehydroacetic acid is distributed...

20060165738 - O/w emulsifier, o/w emulsion and applications thereof: The invention concerns an O/W emulsifier, an O/W emulsion prepared therefrom and the uses thereof. According to the invention the O/W emulsifier contains (a) 70 to 90 wt. % of glyceryl oleate citrate and (b) 10 to 30 wt. % of a viscosity modifier having a viscosity in the range...

20060165740 - Perfume delivery system: Perfume delivery systems, comprising insoluble carrier particles with surface silanols, which have been grafted with an organosilane and carry amino functional groups, a polymer with positively charged functional groups added to said carrier particles and a fragrance adsorbed to or absorbed into the carrier particles. The perfume delivery systems impart...

20060165737 - Reducing the odor of oil components by means of adsorption with polymeric adsorbing agents: A process for reducing the odor of an oil. The oil being treated is first distilled by a carrier vapor or carrier gas distillation to form a distilled oil. The distilled oil is then contacted with a polymeric adsorbent; whereby the odor of the oil is reduced. The polymeric adsorbent...

20060165735 - Stable emulsions of oils in aqueous solutions and methods for producing same: Methods for making highly stable, oxidation-resistant emulsions comprising an oil, an emulsifier, an emulsion stabilizer and water are provided. The invention is particularly well suited for oils that are susceptible to oxidation, such as long chain polyunsaturated fatty acid oils. The resulting emulsion is highly stable and resistant to oxidation,...

20060165747 - Antifungal composition, method and kit for topically treating onychomycosis: An activator comprising a biocompatible base and a known fungicide in the form of an acid salt are mixed together by the user shortly before being applied to the infection so as to react them chemically to produce the free base of the fungicide thereby rendering the composition capable of...

20060165744 - Combination liposomal formulations: The present invention provides a composition comprising a physiologically acceptable carrier and two or more agents encapsulated in a liposome, wherein the combination of the two or more agents possess the following properties: (1) cytotoxicity to tumor cells, (2) nutritional properties, (3) use in application to nails, hair, skin or...

20060165746 - Formulations containing microencapsulated essential oils: The present invention provides for a novel “green” agricultural formulation comprising at least one encapsulated volatile essential oil and a non-volatile vehicle in which said at least one encapsulated volatile essential oil is carried....

20060165748 - Insecticidal and ovicidal composition: The present invention herein provides an insecticidal and ovicidal composition which comprises, as an effective component, at least one member selected from the group consisting of coconut oil, palm kernel oil, triglycerides of saturated fatty acids each having 10, 12 or 14 carbon atoms, and triglycerides comprising, as the constituent...

20060165743 - Method and device to control and condition the behavior of the varroa destructor mite in a beehive, or in other environment where bees reproduce: Method and device to control and condition the behavior of the Varroa destructor mite in a beehive, or in another environment where bees reproduce. The method comprises a step of applying, in the beehive or in the aforesaid environment, a chemical composition including at least one of the following substances:...

20060165749 - Moisture-activated release of fragrances from novel pourable lotion formulations: A method of sequestering volatile fragrances by encapsulating them in the oil phase of a thixotropic microemulsion, and drying to a thin film, and subsequently releasing the volatile oils upon rehydration of the dried film; compositions comprising the volatile fragrances encapsulated in the oil phase of a thixotropic microemulsion, which...

20060165742 - Powdery active ingredient formulations: Novel pulverulent active substance formulations composed of at least one active substance which is solid at room temperature, at least one dispersant, polyvinyl alcohol and if desired, additives, the individual active substance particles being enveloped by a coat of polyvinyl alcohol, being present in the amorphous state, and having diameter...

20060165745 - Sustained release tablets for treatment of aqueous environment and methods for making the same: The present invention provides tablets for treatment of aqueous environment that release at least one active ingredient in a sustained manner so as to provide the treated aqueous environment with the at least one active ingredient for a long period with a single dose. The present invention also provides methods...

20060165750 - Insecticidal composition: A composition of an insecticide, useful particularly but not exclusively for eliminating ants, which comprises polyethylene glycol (PEG) and attractant. The insecticidal action is of a substantially mechanical type, since the PEG ingested by the insect, upon contact with the liquids that are present in the digestive system, expands and...

20060165751 - Medicament incorporation matrix: A coating composition, in both its uncrosslinked and crosslinked forms, for use in delivering a medicament from the surface of a medical device positioned in vivo. Once crosslinked, the coating composition provides a gel matrix adapted to contain the medicament in a form that permits the medicament to be released...

20060165752 - Coated stent: Stents with coatings comprising a combination of a restenosis inhibitor comprising an HMG-CoA reductase inhibitor and a carrier. Also provided are methods of coating stents with a combination of an HMG-CoA reductase inhibitor and a carrier. A preferred example of a restenosis inhibitor is cerivastatin. The stent coatings have been...

20060165753 - Medical device drug release regions containing non-covalently bound polymers: According to one aspect, implantable or insertable medical devices are provided, which contain polymeric release regions that release one or more therapeutic agents. The polymeric release regions, in turn, contain the following: (i) a first bonding polymer having a first polymer block and a first bonding group and (ii) a...

20060165754 - Medical devices containing crazed polymeric release regions for drug delivery: A medical device that contains (a) at least one polymeric release region that either contains crazing or which is adapted to undergo crazing as a result of stresses (e.g., mechanical, chemical or thermal) that are applied during the implantation or insertion of the medical device into a patient; and (b)...

20060165755 - Method for treating otitis externa: A device is provided herein for the treatment of otitis externa. The device (101) comprises a receptacle (103) adapted to store a pharmaceutical composition, and a distal portion (105), in open communication with the receptacle, which is adapted to apply the composition disposed in the receptacle to the meatal tissues...

20060165757 - 5-hydroxysapogenin derivatives with anti-dementia activity: The invention discloses the use of 5-hydroxysapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed....

20060165756 - Method for weight management: The present invention is directed to a method for managing body weight by measuring preload efficiency and having the energy load of a food serving and providing information as to the measured preload efficiency and energy load of the selected food serving to enable an informed choice of an appropriate...

20060165758 - Polymer controlled induced viscosity fiber system and uses thereof: The present invention relates generally to a method of blunting the postprandial glycemic response in a human by feeding an induced viscosity fiber system. The invention also relates to an induced viscosity fiber system and the liquid products that incorporate the induced viscosity fiber system. Further, the invention relates to...

20060165759 - Antacid lozenge containing micronized particles: An organoleptically acceptable antacid lozenge including at least one antacid present in the form of micronized particles having a particle size of less than about 10 microns. The lozenge is a solid oral composition capable of dissolving slowly in the mouth for long lasting administration of an antacid at a...

20060165760 - Composite flexible transpirable device formed from separate layers of textile material joined together by a layer of adhesive polymer: A flexible transpirable composite device formed from two or more layers of textile material securely joined together, characterised in that said joining is achieved by a layer of a transpirable adhesive polymer completely free of solvents interposed between two adjacent layers of textile material, at least one substance having pharmacological...

20060165762 - Absorbent dressing comprising hydrophilic polymer: An absorbent dressing is described which comprises a crosslinked hydrophilic gel absorbent layer comprising a first component polymer comprising a plurality of polymerized monomer units having pendent hydrophilic groups, and pendent Michael donor groups; and a crosslinking agent comprising at least two Michael acceptor groups....

20060165761 - Wound dressings comprising vanadate complexed with organic ligands: The invention relates to wound dressings comprising a tyrosine phosphatase inhibitor that stimulates collagen deposition and fibroblast proliferation thereby accelerating wound healing. Preferred tyrosine phosphatase inhibitors are complexes of vanadate and peroxovanadate with organic ligands....

20060165763 - Pasting agent: A patch comprising a backing layer and an adhesive layer disposed on the backing layer and compounded with an adhesive agent and oxybutynin and/or a pharmaceutically acceptable salt thereof, wherein the adhesive agent comprises an acrylic polymer substantially free of both carboxyl group and hydroxyl group and a rubber polymer,...

20060165764 - Tape preparation: The present invention provides a tape preparation including a support and an adhesive layer directly or indirectly formed on at least one surface of the support, wherein the adhesive layer contains a rubber adhesive containing at least one kind of rubber polymer and capsaicin as an active ingredient. Since the...

20060165765 - Topical glycopyrrolate product: This invention relates to a convenient and safe product and method of applying glycopyrrolate topically in order to reduce excessive sweating in localized areas for those who suffer from this condition. This invention also relates to combining oral and topical delivery of glycopyrrolate to reduce excessive sweating and minimize side...

20060165772 - Combretastatin a-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4....

20060165771 - Compositions for delivery of drug combinations: Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered....

20060165773 - Gene therapy of tumors using non-viral delivery system: The present invention provides a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity. This composition has a high gene transfection efficiency at non-toxic doses and...

20060165770 - Lipid particles having asymmetric lipid coating and method of preparing same: A method of preparing lipid particles having an asymmetric lipid coating is described. The lipid composition of the outer lipid coating of the particles varies from the inner to outer surfaces. The asymmetric lipid particles are formed by preparing a lipid composition containing a charged lipid and a therapeutic agent,...

20060165766 - Method for preparing liposome formulations with a predefined release profile: The present invention provides a novel tool for designing a release profile of an active agent from a liposome in to which it is loaded. According to the invention, a method is provided for preparing a liposomal formulation for delivery of an active agent to a target, the release of...

20060165768 - Novel lipophilic compounds and uses thereof: e

20060165769 - Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations: Compounds and compositions are disclosed for increasing the bioavailability of lipophilic drugs, and more specifically, to solubilizing lipophilic drugs using bioenhancers that cause no efflux inhibition or a desired degree of efflux inhibition. Methods of making and using such compositions are also disclosed....

20060165767 - Thermolabile liposome with a controlled release temperature: The invention relates to a thermolabile liposome with a controlled release temperature for the liposome content, in particular a liposome which is stable at 37° C. in serum and with a controlled release temperature of between 40 and 80° C....

20060165776 - Antidepressant oral pharmaceutical compositions: Novel enteric compositions suitable for oral administration comprising Duloxetine or its pharmaceutical derivatives thereof and methods for preparing such compositions are disclosed. Such compositions contain a core consisting of a Duloxetine or its pharmaceutical derivatives thereof, the said core comprised of a pharmaceutically inert nuclei and the Duloxetine or its...

20060165775 - Capsule and film-forming composition comprising gum arabic: A capsule for oral delivery of a composition comprises 60% to 95% by weight of gum arabic and to the remainder a water-soluble polymer, a hydrocolloid and a plasticizer. The proportion of gum arabic is preferably 70% to 90% by weight of all components. The water-soluble polymer is preferably a...

20060165777 - Dosage forms contained within a capsule or sachet: Provided are pharmaceutical dosage forms within structures such as hollow capsules, gelcaps, or sachets, adapted to allow ingestion of a whole dose or a preferably predetermined fraction of said dose when desired....

20060165774 - Non gelatin films with improved barrier properties: Non gelatin film materials, e.g. hydroxy propyl methyl cellulose comprise e.g. an additive or additives such as an organic acid, e.g. hydroxy carboxylic acid, which form a barrier composition. The resultant films are safe human consumption and find use as a wall material of an ingestible delivery capsule, e.g. containing...

20060165778 - Enteric composition for the manufacture of soft capsule wall: A gel mass is provided that is useful in manufacturing enteric soft or hard capsules, or enteric tablets without coating....

20060165780 - Anticoagulant composition: A solid heparin tablet composition has a melting point of 25° C. or higher and is a continuous lipid component containing one or more polar lipids, one or more non-polar lipids, optionally one or several of water and mono- to trivalent alcohol in an amount of up to 15% by...

20060165784 - Calcium supplement: A dissoluble oral tablet of calcium supplement and the method of making the product are provided. This calcium supplement comprises an exposure area and a coating covered area. The surface ratio between the exposure area and the coating covered area is about 1:1 to 1:12. The exposure area can be...

20060165783 - Compacted lactic acid menthyl ester: The invention relates to lactic acid menthyl ester compacts, a method for the preparation of lactic acid menthyl ester compacts and the use thereof....

20060165785 - Method of chemically stabilizing pharmaceutical formulations with cholesterol: The invention relates to a method of improving the chemical stability of an active ingredient substance in a particulate formulation in chemically reactive environment comprising associating the active ingredient substance with a chemically stabilising amount of cholesterol to form composite particles comprising said active ingredient substance and cholesterol....

20060165779 - Novel method stabilizing bupropion hydrochloride tablets: The present invention relates to a stable bupropion hydrochloride tablet and a method of stabilizing bupropion hydrochloride tablets, which also serves as an improved tabletting process for the preparation of sustained release bupropion hydrochloride tablets....

20060165781 - Orally disintegrating tablets and process for obtaining them: The tablets comprise: at least 59.5% spray-dried mannitol; active ingredient below or equal to 10%, where at least 90% in weight of the active ingredient has a particle size below 100 μm; microcrystalline cellulose 10-18%, with an average particle size of 50 μm and where at least 99% in weight...

20060165782 - Solid compositions comprising gabapentin having improved stability: Solid pharmaceutical compositions of improved stability which comprise gabapentin and a basic compound that is a hydroxide or a salt of a weak acid....

20060165787 - Ceramic structures for controlled release of drugs: The present invention provides compositions for controlled drug delivery, dosage forms, and processes for producing dosage forms. In a composition aspect of the present invention, a composition including a drug and a ceramic structure is provided. The ceramic structure has either a hollow portion wherein the drug is included in...

20060165791 - Controlled release oxycodone compositions: A method for substantially reducing the range in daily dosages required to control pain in approximately. 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation...

20060165792 - Controlled release oxycodone compositions: A method for substantially reducing the range in. daily dosages reguired to control pain-in-approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean...

20060165789 - Lercanidipine modified release compositions: Pursuant to the present invention, it has been found that a modified release composition containing the low permeability and poor solubility drug, lercanidipine, may be prepared which provides for therapeutically effective plasma concentrations of lercanidipine for a period of about 20 to about 25 hours. The modified release composition of...

20060165788 - Lercanidipine ph dependent pulsatile release compositions: Pursuant to the present invention it has been found that a modified release composition containing the low solubility and permeability drug, lercanidipine may be prepared that provides for therapeutically effective plasma concentrations of lercanidipine for 24 hours. The modified release composition of the present invention release pulses of lercanidipine based...

20060165786 - Methods for treating circadian rhythm phase disturbances: A method for treating circadian rhythm phase disorders is described. The invention provides methods to specifically advance or delay the phase of certain circadian rhythms in humans. The disclosed methods relate to the administration of melatonin at times determined with relation to the time of dim light endogenous melatonin onset....

20060165790 - Multiparticulates: Multipartulates of oxycodone can be made by extrusion of a blend which suitably contains (a) oxycodone, (b) water-insoluble ammonium methacrylate copolymer, (c) plasticiser, (d) lubricant and (e) water permeability modifier....

20060165793 - Pharmaceutical preparation to be dispersed before administration: The present invention provides a pharmaceutical preparation to be dispersed before administration which has an adequate viscosity and a suitable flowability even when dispersed in a small amount of water and can be easily administered through an NG tube is provided. Specifically, the pharmaceutical preparation to be dispersed before administration...

20060165797 - Dosage form for treating gastrointestinal disorders: The present invention is directed to drug dosage forms that can be used to treat diseases characterized by abnormal gastric acid secretion. The dosage forms have a core containing a proton pump inhibitor surrounded by an enteric coating or multiple particles containing proton pump inhibitor, each particle being surrounded by...

20060165796 - Extended release formulation of levetiracetam: An extended release pharmaceutical composition of Levetiracetam with once a day dosage regime and the process of preparing it. The extended release tablet of Levetiracetam is with the core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of...

20060165795 - Medicinal compositions comprising a core and a film based on modified cellulose derivatives: A medicinal composition comprising: (a) a core in combination with a medicinally effective unit dose of one or more active medicaments; (b) the core being enclosed within a non-expanded film material comprising a modified cellulose material....

20060165794 - Spheroids, preparation method thereof and pharmaceutical compositions: The invention relates to a directly-compressible gastro-resistant spheroid. The spheroid comprises: (i) a core containing one or more active substances; (ii) a flexible, deformable film which directly coats the aforementioned core and which comprises an enteric polymer and a mixture of saturated and/or unsaturated polyglycosylated glycerides, the fatty acids of...

20060165798 - Oral osmotic dosage form having a high flux membrane: Disclosed are oral osmotic dosage forms and methods wherein a semi-permeable membrane of the oral osmotic dosage form includes from about 23 wt % to about 50 wt % of a flux enhancer and from about 0.01 wt % to about 5 wt % of antioxidant, based on the total...

20060165799 - Bone-filling composition for stimulating bone-forming and bone-consolidation comprising calcium sulfate and viscous biopolymers: The present invention relates to a composition for bone-filling, more particularly, to a bone-filling composition for stimulating bone-formation and bone consolidation comprising calcium sulfate and viscous biopolymers. The composition of the present invention can easily be administered into the missing part of injured bone. Since the composition of the present...

20060165800 - Short duration depot formulations: Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, depot gel compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a short duration of time. The...

20060165801 - Hydrous gel and production process and use of the hydrous gel: A hydrous gel substantially comprising at least two polymers selected from the group consisting of polyacrylic acid, sodium polyacrylate and partially neutralized polyacrylate, and water, the polymers being crosslinked by containing an aluminum compound, wherein the pH when the hydrous gel is 100-fold diluted with purified water is from 6.5...

20060165802 - Medium containing water with increased viscosity, method for production and use thereof: The invention concerns a water-containing medium with an increased viscosity containing a gellable polymer component with phenolic substituents modified with the aid of oxidases, characterized in that it was modified by a) a protein with polyphenol oxidase activity and/or b) an enzyme mixture containing hydrolases, oxidoreductases and peroxidases. The medium...

20060165803 - Pharmaceutical compositions of sertaconazole for vaginal use: The invention relates to monodose mucoadhesive vaginal compositions of sertaconazole or a pharmaceutically acceptable salt thereof for the treatment of vulvovaginal candidiasis....

20060165805 - Magnetic pole matrices useful for tissue engineering and treatment of disease: A magnetic pole matrix chip facilitating the grinding of magnetic particles carrying matter effective for treating a disease or promoting tissue engineering to a disease site or a tissue engineering site, respectively...

20060165806 - Nanoparticulate candesartan formulations: The present invention is directed to compositions comprising a candesartan, such as candesartan cilexitil. The candesartan particles of the composition have an effective average particle size of less than about 2000 nm. The candesartan compositions of the invention are useful in the treatment of hypertension or related cardiovascular conditions....

20060165804 - Polymer compositions for administration to animals: Particulate embolotherapeutic compositions are described in which the particles comprise a matrix polymer expressing at surfaces available for interaction with biological molecules or, usually, blood cells, express zwitterionic groups, usually phosphoryl choline groups. The particles have suitable size and compressibility, for instance controlled by controlling the water content, for use...

20060165810 - Controlled release from block co-polymer worm micelles: Provided is a method of controlling the release of at least one encapsulated active agent from a worm-like micelle, wherein each worm-like micelle comprises one or more amphiphilic block copolymers that self assemble in aqueous solution, without organic solvent or post assembly polymerization; wherein at least one of said amphiphilic...

20060165808 - Microcapsules for the delayed, controlled release of perindopril: The present invention relates to A microcapsule composition allowing the delayed and controlled release of perindopril, or of a pharmaceutically acceptable salt thereof, for administration by the oral route....

20060165809 - Oral pharmaceutical formulation in the form of a plurality of microcapsules for prolonged release of active principle(s) with slow solubility: The invention concerns microcapsules with prolonged release of active principles with low solubility, consisting of a core containing the active principle and coated with a polymer layer which controls the release of the active principle. The aim is that said oral microcapsules containing hardly soluble active principles should have a...

20060165807 - Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s): The invention concerns liquid pharmaceutical formulations, for oral delivery, with modified release of active principle(s) excluding amoxicillin and consisting of suspensions of coated particles of active principles (microcapsules). The microcapsules constituting the dispersed phase of the suspension are designed, according to the invention, to enable modified release of the active...

20060165811 - Method and system for automatic decoding of motor cortical activity: A Switching Kalman Filter Model for the real-time inference of hand kinematics from a population of motor cortical neurons. Firing rates are modeled as a Gaussian mixture where the mean of each Gaussian component is a linear function of hand kinematics. A “hidden state” models the probability of each mixture...

20060165812 - Method and topical formulation for treating headaches: Disclosed herein are methods, topical formulations and kits for treating, ameliorating or at least reducing pain intensity associated with a headache in a host suffering therefrom. These methods, topical formulations and kits use therapeutically effective amounts of at least one from a plurality of active agents that are directly applied...

20060165813 - Topical composition for treatment of skin disorders: The present invention provides a topical composition comprising the combination of zinc ions, ammonium ions and chloride ions for treatment of skin disorders. The invention also relates to a method for treating or preventing a skin disorder using the topical composition of the present invention....

20060165814 - Amines, combination of amines and vanadium and amine vanadium salts for the treatment or prevention of dyslipidemia: Combinations comprising vanadium (IV)/(V) compounds and pharmaceutically acceptable amines are provided. Combinations thereof are provided for the treatment or prevention of dyslipidemia, diabetes, obesity, metabolic syndrome or cardiovascular diseases....

20060165815 - Choline-silicic acid complex with osmolytes and divalent trace elements: The invention relates to a biological preparation comprising orthosilicic and silicic acid, a primary (“constant/first”) osmolyt choline and a weak alkalinizing agent without free hydroxyl groups and to a method for preparing the preparation, comprising: i) hydrolysing a silicon comprising choline solution thereby forming a choline stabilized orthosilicic acid and...

20060165818 - Bioimmune-aggressin composition for suppression of xanthomonad infections in agriculture crops: A composition for treating Xanthomonas spp. infections in agriculture crops wherein the treatment composition is an admixture of T. harzianum, Y. schidigera root extract, Y. schidigera leaf extract, and X. spp. extract. The composition is also efficacious as a pre-infection agent for enhancing the resistance of agriculture crops to such...

20060165817 - Compositions containing cotinus coggygria extract and use thereof in treating wounds: The present invention relates to a method of treating a wound on a tissue be administering to the wound a composition or bandage containg Cotinus coggygria extract....

20060165816 - Herbal compositions useful as chemopreventive and therapeutic agents: Composition derived from traditional Chinese herbal medicines, medicinal plants and extracts thereof, are provided. These compositions can be used as chemopreventive and therapeutic agents....

20060165819 - Topical composition for the treatment of psoriasis and related skin disorders: Compositions and methods of use thereof for the treatment of psoriasis and related skin ailments are disclosed. The compositions include topical skin formulations of glucosamine in an emollient base such as moisturizing cream. In addition to glucosamine, the formulations may include keratolytic substances such as coal tar extract or salicylic...

20060165820 - Herbal supplement to support weight loss: Disclosed herein are herbal and chemical combinations for promoting weight loss. The herbs in the composition can include, among others, green tea, ginger, cocoa, and yerba mate. Other chemicals in the composition can include, among others, caffeine and a pharmaceutically acceptable salt of calcium....

20060165821 - Composition comprising scutellaria baicalensis and their uses thereof: This invention described various formula composite of Scutellaria baicalensis for various diseases and conditions. The formula takes the advantage of our recent discovery of Scutellaria baicalensis can inhibit cyclooxygenase-2 (COX-2) activity and expression, resulting in decrease of prostaglandin synthesis. COX-2 is involved in many biological processes, such as inflammation, pain,...

20060165823 - topical delivery agents and methods for making and using therm: The invention provides methods for making and using topical delivery agents, wherein the delivery agents comprise an oil, e.g., jojoba oil, and an active agent, and formulations made by the methods of the invention....

20060165822 - Pharmaceutical compositions and uses comprising mucuna pruriens seed powder and extracts thereof in the treatment of neurological diseases: The present invention provides pharmaceutical compositions comprising Mucuna pruriens seeds or one or more Mucuna pruriens seed components, substances, fractions or mixtures or substances obtained therefrom. Furthermore, the invention relates to the use of Mucuna pruriens seed powder or one or more Mucuna pruriens components, substances, fractions or mixtures or...

20060165824 - Compositions, kits, and methods for enhancing gastrointestinal health: Disclosed herein are compositions, kits, and methods useful for enhancement of gastrointestinal health. For example, compositions comprising matter derived from a plant of the genus Terminalia; and a soluble fiber are disclosed. Also disclosed are kits wherein the extract of the plant matter and the soluble fiber need not be...

20060165825 - Pharmaceutical compositions: Compositions have been obtained by extracting rhizomes of Fagopyrum dibotrys with alcohol and concentrating the extract to a powder or syrup, optionally followed by fractionation. The extract is demonstrated to be a potent anti-cancer agent. Its activity at the gene level was analysed....

20060165826 - Process for the preparation of antioxidant conserve from indian curry leaves (murraya koenigii spreng): The present invention relates to a simple process for the preparation of safe, environmental friendly, and natural antioxidant conserve of activity ranging between 80-85%, comprising oleoresin from Indian curry leaves (Murraya Koenigii Spreng.), said process-comprising steps of drying the washed curry leaves at temperature ranging between 30-80° C., for time...

20060165827 - Anti diarrhoea compositions: The invention concerns a method for the prevention/curing/treatment of diarrhoea in mammals by administering the mammals an effective daily amount of a composition comprising as active component(s) phytosterols and/or pentacyclotriterpenes as present in or derived from Shea oil as well as a method for the preparation of a food or...

20060159616 - Methods for detecting endocrine cancer: Kallikrein 13 constitutes a novel biomarker for diagnosis, treatment and monitoring of endocrine cancer. A method is provided for diagnosing and monitoring endocrine cancer or a predisposition to endocrine cancer, in a subject comprising detecting hK13 in a sample from the subject. Imaging methods, screening methods for test agents for...

20060159618 - Preparation of compounds useful for the detection of hypoxia: Novel 18F-fluorine compounds useful for non-invasive imaging techniques such as PET, for detecting tissue hypoxia and methods for preparing them are disclosed. Novel intermediate compounds and methods for preparing them are also disclosed. Diagnostic kits useful in practicing the methods of claimed invention are also provided....

20060159617 - Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors: The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors. In another embodiment, the invention relates the methods of imaging tissues, organs or tumors using radiolabeled metal complexes, particularly tissues, organs, or tumors which...

20060159619 - Cell permeable nanoconjugates of shell-crosslinked knedel (sck) and peptide nucleic acids (\"pnas\") with uniquely expressed or over-expressed mrna targeting sequences for early diagnosis and therapy of cancer: A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2′-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds...

20060159620 - Human kininogen d3 domain polypeptide as an anti-angiogenic and anti-tumor agent: Human kininogen domain 3 (HK-D3) polypeptides and biologically active variants and derivatives of HK-D3 are anti-angiogenic. These molecules are used to inhibit angiogenesis or treat a disease or condition in which angiogenesis is pathogenic.. Because of their anti-angiogenic potential, these molecules compounds are useful in the treatment of cancer by...

20060159621 - Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm: This invention is directed to myocardial imaging of human patients having a history of asthma or bronchospasm. In particular, the present invention uses binodenoson as a pharmacological stressor in conjunction with any one of several noninvasive and invasive diagnostic procedures available. For example, intravenous administration may be used in conjunction...

20060159622 - Pharmacodynamic assay for inhibitors of 11-beta-hydroxysteroid dehydrogenase activity in animal tissues: A novel method is provided to measure 11β-hydroxysteroid dehydrogenase activity in intact whole animal tissues in the presence of systemically or ex vivo administered inhibitors of the enzyme. Inhibitors of the type 1 isoform (11β-HSD1) may be useful to treat type 2 diabetes, Metabolic Syndrome, and other metabolic disorders....

20060159623 - Stem cells for use in locating and targeting tumor cells: A composition for locating tumors, the composition includes stem cells. Stem cells for use in locating and treating tumors. A method of locating and treating a tumor by administering to a patient an effective amount of stem cells, wherein the stem cells locate and subsequently treat a tumor....

20060159624 - Buccal, polar and non-polar spray containing zolpidem: Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide zolpidem for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, zolpidem, and optional flavoring agent; formulation II:...

20060159625 - Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use: Formulations are provided for pulmonary administration of an antifungal agent to a patient. Methods of using the formulations in the treatment of antifungal infections are also provided, including treatment of pulmonary aspergillosis with amphotericin B-containing formulations. Methods of manufacturing the formulations to achieve optimum properties are provided as well....

20060159626 - Method for administering a cytokine to the central nervous system and the lymphatic system: The present invention is directed to a method for delivering cytokines to the central nervous system and the lymphatic system by way of a tissue innervated by the trigeminal nerve and/or olfactory nerve. Cytokines include tumor necrosis factors, interleukins, interferons, particularly interferon-β and its muteins such as IFN-βser17. Such a...

20060159627 - Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists: The present invention relates to methods of preventing airway remodeling using A2B adenosine receptor antagonists. This invention finds utility in the treatment and prevention of asthma, COPD, pulmonary fibrosis, emphysema, and other pulmonary diseases. The invention also relates to pharmaceutical compositions for use in the method....

20060159628 - Nanoparticulate benzothiophene formulations: The present invention is directed to benzothiophene compositions, preferably nanoparticulate raloxifene hydrochloride compositions having improved pharmacokinetic profiles, improved bioavailability, dissolution rates and efficacy. In one embodiment, the raloxifene hydrochloride nanoparticulate composition have an effective average particle size of less than about 2000 nm....

20060159629 - Pulmonary delivery particles with phospholipid structural matrix: A pulmonary delivery medicament comprises a plurality of particulates, each particulate having a perforated microstructure comprising a phospholipid structural matrix and active agent, the phospholipid structural matrix comprising greater than about 50% w/w phospholipid, and the particulates having a geometric diameter of from 0.5 to 50 μm. The medicament can...

20060159631 - Compositions and methods for preventing dental stain: This invention relates to compounds and their use in oral hygiene compositions as anti-stain, anti-calculus, anti-bacterial, and anti-malodor agents. These agents are characterized by having two basic building blocks, one with the ability to strongly bind to the tooth surface by containing a functional group that allows the molecule to...

20060159630 - Dental material containing bacteristatic and/or bactericidal substances: The invention relates to dental material containing at least one substance, whose bacteriostatic and/or bactericidal activity develops in the presence of intra-oral micro-organisms. The invention also relates to the use of a substance, whose bacterio-static and/or bactericidal activity develops in the presence of intra-oral microorganisms, for producing dental material....

20060159632 - Drug formulation for mouth or pharynx comprising local anesthetic: Provided is a drug formulation for mouth or pharynx to be used for medical care or treatment for serious stomatitis caused by a side effect of an anti-tumor agent or the like, and for anesthesia in the pharynx, with remarkably suppressed discomfort due to bitter taste although it contains a...

20060159633 - Emulsive water-soluble concentrates: The invention relates to the solubilization of lipophilic substances, preferably from the group of lipids, steroids, terpenes and polar lipids by means of a lecithin/polyol matrix or a lecithin/carbohydrate matrix so as to obtain water-soluble emulsion-like transparent concentrates which are used in cosmetic, dietetic and pharmaceutical products....

20060159634 - Oxazoline mixture: the amounts being I=from 0 to 10% mol, II=from 1 to 90% mol, III=from 1 to 98% mol, IV=from 1 to 98% mol, V=from 0 to 50% mol, VI=from 0 to 50% mol, where R1 is the alkyl radical of a fatty acid or of a hydroxy fatty acid, R2...

20060159636 - Structurally modified titanium dioxides: Pyrogenically prepared, structurally modified titanium dioxides or pyrogenically prepared, structurally modified titanium-dioxide mixed oxides are prepared by the titanium dioxides being treated with a ball mill and optionally being subsequently ground. They may be employed in sunscreen formulations....

20060159635 - Surface-modified pyrogenically prepared titanium dioxides: Surface-modified, pyrogenically prepared titanium dioxides coated with silicon dioxide are prepared by spraying the pyrogenically prepared titanium dioxides coated with silicon dioxide with a surface-modifying agent and then tempering them. They can be used in sun protection formulations....

20060159637 - Surface-modified, structurally modified titanium dioxides: Pyrogenically prepared, surface-modified, structurally modified titanium dioxides and pyrogenically prepared, surface-modified, structurally modified titanium dioxide mixed oxides are prepared by structurally modifying and then surface modifying the titanium dioxide or titanium dioxide mixed oxide. The titanium dioxides can be used to produce sunscreen formulations....

20060159638 - O/w emulsions comprising micronized biologically active agents: Topically applicable cosmetic/pharmaceutical oil-in-water emulsions, well suited for treating or caring for the skin and/or superficial body growths therefrom, include a discontinuous fatty phase dispersed in a continuous aqueous phase and comprise an effective amount of at least one biologically active agent (A) and an effective amount of an emulsifying...

20060159639 - Pseudo body odor composition and perfume composition for inhibiting body odor: A pseudo body odor composition according to the present invention comprises (A) at least one kind selected from (A-1) hydroxyalkynyl carboxylic acids having 5 to 8 carbon atoms and (A-2) alkenyl carboxylic acids having 5 to 8 carbon atoms and one double bond; (B) at least one kind selected from...

20060159640 - Antiperspirant gripping composition: An antiperspirant gripping compound with astringent properties designed to be applied topically to the skin of the hands to enhance the grip of a user on tools, sports equipment or other surfaces. The antiperspirant gripping compound consists of approximately 23% aluminum chlorohydroxide dihydrate, and aluminum hydroxyl chloride dihydrate solution mixed...

20060159641 - Variably crosslinked tissue: Non-glutaraldehyde fixation of an organ or a prosthesis for implantation in a mammal is based upon carbodiimide treatment. A solution containing a sterilizing agent, such as EDC, in combination with a coupling enhancer, such as Sulfo-NHS, and a high concentration of a diamine cross linking agent is used. As a...

20060159644 - Compositions comprising a block copolymer, an amino silicone and a nonpolymeric thickener, and uses thereof: The disclosure provides cosmetic compositions comprising, in a cosmetically acceptable medium, at least one block copolymer comprising at least a first hydrophilic block and at least a second block that is chosen from a second hydrophilic block, wherein the second hydrophilic block is different than the first hydrophilic block, and...

20060159645 - Method of providing lubricious surfaces: This invention relates to a method of providing lubricious surfaces, more particularly to a method of providing lubricious characteristics to skin surfaces that come into contact with other surfaces so as to prevent or treat chafing and/or irritation....

20060159647 - Compositions for hygienic hand disinfection and disinfectant handwashing: The invention relates to a disinfectant composition which includes a) one or more 1- or 2-(C1- to C24-alkyl)glycerol ethers, b) one or more bispyridiniumalkanes and c) one or more amine oxides, and to the use of the composition for hygienic hand disinfection and for disinfectant handwashing....

20060159646 - Hair regenerator: The invention relates to a hair regenerator which is based on a regenerator such as that described in patent of invention 200200105, comprising a mixture of an epidermal growth factor, dexpanthenol and sodium hyaluronate, said mixture being applied by means of intradermic trichotherapy alternated with a surface cosmetic treatment. The...

20060159648 - Novel therapeutic method and compositions for topical administration: There is provided a method for treating a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, photoageing of the face, photoageing of the hands and skin cancer which comprises administering topically to the skin of a patient in need of treatment a pharmaceutical composition...

20060159649 - Wet-skin treatment compositions using specific gum and acrylate systems for enhanced rheology: The invention relates to wet skin treatment compositions having specific gum and acrylate dispersion stabilizer systems providing enhanced rheology (e.g., lotion-like rheology and spreadability) relative to other wet skin compositions....

20060159643 - Cosmetic composition comprising at least one metallic dyestuff: Disclosed herein is a cosmetic composition for making up or caring for keratin materials, comprising, in a cosmetically acceptable medium, a fatty phase and at least one first dyestuff comprising at least one metallic substrate coated with at least one layer of at least one mineral material. Processes for making...

20060159642 - Mascara composition and method of using: s

20060159650 - Composition and method for covalently coupling an antithrombotic substance and a hydrophilic polymer: An antithrombotic composition includes a hydrophilic polymer backbone and an antithrombotic moiety covalently linked to the hydrophilic polymer backbone. The antithrombotic composition is formed by exposing a hydrophilic polymer including a hydroxyl group to an antithrombotic polysaccharide without having to first aminate the hydrophilic polymer....

20060159651 - Gradient molecular weight viscoelastic solutions: A viscoelectric solution for use in a cataract removal and IOL insertion procedure comprises, in a single applicator, a liquid composition of a solution of a compound which has a range of molecular weights from about 500,000 to about 3,800,000 daltons. The applicator is filled with the compound arranged so...

20060159652 - Gd2 ligands: The invention provides ligands of ganglioside GD2, including peptide ligands such as GGITNYNSALM; YCGGITNYNSACY; YCITNYNSCY; YCGGITNYNCY; YCTNYGVHCY; YCTNYGVCY; GGIANYNTS; YCGGIANYNCY; YCGGIANYNTSCY; and, YCIANYNTCY. GD2 ligands of the invention may for example be used to treat or diagnose diseases such as cancers in which cells express GD2, including neuroblastomas....

20060159654 - Protein belonging to the tnf superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof: A method of modulating immune response in an animal is disclosed. Such a method interacting the immature dendritic cells from the animal with an antigen ex vivo so that the immature dendritic cells present the antigen on their surfaces, inducing maturation of the immature dendritic cells ex vivo, and contacting...

20060159653 - Stabilized preparation containing protein: Protein formulations containing a poloxamer as a surfactant, and methods for maintaining the biological activity in protein formulations without adding an antioxidant and for inhibiting the formation of foreign insoluble matters by adding a poloxamer as a surfactant....

20060159656 - Formulations for il-11: Provided by the present invention are novel compositions and methods for obtaining concentrated preparations of IL-11 and formulations of IL-11 suitable for storage and administration....

20060159657 - Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders: Therapeutic formulations comprising an effective amount of IL-2 or other lymphokine and a biodegradable polymeric carrier having reverse gelation properties and the methods of use thereof for local or both local and systemic control of proliferative cell disorders is disclosed. The formulation can be administered intratumorally/peritumorally and forms an IL-2...

20060159655 - Treating immunological disorders using agonists of interleukin-21 / interleukin-21 receptor: Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R agonists can be used by themselves or in combination with anti-inflammatory agents to treat, e.g., ameliorate, symptoms associated with immunological disorders of the nervous system, e.g., multiple...

20060159658 - Methods of treating disease with glycosylated interferon: This invention includes methods for treating conditions with pharmaceutical compositions that comprise glycosylated interferon alpha. Pharmaceutical compositions that can be employed in the present invention include glycosylated interferon alpha 2 species in combination with pharmaceutical carriers, pharmaceutical excipients and/or other agents....

20060159659 - Seneca valley virus based compositions and methods for treating disease: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill...

20060159669 - Novel uses of ppar modulators and professional apcs manipulated by the same: The invention relates to a manipulated professional antigen presenting cell (APC) having increased expression of a CD1 type II molecule, preferably at least a CD1d molecule, relative to a control non manipulated cell. The invention further relates to the use of PPARg modulators in the preparation of a pharmaceutical composition...

20060159670 - Pharmaceuticals containing multipotential precursor cells from tissues containing sensory receptors: Current sources of neural stem and progenitor cells for neural transplantation are essentially inaccessible in living animals. This invention relates to neural precursor cells (stem cells, progenitor cells or a combination of both types of cells) isolated from the olfactory epithelium of mammals that can be passaged and expanded, and...

20060159660 - Method for producing working reagent and for biological prevention or control: The present invention provides an agent to be used in biocontrol and for preventing plants from suffering from disease. The agent includes a microorganism being active on an object; a modeling material mixing therein with the microorganism, and a modeling reagent shaping the modeling material mixed with the microorganism into...

20060159661 - Method for producing working reagent and for biological prevention or control: The present invention provides a method for an agent to be used in biocontrol and for preventing plants from suffering from disease. The method includes providing an agent having a microorganism object therein for controlling and preventing a plant lesion, making the agent contact a plant, and releasing the microorganism...

20060159663 - Growth factor encapsulation system for enhancing bone formation: This invention provides articles of manufacture, compositions of matter and methods related to a growth factor encapsulation system for enhancing bone formation....

20060159666 - Method of potentiating inflammatory and immune modulation for cell and drug therapy: A method for repairing animal tissue damage due to an inflammatory reaction in an animal has the steps of providing umbilical cord blood cells (UCBCs) in a pharmaceutically acceptable form; and administering a sufficient dose of UCBC at an optimal time thereby reducing the injury from the inflammatory reaction. Also...

20060159667 - Rapamycin-resistant t cells and therapeutic uses thereof: Methods for generating highly enriched Th1/Tcl and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also...

20060159668 - Resorbable extracellular matrix for reconstruction of bone: A bone healing combination material includes a matrix carrying cultivated bone-forming cells which may be osteocytes, osteoblasts, stromal stem cells or stem cells committed to differentiation into bone-forming osteoblasts. The matrix is a purified collagen matrix material derived from natural collagen-containing animal tissue, a collagen-free porous bone mineral matrix material...

20060159665 - Seed tear resistant scaffold: A seeded tear resistant scaffold comprising a biocompatible, tear resistant substrate, a biocompatible biodegradable material and optionally cells....

20060159662 - Therapeutic anti-melanoma compounds: The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the...

20060159664 - Tissue graft scaffold: Bioengineered tissue graft scaffolds and method for producing such scaffolds are provided. The scaffolds are useful to replace or repair damaged mammalian tissues and organs....

20060159671 - Uses of sysnergistic bacteriophage lytic enzymes for prevention and treatment of bacterial infections: Methods for treating and preventing bacterial infections are described using at least two lytic enzymes obtained from a bacteriophage isolated from Streptococci. Two of these enzymes, Pal and Cpl-1, showed synergy when tested for cleavage of peptidoglycan in the cell walls of Streptococcus pneumoniae. Moreover, the combination of these two...

20060159672 - Identification of self and non-self antigens implicated in autoimmune diseases: The present invention provides isolated peptides relating to the autoimmune disease Pemphigus vulgaris. The peptides relating to Pemphigus vulgaris are self epitopes derived from human pathogens which are implicated in the aetiology and remissions of the disease. Pharmaceutical preparations for tolerizing and/or immunizing individuals are provided as well as methods...

20060159675 - Compositions and methods for treating coagulation related disorders: Disclosed are methods for preventing or treating sepsis, a sepsis-related condition or an inflammatory disease in a mammal. In one embodiment, the method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to tissue factor (TF)...

20060159676 - Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions: Novel methods of inhibiting angiogenesis, lymphangiogenesis, tumorigenesis, inflammation, or metastasis, or promoting apoptosis with compositions that inhibit the apelin/APJ signaling pathway are provided. Also provided are methods of promoting angiogenesis or lymphangiogenesis, or inhibiting apoptosis with compositions comprising an apelin polypeptide or small molecule agonist. The present invention further provides...

20060159673 - Methods of screening light chain of antibody: The present invention relates to methods of screening for commonly shared light chains, in which the method comprises the steps of (a) generating a host secreting the heavy chain of an antibody that binds to a desired antigen; (b) introducing an antibody light chain library into the host of step...

20060159678 - Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy: The invention relates to the use of modulators of cytokine mediated signalling pathways in combination with integrin αvβ3 receptor antagonists for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising a modulator of cytokine mediated signalling pathways and an integrin αvβ3 receptor antagonist, for...

20060159674 - Signaling intermediates in an in vitro model of alzheimer's disease: The invention provides a novel human protein, FISH adaptor protein, involved in amyloid β-protein-mediated cell death. Also provided are methods for modulating amyloid β-protein-mediated cell death using agents that interfere with the activity of FISH adaptor protein....

20060159679 - Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants: Lyophilized compositions of TFPI or a TFPI variant suitable for long-term storage can be formed by lyophilizing an aqueous formulation of the TFPI or TFPI variant having a pH from about 4 to about 8 with a carbohydrate or amino acid glass forming agent. These lyophilized compositions are stable for...

20060159677 - Tumour necrosis factor peptide binding antibodies: Provided are isolated antibodies or fragments thereof which bind a peptide consisting of residues Gly54-Leu55-Tyr56-Leu57-Ile58-Tyr59-Ser60-Gln61-Val62-Leu63-Phe64-Lys65-Gly66-Gln67-Gly68 (peptide 308) of mature human TNF-α. The antibodies and fragments thereof may be used to identify antibodies capable of binding in the region of mature human TNF-α of amino acid resides 54-68. Antibodies or fragments...

20060159680 - Targeted apherisis for the treatment of rheumatoid arthritis: This invention uses “targeted apheresis” to treat rheumatoid arthritis patients. “Targeted Apheresis” is a process whereby the RF and immune complexes responsible for causing the disease symptoms are selectively removed from the blood by passing the blood through a cartridge containing immobilized IgG. The RF and immune complexes are bound...

20060159681 - Compositions and methods to inhibit cell loss by using inhibitors of bag: The present invention relates to inhibitors of BAG and uses thereof, such as to inhibit cell loss, inhibit parkin sequestration, and/or inhibit formation of protein aggregates. More specifically, the present invention relates to BAG inhibitors used to inhibit neurodegeneration and to treat a neurodegenerative disease, such as Parkinson's disease....

20060159685 - B7-related nucleic acids and polypeptides useful for immunomodulation: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated...

20060159684 - Compositions and methods for the threatment of sepsis: The present invention relates to compositions and methods for the prevention and treatment of blood-borne and toxin mediated diseases, and in particular anti-C5a antibodies for the prevention and treatment of sepsis in humans as well as other animals. The present invention also relates to methods of generating anti-C5a antibodies employing...

20060159682 - Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof: The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs...

20060159686 - Natural killer cell activating factor ii: The invention relates to NKAF II polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to...

20060159683 - Novel method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment: The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment....

20060159689 - Combinations of tumor-associated antigens in diagnostics for various types of cancers: Disclosed herein are methods for matching a cancer condition with an appropriate immunotherapeutic agent and/or regimen. Also disclosed are methods for confirming diagnosis of a particular type of cancer. Embodiments of the invention disclosed herein are directed to the use of effective combinations of TuAAs to optimize the match between...

20060159688 - Method for diagnosing efficacy of xenotypic antibody therapy: The invention concerns methods and compositions for intiating and/or enhancing an immune response by contacting a binding reagent with a soluble antigen, wherein the binding reagent-antigen pair generates an immune response to the antigen....

20060159687 - Modified aerolysin and methods of use for treating lung cancer: Disclosed herein are peptides that include aerolysin (or an aerolysin homolog) linked to an agent that specifically binds to a lung cancer cell, as well as nucleic acid sequences that encode such peptides. Methods of using such peptides and nucleic acid sequences to treat lung cancer are also disclosed....

20060159690 - H-y antigen: The present invention relates to a peptide which is immunologically recognizable as a T cell epitope of the minor Histocompatibility antigen H-Y. The peptide comprises amino acid sequence SPSVDKARAEL (SEQ ID NO: 1) or FIDSYICQV (SEQ ID NO: 2). The peptide is obtainable from the minor Histocompatibility antigen H-Y. Providing...

20060159694 - Combinations of tumor-associated antigens in compositions for various types of cancers: Disclosed herein are methods and compositions for inducing an immune response against various combinations of tumor-associated antigens, which can promote effective immunologic intervention in pathogenic processes. Embodiments of the invention disclosed herein are directed to the use of effective combinations of TuAAs for the immunotherapy of patients with various types...

20060159693 - Idiotypic vaccine: The present invention relates to idiotypic vaccine compositions for use in inducing immunity to p53. The invention preferably relates to a vaccine composition comprising a pharmaceutically acceptable carrier and at least one peptide, wherein the at least one peptide is selected from the group consisting of X1-LLQALKH-Y1, X2-FIRKAYGAATAYAASKKG-Y2 and X3-MQGLQTPYT-Y3...

20060159691 - Ptprk immunogenic peptide: An immunogenic peptide isolated from PTPRK protein represents a novel HLA II restricted epitope recognized by CD4+T cells and is used in cancer immunotherapy or diagnosis....

20060159692 - Transcriptional factor inducing apoptosis in cancer cell: A new method for treating cancer by inducing apoptosis exclusively in cancer cells and killing them is provided. The present invention relates to a transcriptional factor, comprising p53 or a mutated type p53, wherein one or more amino acids are deleted, substituted or added with respect to the amino sequence...

20060159695 - Anti-respiratory syncytial virus antibodies, antigens and uses thereof: Anti-Respiratory Syncytial Virus (RSV) monoclonal antibodies, RSV F protein antigens and their uses are disclosed....

20060159696 - Neutralizing epitope-based growth enhancing vaccine: The invention provides a fusion protein comprising a plant virus coat protein and a GDF8 peptide domain, or antigenic fragment of the GDF8 peptide domain. Plant virus vectors expressing the fusion protein and methods of using these vectors are also provided....

20060159697 - Modified bordetella adenylate cyclase comprising or lacking cd11b/cd18 interaction domain and uses thereof: The invention relates to modified Bordetella adenylate cyclase toxins which are deficient for CD11b/CD18 binding and to their use in the preparation of pharmaceutical composition for the treatment of whooping cough and/or for the protection against Bordetella infection. The invention also relates to specific fragments of Bordetella adenylate cyclase comprising...

20060159698 - Drug product for intestinal disease: The present invention provides a drug product for the prevention, improvement in conditions relating to, and/or treatment of intestinal disease, comprising β(1-3) glucan derived from vegetable material and having a molecular weight of from about 5,000 to about 20,000. The present invention can be widely employed as a drug product...

20060159699 - Flavivirus ns1 subunit vaccine: The present invention relates to NS1 proteins or parts thereof of Flaviviruses, in particular of Dengue viruses useful for vaccination against said Flavivirus and against one or more other Flaviviruses. The invention further concerns the NS1 protein or parts thereof of one Dengue virus serotype, in particular serotype 2, useful...

20060159700 - Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation: Immunogenic compositions for administration to adults particularly to the elderly, to protect them against disease caused by infection by respiratory syncytial virus and influenza virus comprise an immunoeffective amount of a mixture of purified fusion (F) protein, attachment (G) protein and matrix (M) protein of RSV and an immunoeffective amount...

20060159701 - Detoxified mutants of bacterial adp-ribosylating toxins as parenteral adjuvants: The present invention provides parenteral adjuvants comprising detoxified mutants of bacterial ADP-ribosylating toxins, particularly those from pertussis (PT), cholera (CT), and heat-labile E. coli (LT)....

20060159702 - Vaccine against gram-negative bacterial infections: A vaccine, effective in inducing the production of antibodies with which to immunize a second subject passively against infection by Gram-negative bacteria and LPS-mediated pathology, comprises a non-covalent polyvalent complex formed between purified, detoxified LPS derived from E. coli and purified outer membrane protein derived from N. meningitidis. The same...

20060159703 - Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences: Attenuated respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing specific mutations associated with attenuating phenotypes into wild-type or RSV which is incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. Alternatively, recombinant RSV and...

20060159704 - Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immunize against flavivirus and other infectious agents: The present invention relates to a vaccine against infections caused by flavivirus. More particularly to the use of the YF vaccine virus (17D) to express at the level of its envelope, protein epitopes from other pathogens which will elicit a specific immune response to the parental pathogen....

20060159705 - Purification of hbv antigens for use in vaccines: The present invention relates to a method for the production of a hepatitis B antigen suitable for use in a vaccine, the method comprising purification of the antigen in the presence of cysteine, to vaccines comprising such antigens....

20060159706 - Novel insertion sites in pox vectors: The present invention provides novel insertion sites for introducing DNA into pox vectors....

20060159707 - Lawsonia derived gene and related flge polypeptides, peptides and proteins and their uses: The present invention relates generally to therapeutic compositions for the treatment and/or prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by Lawsonia intracellularis or similar or otherwise related microorganism. In particular, the present invention provides a novel gene derived from Lawsonia intracellularis which encodes an immunogenic...

20060159708 - Diphtheria toxin variant: The present invention relates to methods and compositions of modified variants of diphtheria toxin (DT) that reduce binding to vascular endothelium or vascular endothelial cells, and therefore, reduce the incidence of Vascular Leak Syndrome. One aspect of the present invention relates to a polypeptide toxophore from a modified DT, wherein...

20060159709 - Recombinant high molecular weight major outer membrane protein of moraxella: An isolated and purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, having a molecular mass of about 200 kDa, is provided by recombinant means. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic...

20060159710 - Pertussis toxin gene:cloning and expression of protective antigen: A cloned gene encoding the expression of an antigenic mutant pertussis toxin with substantially reduced enzymatic activity has been described....

20060159713 - Bendamustine pharmaceutical compositions: The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases....

20060159712 - Lipid particles comprising bioactive agents, methods of preparing and uses thereof: The present invention relates to a non-liposomal lipid particle comprising an amphiphile-coated complex of a hydrophobic bioactive agent and an inverted hexagonal phase forming lipid, and methods of preparing and kits thereof....

20060159711 - Therapeutic agent for hemorrhoidal disease: An external preparation containing acetylsalicylic acid or its pharmaceutically acceptable salt as an active ingredient for treating anal diseases having therapeutic activity on hemorrhoids (internal hemorrhoid, external hemorrhoid), hemorrhoidal disease owing to anal fissure and other anal diseases together with activity on pain and pruritus....

20060159715 - Conjugate of fine porous particles with polymer molecules and the utilization thereof: A conjugate which comprises fine porous particles (on which functional substance may be adhered) and a polymer based on water-soluble high molecular chain segment, and the use of the conjugate (for the purpose of stably supporting, or slowly releasing, a physiologically active substance, or the like)....

20060159716 - Cosmetic emulsion comprising solid particles, method for preparing cosmetic emulsion, and method of using cosmetic emulsion: The present disclosure relates to a cosmetic composition for making up or caring for the skin in the form of an emulsion comprising an aqueous phase and an oily phase, comprising a dispersion of wax particles with a mean size by volume of less than or equal to 1 μm...

20060159714 - Use of an antioxidant in a dermatological and/or cosmetic composition: The invention relates to a dermatological and/or cosmetic composition which is intended for the treatment of acne, seborrheic dermatitis and skin disorders associated with the formation of comedones. The invention is characterised in that it contains: as active principle, at least one lipophilic antioxidant which is selected from the group...

20060159718 - Method for the production of porous carbon-based molded bodies, and use thereof as cell culture carrier systems and culture systems: The present invention relates to methods for producing carbon-based molded bodies. In particular, the present invention relates to methods for producing porous carbon-based molded bodies by carbonizing organic polymer materials mixed with non-polymeric fillers and subsequently dissolving the fillers out from the carbonized molded bodies. The present invention further relates...

20060159717 - Three dimensional cell protector/pore architecture formation for bone and tissue constructs: Living cellular material is encapsulated or placed in a protective material (cell protector) which is biocompatible, biodegradable and has a three-dimensional form. The three dimensional form is incorporated into a matrix that maybe implanted in vivo, ultimately degrade and thereby by replaced by living cell generated material....

20060159719 - Method and composition for inhibiting cardiovascular cell proliferation: Cardiovascular cell proliferation in a blood vessel subjected to trauma, such as angioplasty, vascular graft, anastomosis, or organ transplant, can be inhibited by contacting the vessel with a polymer consisting of from 6 to about 30 amino acid subunits, where at least 50% of the subunits are arginine, and the...

20060159720 - Bioresorbable sealants for porous vascular grafts: A bioresorbable sealant composition useful for impregnating implantable soft-tissue prostheses includes at least two polysaccharides in combination to form a hydrogel or sol-gel. The sealant compositions may optionally include a bioactive agent and/or be cross-linked subsequent to application of these compositions to the substrate surface....

20060159721 - Drug-containing implants and methods of use thereof: The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia...

20060159723 - Antimicrobial lenses and methods of their use: This invention relates to antimicrobial lenses containing coated zeolites and methods for their production....

20060159722 - Layered aligned polymer structures and methods of making same: This invention includes a method of producing a nanostructured artificial template comprising one or more thin, oriented layer of polymer material. The material is preferably produced by the method of introducing a shearing flow in a predominantly monomeric solution of the self-assembling polymer sub-units to the free surface of a...

20060159725 - Herbal compositions: A composition containing extracts obtained form Fructus Crataegi, Semen Zizyphus, Fructus Schizandrae, and Panax Ginseng. Also disclosed is a method of treating cancer or modulating an immune response in a subject and a method of inducing a cytokine in a cell with the composition....

20060159726 - Method and compositions for potentiating pharmaceuticals with amino acid based medical foods: The methods and compositions for potentiating pharmaceuticals with amino acid based medical foods provides improved cognitive function; induced and maintained sleep; reduced pain, inflammation, blood pressure, anxiety, asthma, duration of viral infection, insulin resistance, and appetite; and treated depression. The amino acid based medical foods, co-packed with at least one...

20060159724 - Nutritional supplement for the management of weight: Described herein is a low-glycemic nutritional supplement to be incorporated into the diet of an overweight or obese patient comprising low glycemic index ingredients including carbohydrate source, a source of protein, and a source of fat, and further comprising a source of green tea extract, a source of 5-hydroxytryptophan (5-HTP),...

20060159728 - Method of feeding milk replacer with carnitine: A method of the present invention includes feeding a calf a milk replacer at an enhanced rate with carnitine. The method of the present invention enhances weight gain, starter intake and reduces weaning time....

20060159727 - Prevention of systemic microbial infection: Composition and methods for the prevention of systemic bacterial infection comprising the oral administration of food, feed and/or major food/feed ingredients or water treated with a terpene composition, water and/or surfactant is disclosed. The composition of the invention can be administered as a spray mist over food and feed while...

20060159730 - Cosmetic or dermatological article comprising a medium that is soluble in water: A cosmetic or dermatological article may include: a medium in the form of at least one sheet of a material that is soluble in water at a temperature lower than 20° C.; and at least one cosmetic or dermatological compound carried by the medium....

20060159729 - Dissolvable pads for solution delivery to a surface: A dissolvable pad for delivery of a solution to a surface includes a water soluble substrate, and a solution retained in or on said water soluble substrate and available for use without activation by water. The water soluble substrate is soluble in water so as to be safely disposable into...

20060159731 - Multi-layer collagenic article useful for wounds healing and a method for its production thereof: A multi-layer collagen article useful for wound healing includes at least two layers; wherein at least one layer, facing the wound side, has an effective amount of non or partially cross-linked collagen; and at least one layer having an effective amount of highly cross-linked collagen matrices. A method for the...

20060159732 - Antioxidant wound dressing materials: A wound dressing material comprising a solid bioabsorbable substrate dyed with an antioxidant dyestuff. The substrate may comprise collagen, chitosan or oxidized regenerated cellulose, and the dyestuff may for example be an aniline or acridine dye. The material preferably also comprises a silver salt, whereby the dyestuff stabilizes the silver...

20060159733 - Method of providing hemostasis to a wound: The present invention is directed to hemostatic wound dressings that contain a substrate for contacting a wound, wherein the substrate includes a wound-contacting surface and is fabricated at least in part from a biocompatible aldehyde-modified polysaccharide having covalently conjugated there with a hemostatic agent and to methods of providing hemostasis...

20060159734 - Topical patch cooling preparation and methods for using the same: Topical patch preparations that contain an odorless physiological cooling agent, and methods for using the same are provided. The subject topical patch preparations are made up of an adhesive gel composition that is present on a support, where the adhesive gel composition includes the odorless physiological cooling agent, a water-soluble...

20060159738 - Cationic liposomes and methods of use: Highly efficient cationic liposomes are provided as a system for the delivery to cells of agents or compounds, such as, compounds capable of silencing a target protein and enzyme stubstrates. The cationic liposomes can be used in methods of detecting the inhibition activity or apparent activity of a target protein...

20060159740 - Hydrophobic photosensitizer formulations for photodynamic therapy: Pharmaceutical liposomal formulations for photodynamic therapy are presented, which are stable in storage as liquid formulations, comprise a hydrophobic photosensitizer and one or more synthetic phospholipids. The liposomal formulations provide therapeutically effective amounts of the photosensitizer for intravenous administration. The formed liposomes contain the hydrophobic photosensitizer within the lipid bilayer...

20060159736 - Liposome formulations of boronic acid compounds: A liposome composition comprised of liposomes having the peptide boronic acid proteasome inhibitor compound bortezomib entrapped in the liposomes is described. The boronic acid compound is entrapped in the liposomes in the form of a boronate ester, subsequent to interaction with a liposome-entrapped polyol. In one embodiment, the liposomes have...

20060159739 - Liposomes containing an entrapped compound in supersaturated solution: A liposome composition having a compound entrapped in a supersaturated solution and method for preparing such a composition are described....

20060159735 - Method of reclaiming drug compound from liposomal drug manufacturing stream: from a feedstock solution of the compound, comprises the steps of assaying a permeate wash for HSPC and cholesterol; processing the permeate wash to form a concentrated solution of the compound if the assay result is lower or equal to a predetermined value; and adding the concentrated solution to the...

20060159737 - Pharmaceutical compositions for local administration: A pharmaceutical composition for local application is disclosed, said composition comprising a nucleic acid as a therapeutic agent, an excipient and a pharmaceutically acceptable vehicle therefor, said excipient comprising a liposome. The excipient comprises an amphoteric liposome having an isoelectric point between 4 and 7.4 and said composition is formulated...

20060159743 - Methods of treating non-nociceptive pain states with gastric retentive gabapentin: Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of...

20060159741 - Pharmaceutical compositions comprising amoxicillin and clavulanic acid: The present invention relates to the formed particles comprising amoxicillin and clavulanic acid, the particles being obtained wet granulation. The invention also relates to the procedure for the preparation of these particles and to the pharmaceutical compositions comprising them....

20060159745 - Probiotic and preservative uses of oil-emulsified probiotic encapsulations: An encapsulation system is provided comprising nitrogen-purge, instant bonding encapsulation method. Specifically, the encapsulation system comprises a composition, a two-piece capsule comprising a capsule cap and a capsule body; a gas to purge oxygen from the composition within the capsule; and a sealing solution to seal the capsule cap to...

20060159742 - Stabilized individually coated ramipril particles, compositions and methods: The present invention relates to novel ramipril crystalline particles with improved stability and bioavailability. More particularly, the present invention is directed to individually coated, single ramipril crystalline particles for pharmaceutical and biopharmaceutical applications in oral therapies that are stabilized against decomposition into degradation products, namely, ramipril-DKP and ramipril-diacid, during formulation...

20060159744 - Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof: The present invention relates to timed dual release dosage forms of short acting hypnotics or salts thereof adapted to release the short acting hypnotic over a predetermined time period, according to a profile of dissolution characterized in that it comprises two release pulses, the first being immediate (lasting up to...

20060159746 - Compositions comprising fatty acids and amino acids: The invention relates to a combination, such as a combined preparation or pharmaceutical or nutritional composition, respectively, which comprises at least one cis-polyunsaturated fatty acid, at least one amino acid, and optionally at least one diabetes medicine for simultaneous, separate or sequential use in the prevention, delay of progression or...

20060159749 - Controlled release and taste masking oral pharmaceutical composition: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution...

20060159748 - Oral immediate release formulation of a poorly water-soluble active substance: The invention is related to an oral immediate release formulation of Benzazepin-1-acetic acid derivatives comprising a) said active substance in an amount of up to 65% of the total weight of the formulation; b) at least 10% w/w an alkaline compound or a mixture of alkaline compounds; c) between 0.1...

20060159750 - Pharmaceutical dosage form bearing pregnancy-friendly indicia: A pharmaceutical dosage form comprising at least one active ingredient and destined for administration to pregnant women. The pharmaceutical dosage form bears pregnancy-friendly indicia apt to improve patient compliance with medically recommended dosage regimen resulting in improved product effectiveness. The pregnancy-friendly indicia is also apt to diminish the incidence of...

20060159747 - Telmisartan and hydrochlorothiazide combination therapy: A pharmaceutical composition comprising about 80 mg of telmisartan or a salt thereof and about 25 mg of hydrochlorothiazide or about 160 mg of telmisartan or a salt thereof and about 50 mg of hydrochlorothiazide, and methods of treating hypertension in patients with such combination....

20060159751 - Controlled release pharmaceutical compositions of carbidopa and levodopa: The present invention relates to controlled release pharmaceutical compositions of carbidopa and levodopa that include a combination of different molecular weight cellulose ethers and in particular, hydroxypropyl cellulose ether....

20060159752 - Extended release matrix tablets: The present invention relates to extended release matrix tablets for oral administration that include a cationic polymer, a water-swellable polymer, and an alginic acid derivative to cause the release rate of the active ingredient of the tablets to be independent of pH and gastric residence time. The active pharmaceutical ingredient...

20060159753 - Matrix type sustained-release preparation containing basic drug or salt thereof: A matrix type sustained-release preparation and a manufacturing method therefor are provided wherein dissolution with low pH dependence of a basic drug or a salt thereof at the early stage of dissolution can be ensured in a dissolution test, and wherein as the dissolution test proceeds, a ratio of a...

20060159754 - Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent: The present invention is directed to solid, sustained-release, oral dosage form pharmaceutical compositions which contain therapeutic amounts of a pharmaceutically active agent, hydroxypropyl methyl cellulose and a non-ionic, hydrophilic polymer selected from the group consisting of hydroxyethyl cellulose having a number average molecular weight ranging from 90,000 to 1,300,000, hydroxypropyl...

20060159755 - Method for producing a controlled release preparation: The invention concerns a method for producing a controlled-release pharmaceutical preparation with a particle-containing coating, the coating being derived from an aqueous dispersion of a film-forming water insoluble polymer and a water soluble pore-forming agent. By suspending, instead of dissolving the pore-forming agent, the resulting coating will contain particles of...

20060159756 - Method to obtain microparticles containing an h+,k+-atp-ase inhibitor: A method for the preparation of homogeneous microparticles containing a H+,K+-ATPase inhibitor by a spray freezing technique characterized in that the medium to be atomized into droplets is having a high solid content and comprising besides the acid labile H+,K+-ATPase inhibitor also a polymer and a liquid in which the...

20060159757 - Pharmaceutical composition for controlled release of beta-lactam antibiotics in combination with beta-lactamase inhibitors: The invention relates to a pharmaceutical composition containing a β-lactam antibiotic and/or a pharmaceutically tolerable salt thereof in the form of coated pellets that may optionally contain a β-lactamase inhibitor and/or a pharmaceutically tolerable salt thereof, some or all pellets comprising coatings that dissolve at different pH values depending on...

20060159758 - Coating composition for taste masking coating and methods for their application and use: The present invention relates to coating compositions for taste masking and methods for applying the coating compositions to dosage forms to mask the taste of a medicinal substance. The taste masking coating compositions generally include a copolymer of acrylate and methacrylate with a quaternary ammonium group in combination with sodium...

20060159760 - Drug composition having active ingredient adhered at high concentration to spherical core: Granule, fine particle or tablet of excellent leaching property, comprising a drug active ingredient in high content realized by forming a layer containing drug active ingredient on core particles through a combination of a method of dispersing and adhering an active ingredient while spraying or adding a binder with a...

20060159761 - Stable extended release oral dosage composition: A film-coated extended release solid oral dosage composition containing a nasal decongestant, pseudoephedrine or salt thereof, e.g., pseudoephedrine sulfate in a core effective to provide a geometric maximum plasma concentration of pseudoephedrine of about 345 ng/mL to about 365 ng/mL at a time of about 7.60 hrs to about 8.40...

20060159762 - Stable pharmaceutical composition comprising an active substance in the form of solid solution: The present invention relates to a novel pharmaceutical comprising an active substance in the form of solid solution. The stability of active substance in the pharmaceutical composition is significantly improved relative to the stability of non-formulated active substance....

20060159759 - Tablet containing water-absorbing amino acid: The present invention provides a tablet which comprises a water-absorbent amino acid and a coating agent which is soluble in ethanol and hardly soluble in water. The tablet of the present invention is useful as amino acid preparations for sports, dieting, or pharmaceuticals, and also useful as nutritional supplements, pharmaceuticals...

20060159763 - Osmotic device containing amantadine and an osmotic salt: The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is modified from a first order release profile to a zero order, pseudo-zero order or...

20060159764 - Process of making a compound by forming a polymer from a template drug: A method of forming polymers in the presence of nucleic acid using template polymerization. These methods can be used for the delivery of nucleic acids, for condensing the nucleic acid, for forming nucleic acid binding polymers, for forming supramolecular complexes containing nucleic acid and polymer, and for forming an interpolyelectrolyte...

20060159767 - Nanoparticulate bicalutamide formulations: The present invention is directed to compositions comprising an acylanilide, such as bicalutamide, having improved solubility in water. The bicalutamide particles of the composition have an effective average particle size of less than about 2000 nm, and are useful in the treatment of prostate cancer....

20060159766 - Nanoparticulate tacrolimus formulations: The present invention is directed to nanoparticulate tacrolimus compositions. The composition comprising tacrolimus particles having an effective average particle size of less than about 2000 nm and at least one surface stabilizer....

20060159768 - Quetiapine granules: Granule formulation of quetiapine and pharmaceutically acceptable salt thereof are described, as are their preparation and their use in treating diseases of the central nervous system such as psychotic disease conditions including schizophrenia....

20060159769 - Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue: A delivery device including at least one stinging capsule and methods of use are described....

20060159770 - Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus: The present invention relates to the use of a composition for treating, preventing and/or improving metabolic dysfunctions associated with Type 2 diabetes mellitus and insulin resistance, said composition comprising intact whey protein, and to nutritional or pharmaceutical compositions and functional food products....

20060159771 - Tamponade compositions and methods for retinal repair: Described herein are methods of repairing retinal tissue using resorbable tamponade compositions that are heavier than aqueous humor and contain one or more glysosaminoglycans....

20060159772 - Fungicidal compositions: Fungicidal compositions are described, consisting of mixtures comprising salts of an alkaline or alkaline-earth metal, Mn or Zn of phosphorous acid and at least a second component selected from compounds having an antifungal activity. The component having an antifungal activity can be selected, for example, from IR5885, IR6141, copper (1)...

20060159773 - Herbal compositions containing hoodia: The present invention relates to herbal compositions containing the Hoodia gordonii and synergistically enhancing ingredients such as green coffee bean extract. The compositions are useful in controlling obesity and supporting the treatment of various health conditions related thereto, including Syndrome X. Methods of treatment using the compositions described herein are...

20060159775 - Chlorite in the treatment of neurodegenerative disease: The invention features methods of treating a macrophage-associated neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), or multiple sclerosis (MS) in a subject by administering chlorite in an amount effective to decrease blood immune cell activation. The invention also features methods of monitoring therapy by assessing blood...

20060159774 - Red tide organism killer: The composition is a red tide organism killer comprising between about 5 percent and about 15 percent sodium hypochlorite and between about 95 percent and about 85 percent inert ingredients in solution and a mixture of the composition and contaminated water. The composition is admixed into the contaminated water at...

20060159776 - Compositions comprising components coated with a liquid impermeable but gas permeable layer, use thereof for treating cutaneous and other exocrine gland diseases: The present invention relates to medically efficacious agents coated with substance that forms a liquid impermeable but gas permeable layer, the treatment of medical conditions therewith, and particularly medical conditions at least partially characterised by blockage or other malfunction of ducts of exocrine glands and especially ducts of sweat glands....

20060159777 - Aqueous acaricidal solution: Acaricidal aqueous solution comprising from 10 to 100 g/l of sodium bicarbonate. Use of this aqueous solution for treating elements of the human environment....

20060159779 - Extracts, compounds and pharmaceutical compositions having anti-diabetic activity and their use: The invention relates inter alia to pharmaceutical compositions containing an extract obtainable from a plant of the genus Trichocaulon or Hoodia having anti-diabetic activity; and to the use of such extracts and to compound (1) as herein defined and its analogues for the manufacture of medicaments having anti-diabetic activity....

20060159778 - Method of treatment and prophylaxis of people's adiposity: The present invention contains a non-medicamental method of the treatment and prophylaxis of an adiposity and also the normalization of a person's weight. This method is based on the inclusion in a diet during the treatment a big volume of the calorie-less, harmless, indigestible cellulose of plant or animal origin...

20060159780 - Prevention and amelioration of acetaminophen toxicity with tea melanin: The present invention relates to a method for preventing and/or reducing the toxicity of acetaminophen which comprises administering to a mammal an amount of tea melanin before or simultaneous with dosage of acetaminophen, a pharmaceutical composition containing tea melanin, and a pharmaceutical composition containing tea melanin and acetaminophen for preventing...

20060159781 - Anthocyanin-rich compositions and methods for inhibiting cancer cell growth: The present invention provides compositions and methods for inhibiting the growth and cell cycle progression in carcinoma cells comprising the step of contacting the cells with an anthocyanin rich extract (ARE) in an amount effective to inhibit the growth and cell cycle progression of the carcinoma cells without effecting the...

20060159782 - Material for promoting skin basement formation: A method for promoting skin basement membrane formation comprises administering matrix metalloproteinase inhibitor or matrix metalloproteinase inhibitor and matrix protein production promoting agent. The matrix metalloproteinase inhibitor is N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbutanamide hydrochloride....

20060159783 - Method for treating cancer using betulinic acid rich herbal extract: This invention relates to an orally effective herbal extract-based composition having broad-spectrum anticancer activity, more specifically a method of treating, inhibiting and/or preventing malignant tumors of the colon, intestine, stomach, breast, melanoma, glioblastoma, lung, cervix, ovary, prostate, oral cavity, larynx, liver, pancreas, kidney, bladder, endothelial cells, leukemia and myeloma using...

20060159784 - Polyherbal compositions and methods for treating viral infections: The present invention relates to pharmaceutical or veterinary or nutritional compositions of polyherbal extracts useful as anti-viral or immune-supporting agents. Particularly, the present invention of polyherbal composition comprises of extracts of Withania somnifera, Mangifera indica and purified Shilajit. This cost effective immune-supporting agent is ideal for use during the maintenance...

20060159786 - Application of dried nettle to the skin: The invention is directed to a composition and method in which dried stinging nettle is applied to the skin proximate a pain site to alleviate pain associated with various inflammatory conditions. The characteristic sting of the stinging nettle is absent in the dried nettle of the composition and method....

20060159785 - Method for isolation of sylimarin from sylibum marianum seeds: This invention relates to a method for isolation of sylimarin from silybum marianum seeds wherein the seeds are grinded without precooling. The follow defatting with hydrocarbon solvent, extraction with medium polarity solvent, removal of water from evaporating residue lagged after extraction, purification of dry extract, separation, washing and drying of...

20060159788 - Method and formulation for treating candidiasis using morinda citrifolia: The present invention features a novel use of processed ingredients from the Indian mulberry plant, and particularly a novel use of one or more processed Morinda citrifolia-based naturaceutical formulations comprising one or more of a processed Morinda citrifolia fruit juice, puree juice, oil or oil extract, dietary fiber, alcohol extract,...

20060159787 - Product with insect-repellent and/or insecticidal activity and method of production thereof: An insect-repellent and/or insecticidal product is described obtained by concentration of by-product vegetable water from olive milling, characterized in that it has a dry matter content of 10% or higher and a pH of 5 or higher; a method for the preparation of such a product is also described comprising...

20060159789 - Enhanced wound healing method, product and composition: A method of obtaining a pathogen shield from nut husks where the composition is useful in promoting the wound healing. The method includes collecting nut husks, extracting fluid resident in the husks, and storing the collected fluid. The extraction process is conducted in an inert environment thereby preventing oxidation of...

20060159790 - Composition for preventing or treating dementia comprising a hydroxycinnamic acid derivative or an extract of a plant of genus angelicae containing same: A composition for preventing or treating dementia comprising a hydroxycinnamic acid derivative of formula (I), decursinol, a pharmaceutically acceptable salt thereof or an extract of a plant of genus Angelicae containing same, wherein, R1 is H or CH3, R2 is —CH═CHCOOH or formula (a)....

20060153770 - Method of treating tumors: A method of treating tumors, such as prostate tumors, breast tumors, non-Hodgkin's lymphoma, and the like, includes the sequential steps of administering to the patient at least one dose of an antiangiogenic cyclo-arginine-glycine-aspartic acid-containing pentapeptide (cRGD pentapeptide); administering to the patient an anti-tumor effective amount of a radioimmunotherapeutic agent (RIT);...

20060153771 - Preparations for measuring gastric emptying ability: Preparations whereby reduction or acceleration of the gastric emptying rate can be noninvasively evaluated: and a method of evaluating the gastric emptying rate by using these preparations. Thus, reduction or acceleration of the gastric emptying rate can be safely and conveniently examined. Namely, theses preparations are useful in objectively diagnosing...

20060153772 - Contextual fear conditioning for predicting immunotherapeutic efficacy: The invention provides methods for determining effective immunotherapeutic agents which may be used for the treatment of cognitive disorders....

20060153774 - Contrast agent coated medical device: A magnetically opaque medical device is disclosed wherein a contrast agent is incorporated into the actual device. The medical device is generally comprised of a base material forming the structure of the device and a contrast agent, such as tocopherol and tocopherol derivative solutions or suspensions, gadolinium, or nickel sulfate...

20060153773 - Contrast medium for mri: Disclosed is an MRI contrast agent which enables direct detection and imaging of exfoliated vascular endothelial sites. The MRI contrast agent comprises an imaging unit which contains an unpaired electron-carrying atom and/or molecule and is capable of amplifying or reducing MRI signals, and a detection unit which is bonded to...

20060153775 - Compounds for targeting endothelial cells, compositions containing the same and methods for their use: The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy....

20060153776 - Echogen microparticles essentially used as a contrast agent for ultrasound exploration and/or as emboli for ultrasound detection: A composition for ultrasonic exploration including echogenic microparticles including a macromolecular network of reticulated hydrophilic polymers and/or copolymers which micro-particles have a diameter between 0.1 μm and 10 μm and are obtained from an inverse mini-emulsion of identical or different monomers or polymers....

20060153777 - Aerosol formulation for inhalation containing an anticholinergic: c

20060153779 - Delivery of stimulants through an inhalation route: The present invention relates to the delivery of stimulants through an inhalation route. Specifically, it relates to aerosols containing stimulants that are used in inhalation therapy. In a method aspect of the present invention, a stimulant is delivered to a patient through an inhalation route. The method comprises: a) heating...

20060153778 - Methods and compositions for minimizing accrual of inhalable insulin in the lungs: Inhalable insulin compositions are provided that rapidly clear from the lungs of patients. Additionally, methods of minimizing insulin accrual after administration of an inhaled insulin composition are disclosed....

20060153780 - Compositions comprising a potassium salt active ingredient, including oral compositions for reducing dental nerve and dentin sensitivity comprising a non-menthol flavoring: The subject invention provides a detergent composition comprising an effective amount of a soluble potassium salt, a sodium (C8-C24) alkylsulfate in an amount effective to remove or loosen debris and/or stains from a surface, and a polar surfactant, said surfactant comprising a hydrophobic portion selected from a (C6-C30) alkyl group...

20060153784 - Novel 2-benzoxazolyl benzene derivatives and their use as uv screening agents: wherein R1 is hydrogen, C1-20-alkyl or C2-20-alkenyl; R2 and R3 are independently a group —C(R4,R5)C(R6)═C(R7R8) (a) or a group —C(R4′,R5′)CH(R6′)CH(R7′,R8′) (b), wherein R4, R5, R6, R7, R8, R4′, R5′, R6′, R7′ and R8′ are independently, hydrogen, C1-10-alkyl or C2-10-alkenyl, or C2-10-alkyl or C3-10-alkenyl containing at least one oxygen atom interrupting...

20060153781 - Repair of dna mutagenic damage: Methods for protecting skin from UV-induced DNA mutagenic damage comprising administration of one or more of equol, dehydroequol, isoflav-3-ene and isoflavan compounds in admixture with a dermally acceptable carrier are described. Also described are methods for preventing skin cancer formation....

20060153782 - Skin photoageing and actinic damage treatment: Use of equol, dehydroequol, and other isoflav-3-enes are described for the prevention and/or treatment of skin photoageing and actinic damage. Methods of treating these conditions are also described....

20060153783 - Triazine derivatives as uv absorbers: The present invention relates to new compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, and R8 independently from each other are hydrogen; C1-C18alkyl; C2-C18alkenyl; C5-C7, cycloalkyl; C1-C6alkylene-C5-C7, cycloalkyl; R9 is hydrogen; C1-C18alkyl; C2-C18alkenyl; C5-C7cycloalkyl; C1-C6alkylene-C5-C7cycloalkyl; C6-C10aryl; A is —S—; —O— or —NR10—, wherein R10 has the...

20060153786 - Compositions and methods for treating conditions of the nail unit: The biodegradable drug delivery systems described here are formulated for implantation into the nail unit and its surrounding tissues for the treatment of various nail unit conditions. The systems include greater than 30% by weight of the active agent, and may be formulated as solutions, solids, semisolids, microparticles, or crystals....

20060153785 - Moisturizers comprising one or more of gamma-polyglutamic acid (gamma-pga, h form), gamma-polyglutamates and gamma-polyglutamate hydrogels for use in cosmetic or personal care products: The present invention relates to a moisturizer comprising γ-polyglutamic acid (γ-PGA, H form), and/or one or more of its salts (i.e., γ-polyglutamate in Na+ form, γ-polyglutamate in K+ form, γ-polyglutamate in NH4+ form, γ-polyglutamate in Mg++ form, γ-polyglutamate in Ca++ form) and/or γ-polyglutamate hydrogel, wherein said moisturizer is used in...

20060153787 - Whitening cosmetics: Whitening cosmetics contain (A) an oil-soluble chamomilla extract and (B) at least one oil selected from esters of carboxylic acids having 2 to 22 carbon atoms with alcohols having 1 to 22 carbon atoms and vegetable oils. These whitening cosmetics provide good feeling of use upon application, and moreover, are...

20060153788 - Enhanced efficacy antiperspirant active: An enhanced efficacy aluminum only salt active. The method for making such active comprises the steps of (a) providing an aqueous solution of an aluminum salt having a Band III polymer concentration of at least about 20%; (b) adding to the aqueous solution of step (a) an aqueous solution of...

20060153789 - Stimulation of hair regrowth: Hair loss is treated by administration of Substance P or a bioactive analog thereof. The subject may have loss of hair due to any of a variety of reasons, including chemotherapy, stress, radiation, male pattern baldness, nutritional deficit. The treatment can be conveniently administered by aerosol....

20060153790 - Two-phase composition and its uses in cosmetics: A composition having two separate phases, one above the other, the composition containing: (1) a bottom aqueous phase, (2) a top oil-in-water emulsion, and (3) at least one anionic surfactant chosen from the sodium salts of esters of dimethicone copolyol and sulphosuccinic acid. The two-phase composition has good cosmetic qualities,...

20060153791 - Repeat sequence protein polymer active agent congjugates, methods and uses: Biomolecular conjugates are provided which comprise the conjugation product of a repeat sequence protein polymer and at least one active agent. Additional aspects provide methods for their manufacture and various industrial and consumer applications....

20060153793 - Aqueous polymer dispersion and use thereof in cosmetics: The present invention relates to an aqueous polymer dispersion which is obtainable by free-radical polymerization of a monomer mixture which comprises at least one amide-group-containing compound, at least one crosslinker and at least one monomer with at least one cationogenic and/or cationic group. The invention further relates to the polymers...

20060153792 - Novel cosmetic formulations based on a gel-forming and/or thickening agent and applications of same: The invention relates to the field of the necessities of life and more particularly to the field of cosmetics, hygiene and skin products. More specifically it relates to aqueous, fluid or gelled, cosmetic compositions intended to be applied to the skin, the mucous membranes or the teguments, characterized in that...

20060153794 - Hair tonics and method of screening the same: There is provided a hair tonic comprising at least two of an inhibitor against 5α reductase type 2, an inhibitor against transforming growth factor β2, and an inhibitor against caspase-3; a method comprising screening for at least two of inhibition against 5α reductase type 2, inhibition against transforming growth factor...

20060153796 - Diisocyanate terminated macromer and formulation thereof for use as an internal adhesive or sealant: A novel macromer is described herein, comprising benzoyl isocyanate terminal moieties and at least two residues of a water-soluble polymer having a molecular weight ranging from 80 to 10,000 adjacent to the carbonyl group of the benzoyl isocyanate moieties, thereby forming at least two ester linkages in the macromer....

20060153795 - Nitric oxide-producing hydrogel materials: Hydrogels releasing or producing NO, most preferably polymerizable biodegradable hydrogels capable of releasing physiological amounts of NO for prolonged periods of time, are applied to sites on or in a patient in need of treatment thereof for disorders such as restenosis, thrombosis, asthma, wound healing, arthritis, penile erectile dysfunction or...

20060153800 - Dna immunization with recombinase/transposase: The present invention relates to improved methods to immunize/vaccinate or stimulate the immune system of animals, including humans, using vectors containing expression cassettes that encode for the DNA of one or more protein/peptide antigens and/or adjuvants, in particular, cytokines like GMCSF, Flt3L, interleukins, and the like, which can be encoded...

20060153802 - Mammalian chemokine reagents: A novel CC chemokine which is from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokine. A chemokine receptor is also provided. Methods of using said reagents and diagnostic kits are also provided....

20060153798 - Methods and compositions for needleless delivery of macromolecules: Methods and compositions for needleless delivery of macromolecules to the bloodstream of a subject are provided herein. In one aspect, the invention provides a delivery construct, comprising a receptor binding domain, a transcytosis domain, a macromolecule to be delivered to a subject, and a cleavable linker. In certain aspects, the...

20060153801 - Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same: A non-polydispersed mixture of conjugates in which each conjugate in the mixture comprises a drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugates. The mixture may be more effective at surviving...

20060153797 - Tissue material and matrix: The present invention relates generally to a tissue preparation including tissue cells and extracts thereof useful for promoting or facilitating the growth, development and differentiation of cells and tissues. More particularly, the present invention provides muscle-derived material comprising intact or extracted extracellular matrix and/or cells as well as cytokines, growth...

20060153799 - Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders: The present invention relates to the use of stem cell factor (SCF) polypeptide, alone and in combination with granulocyte colony stimulating factor (G-CSF) polypeptide, in the prevention or treatment of injury to the brain after cerebral ischemia or neurological disorder. More particularly, the invention provides methods of improving neurological function...

20060153803 - Inhibition of sars coronavirus infection with clinically approved antiviral drugs: The invention relates to methods for treating or inhibiting SARS-CoV infection involving the administration of an interferon, particularly IFN α-n1, IFN α-n3, human leukocyte IFN α or IFN β-1b....

20060153808 - Cancer immunotherapy incorporating p53: A method of stimulating an immune response to a tumor in an immunocompetent subject by administering a p53 expression construct to a tumor. The construct expresses p53 in tumor cells in an amount sufficient to stimulate an immune response against the tumor. Both viral and non-viral delivery systems are contemplated....

20060153804 - Nucleic acid coated particles: Particles are provided which are suitable for delivery from a particle-mediated delivery device. The particles are obtained by precipitating a nucleic acid on inert metal carrier particles in the presence of a nucleic acid condensing agent and a metal ion chelating agent. Also described are processes for preparing the particles,...

20060153810 - Process for preparing retrovirus vector for gene therapy: The present invention provides a process for preparing a retrovirus to be expressed at a high titer by specifically transferring a desired foreign gene into target cells. A pseudotyped retrovirus vector having a high titer can be prepared by transferring a DNA construction wherein a promoter, an loxP sequence, a...

20060153806 - Proteins involved in the regulation of energy homeostasis: The present invention discloses novel uses for energy homeostasis regulating proteins and polynucleotides encoding these in the diagnosis, study, prevention, and treatment of metabolic diseases and disorders....

20060153809 - Recombinant trail vectors and uses thereof: This invention provides a composition comprising a recombinant adeno-associated virus 2/5 (rAAV2/5) which encodes consecutive amino acids 114-281 of the amino acid sequence of the extracellular domain of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). This invention also provides a pharmaceutical composition comprising such composition and a pharmaceutically acceptable carrier. This...

20060153807 - Vector-mediated gene regulation in midbrain dopamine neurons: The present invention provides compositions and methods for vector mediated gene regulation in neurons. Specifically, the present invention provides therapeutic compositions comprising viral vectors that allow for the over-expression and RNAi mediated knockdown of genes in vivo. The present invention further provides methods for treating or preventing neurodegeneration in a...

20060153805 - Viral vectors and the use of the same for gene therapy: The invention relates to viral vectors comprising nucleic acid sequences coding for single chain interleukin-12 (single chain IL-12 or scIL 12) and a costimulator protein, and to the use of said vectors for gene therapy, especially for the treatment of tumours. The invention further relates to adenoviral vectors containing nucleic...

20060153821 - Induction of tumor and viral immunity using antigen presenting cell co-culture products and fusion products: Formulations comprising combinations of APCs and tumor cells and APCs and virally infected cells are disclosed. These formulations generally comprise hybridoma of at least one antigen presenting cell fused to either at least one tumor cell or at least one virally infected cell, or the products of co-cultures of antigen...

20060153820 - Materials and methods relating to the production and maintenance of cell lines: The invention provides methods for maintaining cell lines from primary cells, i.e. non-transformed cells, using expression of the signal transducer of activation and transcription (STAT). The methods are particularly suitable for the maintenance of B-cells....

20060153822 - Alcohol-tolerant malolactic strains for the maturation of wines with average or high ph: Lactic bacterial strains of the genera Lactobacillus and Pediococcus which are capable of initiating and carrying out a complete malolactic fermentation on direct introduction, in the dried, frozen or lyophilised state, without a previous acclimatization step, at a concentration of between 106 and 5×107 UFC/ml, into a wine with an...

20060153811 - Use of viruses and virus-resistant microorganisms for controlling microorganism populations: A lytic virus specific for a target strain of a microorganism and substantially free of undesirable genes may be utilized in processes including control of populations of microorganisms. The virus may include a host-range mutant, or “h-mutant.” A method for generating virus includes growing virus-resistant variants of a target strain...

20060153819 - Bone marrow stromal cells for immunoprotection of transplanted neural stem cells: The present invention encompasses methods and compositions for reducing an immune response to a transplant recipient receiving NSCs by treating said recipient with an amount of bone marrow stromal effective to reduce or inhibit host rejection of the NSCs....

20060153817 - Cartilage and bone repair and regeneration using postpartum-derived cells: Cells derived from postpartum tissue and methods for their isolation and induction to differentiate to cells of a chondrogenic or osteogenic phenotype are provided by the invention. The invention further provides cultures and compositions of the postpartum-derived cells and products related thereto. The postpartum-derived cells of the invention and products...

20060153818 - Cartilage and bone repair and regeneration using postpartum-derived cells: Cells derived from postpartum tissue and methods for their isolation and induction to differentiate to cells of a chondrogenic or osteogenic phenotype are provided by the invention. The invention further provides cultures and compositions of the postpartum-derived cells and products related thereto. The postpartum-derived cells of the invention and products...

20060153812 - Medium for stem cells to be used in intervertebral disk generation and regeneration of intervertebral disk using stem cells: A medium for stem cell in regeneration of intervertebral disc comprising an autologous serum obtained by sterilization and immobilization of serum of an individual having the intervertebral disc to be regenerated, a medium for cell culture and at least one antibiotic and a method for regenerating an intervertebral disc comprising...

20060153813 - Methods of producing differentiated hematopoietic cells for treatment of cytopenia: The present invention generally provides methods for producing differentiated hematopoietic cells, including macrophages, platelets, and granulocytes, by adding cytokines to cultured synchronized bone marrow stem cells at specific phases of the cell cycle. The invention further provides differentiated hematopoietic cells produced by the methods of the invention, as well as...

20060153814 - Porous, matrix, preparation thereof, and methods of using the same: A porous matrix, preparation thereof, and methods of using the same. The porous matrix of calcium alginate is prepared using a plurality of particles containing a multivalent cation, admixing the particles with ionic cross-linked polysaccharides and water to form a mixture, introducing a cross linker to solidify the mixture, dissolving...

20060153816 - Soft tissue repair and regeneration using postpartum-derived cells and cell products: Cells derived from postpartum tissue and products thereof having the potential to support cells of and/or differentiate to cells of a soft tissue lineage, and methods of preparation and use of those postpartum tissue-derived cells, are provided by the invention. The invention also provides methods for the use of such...

20060153815 - Tissue engineering devices for the repair and regeneration of tissue: Tissue engineering devices for use in the repair or regeneration of tissue made of support scaffolds and cell sheets....

20060153823 - Compositions and methods for nutritional supplementation: The present invention relates to compositions, that may be swallowable, chewable or dissolvable, comprising various vitamins, and in a specific embodiment, comprise vitamin B6, vitamin B12, folic acid, and CoQ10, and methods for using these compositions for nutritional supplementation in order to prevent, treat and/or alleviate the occurrence or negative...

20060153824 - Methods and kits for co-administration of nutritional supplements: The present invention relates to methods of co-administration of various vitamin and mineral compositions, and in a specific embodiment, comprise co-administering one composition comprising vitamin B6, vitamin B12, folic acid, and CoQ10 and a second composition comprising omega-3 fatty acids for nutritional supplementation in order to prevent, treat and/or alleviate...

20060153825 - Use of protein histidine phosphatase: The invention relates to the use of polypeptides with protein histidine phosphatase activity derived from mammalians, antibodies directed against them and DNA or RNA sequences complementary to mRNA sequences encoding polypeptides with protein histidine phosphatase activity for the modulation of ATP-citrate lyase and treatment of correlated pathophysiologic functions....

20060153826 - Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof: Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and to its application for genome engineering and gene therapy....

20060153827 - Chimeric protein: A chimeric protein is disclosed for promoting repair and regeneration of neurons damaged by disease or physical injury wherein the chimeric protein is a combination of a first polypeptide possessing matrix modification activity and a second polypeptide possessing regenerating activity for neural cells....

20060153828 - Method of reducing the viscosity of mucus: Disclosed is a pO157 plasmid-specified polypeptide found in E. coli EDL933 and other E. coli that binds to and cleaves C1-esterase inhibitor, and antibodies specific for the polypeptide. Also disclosed are methods employing the polypeptide for diagnosing enterohemorrhagic E. coli infection, identifying potential inhibitors of its activity, and reducing viscosity...

20060153830 - Proteases from carica having mitogenic activity and their methods of use: Proteases having mitogenic activity isolated from the genus Carica are provided. In particular the proteases are cysteine proteases isolated from Carica candamarcensis. In addition, the recombinant forms of the protease, including fragments and mutants with substantial homology are provided. Also provided are pharmaceutical compositions useful for treating wounds that include...

20060153829 - Stable formulations of purified proteins: This application provides methods of improving protein replacement therapy by combining protein replacement therapy with active site-specific chaperones (ASSC) to increase the stability and efficiency of the protein being administered. The application further provides stable compositions comprising the purified protein and an ASSC, and methods of treatment by administering the...

20060153831 - Antithrombosis enzyme from the snake venom of agkistrodon acutus: This invention features an antithrombosis enzyme extracted and purified from the snake venom of Southern-Anhui Agkistrodon acutus and pharmaceutical uses thereof....

20060153832 - Immunomodulating polymers: Methods and products for inducing IL-2 secretion, inducing IL-10 secretion, activating T cells, suppressing IgG antibody response to specific antigen, promoting allograft survival, reducing postoperative surgical adhesion formation, and protecting against abscess formation associated with surgery, trauma or diseases that predispose the host to abscess formation are provided. The methods...

20060153833 - Anti hepatitis c virus antibody and uses thereof: Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable aof neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are to vectors...

20060153838 - Fc region variants: The present invention provides polypeptide Fc region variants and oligonucleotides encoding Fc region variants. Specifically, the present invention provided compositions comprising novel Fc region variants, methods for identifying useful Fc region variants, and methods for employing Fc region variants for treating disease....

20060153836 - Molecules and methods for inhibiting shedding of kim-1: Disclosed are antibodies that inhibit proteolytic release of a soluble KIM-1 polypeptide from KIM-1 expressing cells. Also disclosed are methods of using the antibodies to inhibit shedding of the KIM-1 polypeptide....

20060153834 - Purification of immunoglobulins using affinity chromatography and peptide ligands: An immunoglobulin binding peptide having the general formula, from amino terminus to carboxy terminus, of Z-R1—R2—R3—R4—R5—R6—X, is described, wherein: R1 is H or Y; R2 is a hydrophobic, preferentially aromatic, amino acid (for example W, F, Y, V); R3 is a positively charged or aromatic amino acid (for example R,...

20060153837 - Treating autoimmune diseases with humanized anti-cd401 antibodies: The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases; and an immunosuppressant during transplantation of heterologous cells, tissues or organs, cell therapy, and gene therapy....

20060153835 - Treatment of pre-eclampsia in pregnant women using targeted apheresis: This invention uses “targeted apheresis” to treat pregnant women who are at risk of developing eclampsia. “Targeted Apheresis” is a process whereby the sFlt-1 receptors responsible for causing the disease symptoms are selectively removed from the blood by passing the blood through a cartridge containing either immobilized PIGF, and/or through...

20060153841 - B7-4 polypeptides and uses therefor: The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a...

20060153842 - Immunosuppressive combination and its use in the treatment or prophylaxis or insulin-producing cell graft rejection: A pharmaceutical combination comprising an accelerated lymphocyte homing agent in free form or in pharmaceutically acceptable salt form, and one or more compounds selected from the group consisting of an antibody to the IL-2 receptor, an immunosuppressive macrocyclic lactone and a soluble human complement inhibitor is used to treat or...

20060153840 - Methods for preventing or treating a condition or a disease associated with angiogenesis: A method for regulating angiogenesis in a subject in need thereof, comprising administering to said subject an effective amount of a substance capable of modulating the activity of a netrin-1 receptor....

20060153839 - Production of bispecific molecules using polyethylene glycol linkers: The invention relates to a bispecific molecule comprising a first recognition binding moeity that binds a Cab-like receptor cross-linked using a poly-(ethylene glycol) (“PEG”) linker with one or more second recognition binding moieties that bind a molecule. The invention also relates to methods of producing such bispecific molecules and to...

20060153843 - Method of immunomodulation: The present invention relates generally to a method for modulating the activity of cells of the immune system, including stimulator and responder cells and to agents useful therefor. More particularly, the present invention relates to a method for preventing or down-regulating one or more functional activities of stimulator and responder...

20060153844 - Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs: The present invention includes use of a biological response modifier (BRM) to modulate an immune response in a subject while avoiding or limiting common side-effects associate with BRM use. The BRMs of the present invention can be injected into a secondary lymphatic organ of the subject or into an area...

20060153850 - Antibodies to m-csf: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single...

20060153846 - Formulation of human antibodies for treating tnf-alpha associated disorders: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability....

20060153845 - Method for correcting immune respones and medical agent: The principle of the present invention is the use of an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to cytokines implicated in the course of inflammation, including autoimmune inflammation, the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably according to...

20060153847 - Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc: Described herein are methods and compositions for inhibiting, treating and reversing intervertebral disc disorders using transcription factor inhibitors. In certain embodiments, the transcription factor inhibitor targets the transcription factor NF-κB. Also described are methods and compositions where intervertebral disc disorder is reversed using a decoy oligodeoxy-nucleotide that blocks NF-κB....

20060153849 - Methods of treatment with an antibody that suppresses growth differentiation factor-14 activity: Growth differentiation factor-14 (GDF-14) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the GDF-14 polypeptide and polynucleotide sequences....

20060153848 - Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis: The present invention provides a synergistic composition and methods for treating neoplastic or cancerous growths as well as for treating such patients in order to restore or boost hematopoiesis. The present invention comprises administration of the combination of a cytotoxic T-lymphocyte inducing composition and at least one agent which is...

20060153851 - Clasp proteins: The present invention relates to a cell surface molecules, designated cadherin-like asymmetry proteins (“CLASPs”). In particular, it relates to CLASP-2 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP function....

20060153852 - Novel human jak2 kinase: The present invention provides a polynucleotide (hjak2) which identifies and encodes a novel human Jak2 kinase (HJAK2) which was expressed in the placenta. The present invention also provides for antisense molecules and oligomers designed from the nucleotide sequence or its antisense. The invention further provides genetically engineered expression vectors and...

20060153853 - Altered insulin-like grwoth factor binding proteins: Altered IGFBPs are able to bind IGF, but the release is inhibited by resistance to protease cleavage and/or reduced binding to extracellular matrix (ECM). Alterations have been made in IGFBP-2 to the linker domain in particular and to two amino acid motifs found to be important for ECM binding. IGF-1...

20060153854 - Antibody induced cell membrane wounding: Compositions and methods for inducing cell membrane wounding, cell permeabilization and cell killing are provided. The composition comprises a polyvalent agent that binds to a highly expressed cell surface antigen present on the surface of a cell. Preferably, the cell surface antigen is associated with the cytoskeleton of the cell....

20060153855 - Prevention and treatment of the porcine reproductive and respiratory syndrome (prrs): The present invention relates to the use of compositions of specific anti-PRSSV immunoglobulins obtained from the egg yolk of hens hyperimmunized with PRRS virus. The immunoglobulins are obtained through the extraction of the aqueous phase of the yolk through the use of hydroxypropylmethylcellulose phtalate at a final concentration of 0.05%...

20060153856 - P. aeruginosa mucoid exopolysaccharide specific binding peptides: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to P. aeruginosa mucoid exopolysaccharide. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of P. aeruginosa infection and related disorders (e.g., cystic fibrosis). Some antibodies of the invention enhance opsonophagocytic...

20060153857 - Method of treating staphylococcus aureus infection: The present invention provides a method of preventing or treating bacteremia caused by Staphylococcus aureus, comprising administering a monoclonal or polyclonal antibody composition comprising antibodies specific for one or more S. aureus antigens. In one specific embodiment, the composition is a hyperimmune specific IGIV composition. In another specific embodiment, the...

20060153859 - Ganglioside-klh conjugate vaccine with qs-21: This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject,...

20060153858 - Method of inducing a ctl response: Disclosed herein are methods for inducing an immunological CTL response to an antigen by sustained, regular delivery of the antigen to a mammal so that the antigen reaches the lymphatic system. Antigen is delivered at a level sufficient to induce an immunologic CTL response in a mammal and the level...

20060153861 - Bcr-abl imatinib resistance-associated peptides and methods of use thereof: The present invention is directed to immunogenic peptides, compositions and vaccines comprising same, and methods of use thereof for treating, inhibiting or reducing the incidence of a cancer associated with an activated kinase, and methods of generating a heteroclitic immune response against, or cytotoxic T cells specifically recognizing cancer cells...

20060153860 - Novel antigen-binding polypeptides and their uses: Novel antigen-binding polypeptides (ABP) and uses thereof are provided....

20060153864 - Papilloma virus-like particles, fusion proteins as well as processes for their production: The invention relates to the recombinant production of proteins as well as VLPs which are suitable as a vaccine for therapeutic and prophylactic vaccination. The invention also relates to processes for the production and purification of recombinant papilloma virus proteins and fusion proteins....

20060153862 - Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses: An immumogenic polypeptide for inducing antibodies that neutralize the immunosuppressive and/or angiogenic activity of an E7 protein from Papillomavirus, wherein said immunogenic polypeptide consists of an E7 protein from Papillomavirus that has been inactivated so as to eliminate at least 70% of the immunosuppressive and/or angiogenic activity of the non-inactivated...

20060153863 - Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory iga's: A method for inducing a mucosal immunity with production of secretory IgA antibodies that neutralize of block a native E7 protein originating from cancerous cells, from cells infected by a human Papillomavirus or from an immune system cell. The method includes administering to a patient in need thereof, a vaccine...

20060153865 - Antigenic peptides: A method for designing antigenic peptide libraries accounts for naturally occurring and potential variability in a group of protein sequences from a variable pathogen. The peptide libraries can elicit an immune response against a range of pathogen variants....

20060153866 - Novel antigen constructs useful in the detection and differentiation of antibodies to hiv: Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constructs containing additional Group O sequences...

20060153867 - Pharmaceutical formulation: A pharmaceutical formulation for a PKC modulatory peptide and a transport moiety comprising the aforementioned components and an anti-aggregant....

20060153868 - Process for the preparation of an improved brucella strain plasmid to develop the strain and the vaccine comprising the said strain: A Brucella bacterium is modified by partial or complete deletion of the pgm gene, rendering the bacterium incapable of synthesizing a key enzyme in the metabolism of bacterial sugars. A live vaccine for immunization, prophylaxis or treatment of brucellosis comprises such a bacterium, either lyophilized or in a pharmaceutical vehicle....

20060153869 - Multibacterial vaccines and uses thereof: The present invention provides methods for establishing standards for Gram-negative, Gram-positive, and mixed bacterial cultures. The present invention also provides methods for reproducing Gram-negative, Gram-positive, and mixed bacterial cultures. The present invention further provides methods for preparing multibacterial vaccines. Also provided are multibacterial vaccines prepared in accordance with these methods,...

20060153870 - Method for the recovery of non-segmented, nagative-stranded rna viruses from cdna: Methods for producing infectious, non-segmented, negative-stranded RNA viruses of the Order Mononegavirales are provided that involve coexpression of a viral cDNA along with essential viral proteins, N, P, and L in a host cell transiently transfected with an expression vector encoding an RNA polymerase. In alternate methods, after the host...

20060153871 - H3 equine influenza a virus: The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof....

20060153872 - Methods of producing influenza vaccine compositions: Methods and compositions for the optimization and production of influenza viruses, e.g., ca influenza B strains, in eggs and host cells suitable as influenza vaccines are provided....

20060153874 - Recombinant poxvirus comprising at least two compox ati promoters: The invention concerns recombinant poxviruses comprising in the viral genome at least two expression cassettes, each comprising the cowpox ATI promoter or a derivative thereof and a coding sequence, wherein the expression of the coding sequence is regulated by said promoter. The virus may be useful as a vaccine or...

20060153873 - Smallpox vaccine: The invention provides attenuated vaccinia virus vaccines that can be used in methods to prevent or treat small pox in patients, as well as methods of obtaining such vaccines....

20060153875 - Novel brachyspira hyodyseteriae vaccine: The present invention relates to nucleic acid sequences encoding a 61 kD and a 20 kD Brachyspira hyodysenteriae lipoprotein and to parts of such nucleic acid sequences that encode an immunogenic fragment of such lipoproteins, and to DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such...

20060153876 - Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease: Compositions and methods of modulating cellular function and treatment of disease in mammals comprising locally administering a regulated SNARE inhibitor and a translocating agent to the mammal. Regulated SNARE inhibitors include clostridial neurotoxins, tetanus neurotoxin and their free light chain portions and IgA protease. Translocating agents include acids, encapsulating vectors,...

20060153877 - Remedies for dissease with hypermyotonia: An M toxin of type A botulinum toxin (HA-negative substance) and a mixture of L toxin and LL toxin (HA-positive substance) are compared and examined in inhibitory action for neuromuscular transmission and therapeutic index. As a result, it is found that M toxin of type A botulinum toxin has characteristics...

20060153878 - Adhesin as immunogen against enterotoxigenic escherichia coli: The inventive subject matter relates to the methods for the induction of immunity and prevention of diarrhea resulting from Escherichia coli. The inventive subject matter also relates to the use Escherichia coli adhesins as immunogens and to the construction of conformationally stability and protease resistant Escherichia coli adhesin constructs useful...

20060153879 - Streptococcal c5a peptidase vaccine: Novel vaccines for use against β-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP,...

20060153880 - Pharmaceutical use of alpha antigen or alpha antigen gene: The α antigen-encoding gene and the α antigen protein suppress the production of interleukin-4 etc., improve the Th2 type cytokine-dominant state, and furthermore inhibit various conditions of allergic diseases such as IgE production, histamine release and eosinophil infiltration, and therefore they are very effective for the prevention or treatment of...

20060153881 - Anti-plasmodium compositions and methods of use: Compositions that inhibit the binding of Plasmodium falciparum to erythrocytes include a family of erythrocyte binding proteins (EBPs). The EBPs are paralogues of the P. falciparum binding protein EBA-175. The present invention includes peptides of the paralogues that prevent the binding of P. falciparum. Antibodies specific for each paralogue that...

20060153882 - Anti-allergic pharmaceutical composition containing at least one allergen and at least on antihistamine compound: The present invention relates to an anti-allergic pharmaceutical composition containing at least two active agents chosen among: (i) one allergen, (ii) one antihistamine compound, (iii) one inhibitor of histamine synthesis, said active agents being associated in said composition with a pharmaceutically acceptable vehicle....

20060153883 - Hm1.24-utilizing cancer vaccines: A cancer vaccine containing as an active ingredient an antigen-specific dendritic cell pulsed by an HM1.24 protein, HM1.24 peptide or transduced with an HM1.24-encoding gene, or HM1.24 protein-encoding DNA or RNA....

20060153884 - Peptide fragments of the harp factor inhibiting angiogenesis: Peptide fragments 13-39 and 65-97 of the HARP factor, which inhibit angiogenesis. Advantageously, the peptides can be associated with the peptide 111-136 of HARP. The invention also concerns pharmaceutical compositions comprising the peptides or nucleic acids encoding the peptides, and their use for treating pathologies associated with an angiogenesis, in...

20060153885 - Dry eye treatment: This invention relates to an emulsion composition for the formation of an artificial tear film over the ocular surface of the eye capable of providing mechanical lubrication for the ocular surface while reducing evaporation of fluid therefrom. The emulsion is desirably in the form of a meta stable emulsion and...

20060153886 - Ambiphilic porous matrix: Compositions are described which are capable of forming external reservoirs comprising a polymeric matrix for adsorbing sebum in exchange for beneficial oils and transfer of hydrating components to the skin. The compositions may be lotions, creams, gels, pastes, lip sticks and water and oil systems. There is also described a...

20060153887 - Cosmetic article and process for obtaining a cosmetic article in a unit dose: A COSMETIC ARTICLE AND PROCESS FOR OBTAINING A COSMETIC ARTICLE IN A UNIT DOSE, said cosmetic article comprising: a base substrate (10) having an upper face (11); a cosmetic product (20) which is deposited and retained, in a unit dose, onto a load region (13) of the upper face (11)...

20060153889 - Discontinuous surface coating for particles: The present invention relates to particle compositions comprising a core particle that is partially coated with a first hydrophilic deposit and a hydrophobic polymeric finish, contains a small amount of water, and a compatible active present in the deposit, the finish or both. Additional alternating deposits, hydrophobic, hydrophilic or both,...

20060153888 - Methods for scavenging oxidizing nitrogen and oxygen species with fragrances having antioxidative properties: Methods and compositions for scavenging reactive molecules, including free radicals, reactive oxygen and reactive nitrogen species, in the air are described. More specifically, methods and compositions for scavenging reactive molecules in the air before the reactive chemicals contact the skin or other tissue surface are described. The scavenging occurs by...

20060153890 - Insect repellent: or a supernatant or a squeezed liquid obtained by squeezing leaves, flowers, branches, stems, or roots of the spiraea group plants or grinding together with water and other solvent leaves, flowers, branches, stems, or roots of the spiraea group plants are used as an insect repellent as it is or...

20060153891 - Meta-stable insect repellent emulsion composition and method of use: There is provided an improved insect repellent emulsion composition. The composition has an inner discontinuous phase and an outer continuous phase. The inner discontinuous phase and/or outer continuous phase has an insect repellent active therein. The inner discontinuous phase is generally dispersed in the outer continuous phase and is in...

20060153892 - Protein-resistant articles: This invention relates to the reduction of interaction of biological systems with foreign substrates. Some applications require that the contact of a biological fluid with a foreign surface, such as a container for that fluid, have minimal interactions with that surface. Because the adsorption of proteins at surfaces mediates much...

20060153895 - Drug-containing implants and methods of use thereof: The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia...

20060153896 - Methods and devices for improving biofixation of implantable vascular devices: Methods and devices for improving biofixation of implantable vascular devices are provided. The methods and devices improve biofixation of implantable vascular devices by providing one or more thrombus-eliminating agents at a treatment site before and/or during and/or after vascular device implantation....

20060153894 - Multi-compartment delivery system: This invention provides devices designed to effectively deliver multiple biological entities in combination for tissue engineering. In particular, the present invention provides devices capable of delivering cells or clusters of cells, such as islets of Langerhans, in combination with a therapeutic compound, such as an angiogenic growth factor, for the...

20060153893 - Therapeutic composition for bone infectious disease: A biodegradable composition containing an antibiotic or a physiologically active substance for use in surgical treatment of infection. A highly safe and biocompatible composition showing appropriately sustained release of an antibiotic or physiologically active substance which produces excellent antibiotic and bone regenerating effects. A composition having excellent effects in treatment...

20060153898 - Nocturnal muscle enhancing composition and method: A method and nutrient supplement composition for nocturnal administration to human subjects where the nutrient supplement composition includes both a sustained timed release portion and a rapid release portion, both portions containing a mixture of edible food proteins and edible amino acid building blocks with a portion of these key...

20060153899 - Palatinose for enhancing dietary supplement and pharmaceutical delivery: The present invention is directed to a dietary supplement comprising palatinose or a derivative thereof. The dietary supplement may be a nutritional product, a sports performance product, a weight loss product or a meal replacement product. The present invention is also directed to a method of increasing the absorption of...

20060153897 - Zinc-containing foods: It is intended to provide foods such as health (supplementary) foods, nutrition (supplementary) foods and foods with health claims (foods for specified health uses and foods with nutrient function claims) containing zinc compositions which are less toxic and have a high insulin-like activity. Foods containing organic compounds capable of forming...

20060153900 - Dietary supplement for treatment of lipid risk factors: A dietary supplement is provided for the treatment of lipid risk factors comprising nicotinic acid, pantethine and lemon/orange flavonates. This supplement provides significant benefit in affect on major cardiovascular disease (“CVD”) lipid risk factors, including LDL-C, HDL-C, and Tg in a non-prescription formulation. Also described are methods for treatment of...

20060153901 - Method and composition for the control of gastrointestinal parasites in animals: The present invention provides methods and compositions for controlling gastrointestinal parasitic infections in animals. More specifically, the invention involves the use of sericea lespedeza (Lespedeza cuneata), commonly referred to as Chinese bush clover, in the diet of animals to control nematodal gastrointestinal infections....

20060153902 - Overexpression of phytase genes in yeast systems: The present invention relates to a method of producing a heterologous protein or polypeptide having phytase activity in a yeast system. The invention also provides proteins having phytase activity which have increased thermostability. Yeast strains which produce a heterologous phytase and the vectors used to produce the phytase are also...

20060153903 - Polymer sustainedly -release polymer amino acid derivative, cosmetic and fiber construct containing the polymer of producing the same and method for regenerating the same: The object of the present invention is to provide a polymer which achieves an effect of supplementing the water-retaining function of horny layer and keeping the normal skin by a gradual supplying of an amino acid derivative to the skin through moisture containing electrolyte salt such as sweat perspired from...

20060153904 - Non-woven fiber assemblies: A non-woven fiber assembly comprises one or more fibers containing an adhesive component, an elastomeric component, and a hydrophilic component. A method of making a non-woven fiber assembly comprises the steps of providing one or more fiber-forming materials comprising an adhesive component, an elastomeric component, and a hydrophilic component, and...

20060153905 - Transdermal pharmaceutical formulation for minimizing skin residues: This invention relates to novel transdermal or transmucosal pharmaceutical formulation which reduces the occurrences of contamination of other individuals and the transference to clothing of the user. The novel formulation includes at least one pharmacologically active ingredient, and a solvent system having a monoalkylether of diethylene glycol and a glycol...

20060153907 - Liposome formulations of boronic acid compounds: A liposome composition comprised of liposomes having a peptide boronic acid proteasome inhibitor compound entrapped in the liposomes is described. The boronic acid compound is entrapped in the liposomes in the form of a boronate ester, subsequent to interaction with a liposome-entrapped polyol. In one embodiment, the liposomes have an...

20060153906 - Pharmaceutical product for endonasal administration for treating central nervous system disease and disorders: The invention concerns a pharmaceutical product consisting of one or more standard active substances and/or of one or more standard metabolites acting on the central nervous system. Said active substances are added with substances acting on the nasal mucous membrane for endonasal administration....

20060153909 - Hard capsule: The present invention is directed to a hard capsule filled with a solution containing an active ingredient, characterized in that the solution contains an inorganic chloride and has a water content (w) of 10<w≦80% and a water activity (a) of 0.50≦a≦0.90, and that the capsule is made of a base...

20060153910 - Lowering blood glucose, urea, cholesterol, triglycerides and normalizing homocysteine levels by dietary addition of selected essential amino acids and three vitamins: Administration of a dietary supplement consisting of L-Tryptophan (80 mgs), L-Methionine (90 mgs), L-Valine (103 mgs), L-Lysine Monohydrochloride (128 mgs), Vitamin B-12 (0.5 mg), Vitamin B-6 (10 mgs), and Folic Acid (0.4 mg) has been shown to reduce postprandial peak blood glucose, lower urea formation, reduce cholesterol and triglyceride blood...

20060153911 - Method for preserving reduced coenzyme q10: The present invention has its object to provide a method for stably preserving a capsule containing reduced coenzyme Q10, which is useful as foods, functional nutritive foods, specific health foods, nutritional supplements, nutrients, animal drugs, drinks, feeds, cosmetics, medicines, remedies, preventive drugs, etc. The present invention relates to a method...

20060153908 - Spherical pellet formulations: A process for preparing spherical pellets comprising (a) a water-soluble active ingredient soluble, freely soluble or very soluble in water; and in particular having a water-solubility of ≧0.5 g/ml; (b) a spheronizing agent; (c) a dry lubricant, said method comprising preparing a mixture of the active ingredient, the spheronising agent,...

20060153912 - Choline ascorbate formulations: The invention relates to novel choline ascorbate-containing formulations; processes for their preparation and their use in human or animal foods, or human or animal food supplements or pharmaceuticals....

20060153913 - Solid formulation with improved solubility and stability, and method for producing said formulation: The present invention relates to a solid formulation with improved solubility and maintained stability including a chemical substance poorly soluble in water as a pharmaceutically active ingredient formulated in an improved manner. More specifically, the present invention relates to a solid formulation having improved water-solubility which comprises a chemical substance...

20060153914 - Chronotherapeutic diltiazem formulations and the administration thereof: A controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg or more (as desired) of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form...

20060153915 - Sustained-release preparations and method for producing the same: The present invention relates to sustained-release preparations prepared by double granulation and methods for producing the same. The sustained-release preparation according to the present invention enables maintenance of effective blood concentration of drug for many hours via sustained release of the drug over 12 hours or more, and further its...

20060153917 - Enteric coated bead comprising ixabepilone, and preparation and administration thereof: e

20060153916 - Novel dosage form: A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active...

20060153918 - Dosage forms with an enterically coated core tablet: The present invention provides a pharmaceutical dosage form for oral administration to a patient comprising an enterically coated core tablet sheathed in an annular body of compressed powder or granular material. The present invention also provides a pharmaceutical dosage form for co-administration of two or more active pharmaceutical ingredients. The...

20060153919 - Ligand-mediated controlled drug delivery: Disclosed are systems and methods that can be utilized to define and control the delivery rate of a biological agent from a carrier matrix such as a biocompatible hydrogel. The carrier matrices of the present invention can include ligands incorporated within the matrix at a predetermined concentration level (CLT). In...

20060153920 - Lyophilized pharmaceutical compositions: Pharmaceutical compositions that include a poorly water-soluble therapeutic compound, an aqueous solvent, a nonvolatile cosolvent and a bulking agent. The pharmaceutical compositions can be orally ingested or administered parenterally. The pharmaceutical compositions can further be lyophilized to form a pharmaceutically acceptable cake that can be administered orally, e.g., as a...

20060153922 - Light induced immobilisation: The present invention involves a method of coupling disulfide bridge containing proteins to a carrier by inducing the formation of thiol groups on a protein with irradiation, and coupling the protein to the carrier. The formation of thiol group(s) in the protein is a consequence of the disruption of disulfide...

20060153921 - Method for preparation of particles from solution-in-supercritical fluid or compressed gas emulsions: The present invention provides a method of producing particles from solution-in-supercritical fluid or compressed gas emulsions. In accordance with the method of the invention, a solution that includes a solute dissolved in a solvent is contacted with supercritical fluid or compressed gas to form a solution-in-super critical fluid or compressed...

20060153923 - Nanoparticles of polypoxyethylenated derivatives: The invention relates to nanoparticles of polyoxyethylenated derivatives, having a size of less than 1 micrometer, for the administration of pharmaceutically- or cosmetically-active ingredients. The inventive nanoparticles comprise a biodegradable polymer, a polyoxyethylene-derived block copolymer and at least one pharmaceutically- or cosmetically-active ingredient. The invention further relates to the method...

20060153925 - Novel solid pharmaceutical composition comprising amisulpride: The invention relates to a solid pharmaceutical composition for oral administration of amisulpride, which comprises at least one coated amisulpride particle and at least one pharmaceutically acceptable excipient suitable for an orodispersible administration of the composition....

20060153924 - Selection by compartmentalised screening: The invention describes a method for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, by compartmentalizing the compounds into microcapsules together with the target, such that only a subset of the repertoire is represented in multiple copies...

20060153926 - Compositions, products and methods for controlling weight in a mammal: Compositions for controlling mammalian weight, said compositions comprising one or more lipolytic agents for stimulating mammalian lipolysis and/or thermogenic agents for modulating mammalian thermogenesis. Products, consumer and otherwise, comprising said compositions and methods of using both the present compositions and products to control mammalian weight....

20060153927 - Physiological tissue repair and functional organ regeneration by cultivation of regenerative stem cells in vivo and in situ: The present invention provides novel compositions and methods for pharmaceutical or nutraceutical use in an animal, preferably in a human. In one aspect, compositions and methods are provided for promoting cell growth, tissue repair and organ regeneration, preferably in vivo and in situ. The composition comprises a sterol compound dissolved...

20060153928 - Aminion-origin medical material and method of preparing the same: It is intended to provide an amnion-origin medical material which can be easily handled and fully sterilized and, moreover, favorably acts as a base material for forming a cell layer thereon. This material is prepared by: (i) removing the epithelial layer from the amnion while remaining at at leaset a...

20060153929 - Use of solid phase synthesis to modify and to assemble nanoparticles: Methods of modifying nanoparticle surfaces using solid phase synthesis, methods of releasing nanoparticles from solid phase synthesis supports using photolytic cleavage, and methods of assembling nanoparticle structures are disclosed. Nanoparticles comprising a positionally distinguishable surface area comprising a ligand are also disclosed....

20060153930 - Drug-containing sustained release microparticle, process for producing the same and preparation containing the microparticle: Sustained release microparticles suitable for various types of drugs, or drug-containing sustained release microparticles capable of sustained release of drugs over a period of three days or more and capable of inhibiting initial burst release; a process for producing the same; and preparations containing the microparticles are disclosed. The drug-containing...

20060153932 - Method of treating hyperphosphataemia using lanthanum hydroxycarbonate: This disclosure relates to the treatment of subjects at risk for chronic kidney disease (CKD), having stage one to five CKD, having hyperphosphataemia, susceptible to or suffering from soft tissue calcification associated with CKD, or susceptible to or suffering from hyperparathyroidism, by orally administering a pharmaceutical composition containing a therapeutically...

20060153931 - Prevention of flap necrosis in plastic surgery: NO, NO donor or prodrug that causes formation of nitrosothiol in tissue optionally in combination with lidocaine is topically applied to pedicle of a pedicle flap or other source of blood supply to prevent necrosis in pedicle flap or in any microvascular surgery. Composition containing drug is formulated with nitrosylated...

20060153933 - Synergistic compositions: Synergistic compositions useful as fungicides, comprising aminosulfones and at least one other fungicide are provided....

20060153934 - Combination therapies of cicletanine and magnesium: Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing hypertension and complications in patients with diabetes and/or metabolic syndrome. More particularly, aspects of the present invention are related to using a combination of cicletanine and magnesium for treating and/or preventing...

20060153935 - Stabilizing salicylate compositions and method of preparation for oral and topical use: Salicylic acid or acetylsalicylic acid are combined with citric acid and then mixed with a concentrated potassium hydroxide solution to form a stable compound of either potassium salicylic acid or potassium acetylsalicylic acid that can be used to make lotions, creams, gels or ointments for topical formulations or mixed to...

20060153936 - Flavonoid solubilizing agent and method of solubilizing flavonoid: A flavonoid solubilization agent capable of highly solubilizing flavonoids such as isoflavone, baicalin, rutin and naringin whose solubility is generally low; and a method of effecting the above solubilization. Flavonoids can be solubilized by causing a flavonoid and soybean saponin and/or malonyl isoflavone glycoside to be co-present in an aqueous...

20060153937 - Synergistic composition for the treatment of diabetes mellitus: The present invention relates to a synergistic composition for the treatment of diabetes in a subject in need thereof, said composition-comprising Trigonelline of concentration ranging between 20 to 30%, amino acids of concentration ranging between 20 to 60%, and soluble fiber of concentration ranging between 10 to 60%, optionally along...

20060153938 - Eye -rinse solution made of grape juice: This is an eye-rinse remedy solution which relieves migraine headaches. There are two ingredients to this solution. They are unpolluted, filtered or distilled water and the juice from the fresh grapes. The preferable solution is one part water (H2O) to the one-half part to one part juice from fresh grapes....

20060153939 - Method of obtaining and treating compounds from ozonized unsaturated vegetable oils for pharmaceutical compositions for medical and veterinary use: The invention relates to a method of obtaining a stable product of natural vegetable origin, particularly macadamia oil, which is treated in a reactor in which the oil is exposed to a continuous flow of ozone and, subsequently to a feedback of end gases under the influence of an electromagnetic...

20060153940 - Use of physiologically active fatty acids: Compositions comprising physiologically active fatty acids, salts and esters thereof are disclosed, and may be used in combination with extracts of Castanea sativa or active principles thereof for treating lipodystrophy by administering to a patient in need thereof....

20060153941 - Pharmaceutical compositions comprising cabbinochreme type compounds: The invention relates to the use of cannabichromene type compounds and derivatives thereof in the treatment of mood disorders....

20060147371 - Water-soluble compound: A water-soluble magnetic anti-mitotic compound with a water-solubility of at least 100 micrograms per milliliter, a molecular weight of at least 150 grams per mole, a mitotic index factor of at least 10 percent, a positive magnetic susceptibility of at least 1,000×10−6 cgs, and a magnetic moment of at least...

20060147375 - Antibodies and related molecules that bind to psca proteins: w

20060147373 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same....

20060147374 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same....

20060147372 - Dna encoding mck-10, a novel receptor tyrosine kinase: The present invention relates to the novel family of receptor tyrosine kinases, herein referred to as MCK-10, to nucleotide sequences and expression vectors encoding MCK-10, and to methods of inhibiting MCK-10 activity. The invention relates to differentially spliced isoforms of MCK-10 and to other members of the MCK-10 receptor tyrosine...

20060147376 - Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier: The present invention provides a controllably degradable cationic polymer for delivery of biomolecules (nucleic acids, peptides, etc.), drugs, molecules used in medical imaging applications, sensitizing agents used in cancer treatments, and molecules used in tissue engineering. The present invention also provides a method for synthesizing the polymer according to the...

20060147377 - Animal model for the fast identification of pharmaceutical active compounds in vivo: In a first aspect the present invention provides a tumor cell line stably transfected with an expression vector containing a reporter gene, preferably a fluorescent protein, operably linked to a promotor that also controls expression of a protein that is associated with tumor regression, stabilisation of tumor growth or inhibition...

20060147381 - Microparticles for selectively targeted hyperthermia: A microparticle composition(s) comprising nanomagnetic particles and a matrix, wherein said microparticle composition(s) have a least one of the following properties: (a) a VAR of at least about 1 Watts/cm3 subject to appropriate field conditions; (b) a density of about 2.7 or less: or (c) a size of about 100...

20060147380 - Integrin targeted imaging agents: Emulsions preferably of nanoparticles formed from high boiling liquid perfluorochemical substances, said particles coated with a lipid/surfactant coating are made specific to regions of activated endothelial cells by coupling said nanoparticles to a ligand specific for αvβ3 integrin, other than an antibody. The nanoparticles may further include biologically active agents,...

20060147378 - Azulene dimer-quenched, near-infrared fluorescent probes: An intramolecularly-quenched, near-infrared fluorescence probe that emits substantial fluorescence only after interaction with a target tissue (i.e., activation) is disclosed. The probe includes a polymeric backbone and a plurality of near-infrared fluorochromes covalently linked to the backbone at fluorescence-quenching interaction-permissive positions separable by enzymatic cleavage at fluorescence activation sites. The...

20060147379 - Targeted, nir imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging: Compounds and methods related to NIR molecular imaging, in-vitro and in-vivo functional imaging, therapy/efficacy monitoring, and cancer and metastatic activity imaging. Compounds and methods demonstrated pertain to the field of peripheral benzodiazepine receptor imaging, metabolic imaging, cellular respiration imaging, cellular proliferation imaging as targeted agents that incorporate signaling agents....

20060147385 - Nasal spray steroid formulation and method: The present invention relates to an improvement in a method of contraception, in treatment of benign gynecological disorders, and in hormone replacement. The improved method includes administering intranasally an estrogenic compound and an androgenic compound, and in some embodiments an optional progestin compound, in a once-daily bolus formulation comprised of...

20060147383 - Sprayable compositions comprising pharmaceutical active agents, volatile silicones and a non-volatile oily phase: Compositions in the form of a spray contain a pharmaceutical active agent, at least one volatile silicone and a non-volatile oily phase, formulated into a physiologically acceptable medium, are well suited for improved transdermal administration in cosmetics and dermatology....

20060147382 - Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases: The invention relates to the administration of roflumilast and an anticholinergic agent selected from the group of an ipratropium, oxitropium or tiotropium salt for the treatment of respiratory diseases....

20060147386 - System and method for intranasal administration of lorazepam: A therapeutic composition of lorazepam and its pharmaceutically acceptable derivatives are provided for intranasal administration of at least one predetermined volumetric unit dose in the form of a spray by means that delivers one or more therapeutically prescribed unit doses that are highly accurate as to the volume discharged and...

20060147384 - Use of secretin-receptor ligands in treatment of cystic fibrosis (cf) and chronic obstructive pulmonary disease (copd): The invention is based on the finding that the secretin receptor is expressed in tissues present in the distal lung of humans. In patient with CF, levels of the receptor are elevated compared to normal tissue. Treatment of tissue by secretin stimulates the movement of negative ions in the tissue....

20060147389 - Devices and pharmaceutical compositions for enhancing dosing efficiency: The present invention relates to enhancing the dosing efficiency of pharmaceutical dry powder formulations administered by pulmonary inhalation. In particular, the present invention relates to the provision of dry powder inhalers and dry powder compositions which reproducibly achieve a much higher delivered dose of the pharmaceutically active agent than currently...

20060147388 - Pharmaceutical compositions for nasal delivery: According to the invention there is provided a powdered pharmaceutical formulation suitable for nasal delivery which is a freeze-dried blend of active material and excipient(s) containing: 0.5-50% by wt of active material 50-99.5% by wt of excipient(s), and in which at least 0.1% by wt of the blend is an...

20060147387 - Process to minimize loss through adhesion to equipment surfaces: The invention relates to a new process for preparing combination formulations of inhaled glucocorticoids and beta 2-agonists e.g. budesonide in combination with formoterol. The process aims at minimizing adhesion of one or more of the ingredients to equipment surfaces by adding the ingredients to a container in a stepwise manner....

20060147390 - Cosmetic, dermatological or pharmaceutical preparations of lipid/wax mixtures containing gases: A cosmetic, dermatological or pharmaceutical preparation comprising from 10% to 99% by weight of one or more lipids, from 1% to 90% by weight of one or more waxes and at least 20% by volume of one or more gases....

20060147391 - Composition for enhancing oral health: Disclosed is composition for enhancing oral health, which includes 0.0001˜10 wt % of Xanthorrhizol on the basis of the total weight of the composition, and 0.01˜10 wt % of at least one antibacterial activity enhancer selected form the group consisting of alkyl sodium sulfate, sodium lauroyl sarcocinate and sodium methylcocoyltaurate....

20060147392 - Agent for dissolving dental calculi and dental caries: An agent for dissolving dental calculus and/or dental caries, which comprises one or more kinds of substances selected from the group consisting of inositol phosphoric acid esters (e.g., phytic acid), polyphenols (e.g., Perilla frutescen var. crispa polyphenols), phosphoric acids, edetic acid salts, tartaric acid, malic acid, citric acid, and glycolic...

20060147394 - Tooth whitening composition containing cross-linked polymer-peroxides: In various embodiments, the present invention provides a tooth whitening composition comprising a peroxide composite and an orally acceptable carrier. The peroxide composite comprises a peroxide compound and a porous cross-linked polymer, preferably in the form of a microporous particulate. The peroxide compound can be sorbed onto the porous crosslinked...

20060147393 - Use of hyaluronic acid for preparing compositions for treating oral cavity aphthas: Use of hyaluronic acid as the sole active ingredient for preparing compositions in particular for topical use for treating oral cavity aphthas....

20060147395 - Protein formulation: The present invention relates to a new and improved low-concentration formulation of an active enamel substance, such as an enamel matrix, enamel matrix derivative and/or an enamel matrix protein, intended to be used as therapeutic, as prophylactic and/or as cosmetic agent. In the present invention, said active enamel substance is...

20060147396 - Composition containing ascorbic acid: The invention relates to a composition in oil-in-water emulsion form containing ascorbic acid or a derivative thereof, at least one polysaccharide hydrophilic gelling agent, at least one C16-C22 fatty acid sorbitan ester, at least one ethoxylated fatty acid ester and at least one polymer containing a sulpho-functional monomer....

20060147397 - Composition for preparation for external use on skin and method of using the same: Disclosed is a composition containing a compound represented by formula (1) below, and a particular class ingredient. In formula (1), R1 represents —CH2OH or COOR6, R6 represents hydrogen, lower alkyl group having the number of carbon atoms of 1 to 3 or cation capable of forming a salt with COO−,...

20060147398 - Dendrite elongation inhibitor for melanocyte and skin preparation for external use containing the same: s

20060147399 - Non-pressurized post-application expanding composition: A post-application expanding composition for application to hair fibers of the scalp, eyebrows or eyelashes is provided. The composition comprises at least one surfactant, a solvent for the surfactant, and a volatile agent in an amount that will cause the surfactant and solvent to interact and foam on the hair...

20060147400 - Composition, especially a cosmetic composition, containing at least one alkyl para-hydroxybenzoate and at least one lipophilic amino acid derivative: The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, at least one alkyl para-hydroxybenzoate and at least one lipophilic amino acid derivative, to its cosmetic uses, and to the cosmetic treatment process comprising the application of a composition according to the invention to the skin....

20060147401 - Skin material for external use and antiprutiric agent for external use and wrinkle-instrument using the same: A skin composition for external use containing an acidic composition (A) which contains an alginate(s), at least one of weak acid selected from among phosphoric acid-type weak acids and ethylenediaminetetraacetic acid-type weak acids, and water; and a solidifying/gelling agent (B) containing a calcium salt(s) which is to be supplied to...

20060147402 - Composition comprising a sequenced polymer and a gelling agent: The present invention provides a cosmetic composition comprising, in a cosmetically acceptable organic liquid medium, at least one non-elastomeric film-forming ethylenic linear block polymer, and a gelling agent for the said organic liquid medium. The invention further provides for the use of the combination of such a block polymer and...

20060147403 - Non-transfer cosmetic composition comprising a sequenced polymer: The invention relates to a cosmetic composition comprising at least one cosmetically acceptable organic liquid medium and at least one film-forming linear block ethylenic polymer, the said polymer being such that, when it is present in sufficient amount in the composition, the said composition is capable of forming a deposit...

20060147404 - Synthetic thickeners for cosmetics: Disclosed are inverse emulsions for the preparation of cosmetic formulations wherein the weight ratio between the aqueous phase and the organic phase is from 4:1 and 2:1 and containing Ron 20 to 70% buy weight of an acrylic polymer obtained by inverse emulsion polymerisation of from 55 to 75% by...

20060147405 - Method for treating urushiol induced contact dermatitis: A solution for urushiol induced contact dermatitis is provided for in a topical solution. According to the invention, a method is provided for applying a composition of substances to the affected area, working the composition into the affected area, and removing the composition from the affected area. The composition comprises...

20060147406 - Viscous products for use on the body: Viscous products for use on the body are formulated from a first low viscosity component formulation and a second low viscosity component formulation. The viscous products can be post-foaming and heated upon reacting the first low viscosity component formulation with the second low viscosity component formulation. The viscous products are...

20060147408 - Skin cleansing and sloughing solution: A composition and process for removing dry and callused skin from a human foot comprising the steps of: a) providing a composition consisting essentially of at least about 37.2% (w/v) but less than 54.31% (w/v) isopropyl alcohol; about 29.59% (w/v) but less than 73.97% (w/v) sodium bicarbonate and about 0%...

20060147407 - Use of plant extracts to prevent and/or reduce the signs of subjective discomfort and/or irritation in the topical application of cosmetic products: The present invention describes compositions and methods for treating, preventing and improving the appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating skin irritation, inflammation, and/or the signs of visible or subjective discomfort, wherein the compositions include natural plant constituents that inhibit at least one cytokine. The plant extracts...

20060147409 - Biocompatible crosslinked polymers with visualization agents: Biocompatible crosslinked polymers, and methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water soluble precursors having electrophilic and nucleophilic functional groups capable of reacting and crosslinking in situ. Methods for making the resulting biocompatible crosslinked polymers biodegradable or not are provided,...

20060147410 - Use of marine fungus originated compounds as antifouling agents: Compounds originally isolated from marine fungi are useful as antifouling (antibacterial and/or anti-larval settlement) agents. The compounds are 3-chloro-2, 5-dihydroxy benzyl alcohol, cyclo-(Pro-Phe),3-methyl-N-(2-phenylethyl) butanamide, and succinic acid. The compounds are non-toxic or low-toxic. They can be used alone or in combination, as active ingredients for making environment-friendly antifouling formulations/coatings....

20060147414 - Nano-structured blood substitutes: An improved synthetic blood substitute which exhibits excellent long-term storage stability at both high and low temperatures is suitable for use in various biomedical and biotechnical applications, including resuscitation of trauma victims that have suffered massive hemorrhaging, and transfusions for human and veterinary surgical procedures. The artificial blood solution comprises...

20060147411 - Novel compounds for the treatment of sickle cell disease: Compounds have been designed to inhibit the action of cytochrome b5 in the physiological re-reduction of auto-oxidized hemoglobin (methemoglobin), for the purpose of increasing methemoglobin levels in the blood of patients as a treatment for sickle cell disease. Administration of the compounds mimics congenital deficiencies in cytochrome b5, in which...

20060147413 - Photochemical activation of surfaces for attaching biomaterial: A water-soluble photo-activatable polymer including: a photo-activatable group adapted to be activated by an irradiation source and to form a covalent bond between the water-soluble photo-activatable polymer and a matrix having at least one carbon; a reactive group adapted to covalently react with a biomaterial for subsequent delivery of the...

20060147412 - Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same: Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same are disclosed. The medical article generally comprises an implantable substrate having a coating, and the coating contains a poly(hydroxyalkanoate)....

20060147415 - Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing: A composition and a method of treating a subject with respect to a pathological condition comprised by the subject. The composition comprises a sulfated saccharide conjugated to a polymer. The method comprises administering to the subject a composition comprising a sulfated saccharide conjugated to a polymer or a sulfated saccharide....

20060147416 - Method of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myelodysplastic syndromes: Methods of treating, preventing and/or managing a myelodysplastic syndrome are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient, and/or blood or cells for transplantation therapy....

20060147417 - Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use: The present invention relates to isolated immunogens and their use in the treatment of diseases that are treatable with neutralization of IL-13, such as COPD, asthma and atopic disorders such as hayfever, contact allergies and atopic dermatitis. In particular the invention relates to the neutralization of the biological effects of...

20060147421 - Methods and compositions for treating and preventing infection using human interferon regulatory factor 3: The present invention relates to IRF3 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human IRF3 protein. IRF3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods of gene therapy using polynucleotides encoding IRF3...

20060147420 - Oncolytic adenovirus armed with therapeutic genes: The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway....

20060147418 - Recombinant double stranded rna phages and uses thereof: The present invention provides recombinant double stranded RNA phages (rdsRP) that express dsRNA-encoded genes in eukaryote cells. Recombinant dsRNA phages are useful for the expression of dsRNA expression cassettes encoding passenger genes, such as, but not restricted to, vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in...

20060147419 - Recombinant vaccine viruses expressing il-15 and methods of using the same: The invention is directed to compositions capable of augmenting the immunogenicity of a vaccine. The composition, or adjuvant, is administered to a mammal in need thereof in sequential or concurrent combination with a vaccine antigen. In one preferred aspect, the adjuvant is provided in the form of a recombinant poxvirus...

20060147422 - Selective induction of apoptosis to treat ocular disease: The invention is directed to a method of prophylactically or therapeutically treating choroidal neovascularization, wherein the method comprises directly administering to the eye a therapeutic factor or a nucleic acid sequence that encodes a therapeutic factor, which he expressed to produce the therapeutic factor, to selectively induce apoptosis of endothelial...

20060147434 - Different dendritic cell subsets: It is intended to provide expired dendritic cells having characteristics of the following (E1) to (E3): (E1) not shifting into a mature type due to an action of a natural immune stimulant or a permanent immune potentiator;(E2) having the same shape as immature DC; and (E3) expressing IL-10. It is...

20060147435 - Methods for regulation of stem cells: Methods are provided for increasing stem cells, hematopoietic progenitor/stem cells, mesenchymal progenitor/stem cells, mesodermal progenitor/stem cells, muscle progenitor/stem cells, or neural progenitor/stem cells in vivo in a mammalian subject. Methods are also provided for treating an immune related disease, a mesenchymal/mesoderm degenerative disease, or a neurodegenerative disease in a mammalian...

20060147436 - Novel ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons: Novel proteins IR1B1 and IR1B4 have been isolated which bind to the type I IFN receptor IFNAR1 and function in the cellular response to IFNs. DNA encoding such proteins in either the sense or anti-sense orientation can be administered to either enhance or inhibit the cellular response to IFNs. Antibodies...

20060147437 - Use of pigmented retinal epithelial cells for creation of an immune privilege site: The present invention relates to a novel in vivo method for creation of a localized immunosuppressive environment in tissue. The method involves the transplanting of pigmented retinal epithelial cells into a mammal thereby producing a localized immunosuppressive environment. The transplanted pigmented retinal epithelial cells may also be used to produce...

20060147423 - Transungual device: Disclosed herein is a transungual device comprising at least one active agent chosen from extracts of a non-fruiting, non-photosynthetic filamentous bacterium, dialkyl sulphones, and mixtures thereof. Also disclosed herein is a method for the cosmetic treatment of nails comprising applying the transungual device to the nails....

20060147438 - Bacterial bioherbicide for control of grassy weeds: The present disclosure concerns specific Pseudomonas fluorescens and Pseudomonas putida strains, specific genes and their corresponding specific gene products, the specific bioherbicide molecules whose synthesis or secretion is controlled by those genes and gene products, and methods of using these molecules to control deleterious weeds....

20060147430 - Adipose-derived stem cells for tissue regeneration and wound healing: Compositions and methods for promoting tissue regeneration, particularly skin regeneration, with adipose-derived stem cells are provided. Additionally methods and compositions for promoting tissue regeneration with adipose-derived stem cell side population cells are provided. The adipose-derived cells are administered in a tissue regenerating effect amount optionally with a bioactive agent. Additionally...

20060147428 - Allogeneic and xenogeneic transplantation: The invention provides methods for restoring or inducing imnmunocompetence, the methods including the step of introducing donor thymic tissue into the recipient. The invention also provides methods for inducing tolerance in a recipient including introducing donor thymic tissue into the recipient. The invention further provides methods of inducing tolerance including...

20060147433 - Extracellular matrix composite materials, and manufacture and use thereof: Described are preferred extracellular matrix composites including a first extracellular matrix material having a second extracellular matrix material deposited thereon. The preferred materials are made by culturing cells in contact with an extracellular matrix graft material in a fashion to cause the cells to biosynthesize and deposit extracellular matrix components...

20060147429 - Facilitated cellular reconstitution of organs and tissues: One aspect of the invention provides improved methods for the production of at least substantially cellularly human solid organs and solid tissues in non-human mammalian hosts. Related aspects of the invention provide: transplantation-based methods for obtaining organ and/or tissue-specific gene expression and/or phenotypes with respect to selected cell types and/or...

20060147424 - Human bone stem cells: A bone stem cell which may be supplied stably and which is free from the problem about the compatibility in transplantation is disclosed. The bone stem cell according to the present invention is separated from human amniotic mesenchymal cell layer. The bone stem cell may be used for osteogenesis in...

20060147427 - Method for immunotherapy of tumors: A method for making dendritic cells reactive to an antigen comprises obtaining a sample of dendritic cells and contacting the cells with the antigen and at least one Toll-like receptor stimulant. Dendritic cells activated by this method provide a means for treating tumors and for creating animal models of autoimmune...

20060147431 - Methods for the treatment of lysosomal storage disorders: Provided herein are methods for the treatment of lysosomal storage disorders characterized by a missing or defective secreted lysosomal enzyme. Such lysosomal storage disorders include, but are not limited to neuronal ceroid lipofuscinoses. The disclosed methods involve the transplantation of human multipotent neural stem cells into the CNS of patients...

20060147426 - Multilineage-inducible cells and uses thereof: Described herein are post natal, multilineage inducible cells (MIAMI cells). In some examples, the cells are isolated from non fractionated, adult (males and females 3 to 72 years old) human bone marrow under cell culture conditions, which are believed to resemble an in vivo niche microenvironment in which primitive multipotent...

20060147432 - Tolerogenic antigen-presenting cells: It has been found that dendritic cells can be prepared which cannot mature. These cells can provide signal 1 to T cells but cannot provide co-stimulatory signal 2. T cells which are stimulated by the permanently immature dendritic cells therefore anergise, so the dendritic cells are tolerogenic rather than immunogenic....

20060147425 - Use of enteric glia to promote functional nerve connections: Methods of promoting functional regeneration of injured nerve fibers are described. The methods involve administering enteric glial cells to an animal with a nerve injury or neurodegenerative disease. The method is also useful in inducing formation of a blood-brain barrier in the nervous system....

20060147439 - Agent and compositions comprising the same for inhibiting lipases and phospholipases in body fluids, cells and tissues: The present invention deals with a protein and compositions comprising the same for inhibition of lipases and phospholipases in the body fluids, cells, and tissues for the prevention and treatment of metabolic syndrome, cardiovascular disorders, and inflammatory diseases. The protein is either isolated from plant species or synthesized or produced...

20060147440 - Antioxidant pharmaceutical compound, method for producing polypeptide and method of cure: The invention relates to a pharmaceutical compound for antioxidant protection of cells, tissues and entire organism against hyperproduction of fee radicals. The inventive compound comprises an effective quantity of at least one antioxidant in the form of a main acting component. Said antioxidant is selected from a group consisting peroxiredoxine,...

20060147441 - Plasminogen fragment having activity to inhibit tumor metastasis and growth and process for preparing same technical field: The present invention provides a plasminogen fragment with the activity to inhibit tumor metastasis and growth, a process for preparing said fragment and an agent for inhibiting tumor metastasis and growth comprising said fragment as an active ingredient. The plasminogen fragment of the present invention is prepared from a elastase...

20060147442 - Biocides: The present invention relates to the use of biocide (e.g., bactericidal enzyme) to target pathogens. In particular, the present invention provides biocides for use in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., water purification)....

20060147443 - Synthetic biomaterials having incorporated therein bioactive factors through enzymatically degradable linkages: Synthetic biomaterials containing bioactive factors or modified bioactive factors that are covalently bound to the synthetic precursor components and/or biomaterials by an enzymatically degradable linkage are described herein. Further described are methods to covalently bind bioactive factors to synthetic biomaterials by means of enzymatic catalysis, the biomaterials produced therewith and...

20060147444 - Biosynthetic binding proteins for immuno-targeting: Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding...

20060147446 - Humanized antibodies to human gp39, compositions, and therapeutic uses thereof: The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases....

20060147445 - Immunoglobulin dna cassette molecules, monobody constructs, methods of production, and methods of use therefor: Featured are DNA molecules, expression vectors, and host cells useful for creation of immunoglobulins, as well as novel immunoglobulin molecules termed monobodies. Additionally provided are methods of production of immunoglobulins, including monobodies, as well as methods of using the disclosed immunoglobulin and monobody constructs, expression vectors and host cells containing...

20060147449 - Method of using cd100 (or sema4d) to mediate platelet activation and inflammatory responses: This invention relates to methods of treating platelet disorders and/or endothelial cell disorders by modulating sema4D/CD100 activity. Specifically, this invention involves the use of compounds to increase or decrease the level of soluble sema4D/CD100....

20060147447 - Secreted peptides: The invention provides secreted active peptides, methods and compositions for making such peptides, and methods of using the peptides in detection assays, for disease diagnosis, for disease treatment and for drug development....

20060147448 - Treatment of immunological renal disorders by lymphotoxin pathway inhibitors: The disclosure relates to treatment of immunological disorders, including but not limited to renal disorders associated with immunoglobulin deposits. The disclosure further relates to the lymphotoxin pathway. Compositions comprising lymphotoxin pathway inhibitors are described....

20060147452 - Antibody variable region of a monoclonal antibody against human tumor necrosis factor alpha and a gene encoding the same: An antibody variable region of a monoclonal antibody specifically binding to human tumor necrosis factor-α contains at least one of a heavy chain variable region and a light chain variable region having specific complementarity determining regions therein. A nucleic acid molecule encoding the same, a recombinant vector containing the nucleic...

20060147450 - Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists: This invention relates to the field of cardiac disease. More specifically, the invention relates to methods using an NGF antagonist for treating and preventing cardiac arrhythmia and methods of preventing death due to cardiac arrhythmia....

20060147451 - Modulators of hepatocyte growth factor activator: The invention provides methods and compositions for modulating hepatocyte growth factor activator function....

20060147454 - Human serine protease and serpin polypeptides: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing...

20060147453 - Methods and compositions for modulating and detecting wisp activity: Methods and compositions for use in modulating the activity(s) of WISP-1 polypeptide are provided. WISP-1 antagonists include anti-WISP-1 antibodies, WISP-1 immunoadhesins and WISP-1 variants (and fusion proteins thereof) which inhibit or neutralize induction or secretion of HAS2, HA, CD44 or RHAMM by native human WISP-1 polypeptide in at least one...

20060147455 - Gastric and colon cancer-associated antigens: The application discloses caner-associated genes and their products, especially those identifiable by SEREX. The genes and products are used to identify, track and treat cancer. Preferably the cancer is a gastro-intestinal cancer....

20060147456 - Induction of apoptosis in toll-like receptor expressing tumor cells: Some types of cancer cells express one or more Toll-like receptors (TLRs). These TLRs are therapeutic targets. The invention relates to methods for treating Toll-like receptor expressing cancers and tumor cells by selecting a TLR expressing tumor cell and contacting the cell with a therapeutically effective amount of a TLR...

20060147457 - Purified composition of bispecific molecules and methods of production: The invention provides a method for producing purified compositions of bispecific molecules each comprising (a) an antigen recognition portion that binds a C3b-like receptor and (b) one or more double-stranded DNA molecules cross-linked to the antigen recognition portion. In particular, the invention provides a method for purifying bispecific molecules using...

20060147460 - Anticancer vaccine and diagnostic methods and reagents: The invention provides a method for vaccinating a patient against a malignancy comprising introducing a protein or peptide comprising of all or an immunogenic fragment of a cyclin protein into the patient. The invention further provides a method of identifying tumor antigens....

20060147459 - Epitope composition for sublingual, buccal or enteric administration prepared by hydrolysis of antigenic structures with chymotrypsin: In the case of a module (1) for a data carrier (11) designed for contactless communication, the module (1) has a chip (3) with at least two pairs (20, 21) of chip connection contacts (4, 5, 6, 7) and with at least two pairs (22, 23) of module connecting plates...

20060147458 - Vaccines: Novel MUC-1 DNA constructs are provided that have reduced homology to native MUC-1. Pharmaceutical compositions containing such MUC-1 constructs are provided....

20060147462 - Compounds from moraxella catarrhalis: This invention provides BASB020 polypeptides and polynucleotides encoding BASB020 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses....

20060147461 - Use of clya hemolysin for excretion of proteins: The disclosure below provides a protein export system for efficiently producing recombinant protein from a host cell. In a preferred embodiment, the protein export system utilizes protein export machinery endogenous to the host bacterium into which the protein export system vector is introduced....

20060147463 - Hsp20 inhibits amyloidogenesis and neurotoxicity: The present invention compositions and methods of using at least a portions of an isolated and purified α-crystallin polypeptide that includes one or more β-pleated sheets and that prevents neurotoxicity and amyloidogenesis....

20060147464 - Chicken astrovirus type 2: The present invention provides a new chicken astrovirus (CAstV). This chicken astrovirus (CAstV-2) is immunologically distinct from known avian astroviruses and can be used to prepare vaccines....

20060147465 - Methods for the accumulation and retention of immune-enhancing, bacterial-derived ribonucleotides (orn) in bacteria: The invention relates to methods for the accumulation and retention of immune-enhancing, bacterial-derived ribonucleotides smaller than 10,000 Daltons (ORN<10 kDa) in bacteria that are produced when bacteria are grown naturally, allowing the pH of the growth medium to become acidic. The immune-enhancing, bacterial-derived ribonucleotides (ORN) and bacteria comprising ORN are...

20060147466 - Mucosal combination vaccines for bacterial meningitis: A composition for mucosal delivery, comprising two or more of the following: (a) an antigen which induces an immune response against Haemophilus influenzae; (b) an antigen which induces an immune response against Neisseria meningitidis; and (c) an antigen which induces an immune response against Streptococcus pneumoniae. The combination allows a...

20060147468 - Inactivated influenza virus vaccine for nasal or oral application: The invention relates to nasal or oral administration of a compound containing inactivated influenza virus antigen and aluminum as adjuvant for the prophylaxis of influenza virus infections. Said vaccine is especially suitable for inducing a mucosal IgA immune response and systemic IgG immune response....

20060147467 - Materials and methods for immunizing against fiv infection: The subject invention pertains to methods and compositions for protecting feline animals from infection by FIV using immunogens derived from primate immunodeficiency viruses, including HIV and SIV. Methods for vaccinating feline animals with the subject vaccine compositions are described. Feline animals vaccinated according to the methods and compositions of the...

20060147469 - Recombinant hepatitis a virus antigens obtained in plant cells: Generation of genetic constructions based on modified fragments of the hepatitis A virus (HAV) genome, using the strain M2, isolated in Cuba. Nucleotides sequences of these fragments fused to the appropriated localization and regulation signals, are expressed in transgenic plant. The obtained recombinant antigens of the HAV are composed of...

20060147470 - Cross-protective epitopes of moraxella catarrhalis and use thereof: The present invention broadly relates to immunogenic compositions for administering to a host susceptible to Moraxella catarrhalis infection. More particularly, the invention is directed to the identification of cross-reactive epitope sequences of the CopB protein of Moraxella catarrhalis....

20060147471 - Compositions, methods and devices for preparing less painful botulinum toxin formulations: Devices, methods and kits are disclosed for preparing and administering less-painful formulations of Botulinum toxin. The devices, methods and kits of the present invention are comprised of or use an acidic formulation of Botulinum toxin, or, in certain embodiments, a freeze- or flash-dried composition of Botulinum toxin, having a long...

20060147473 - Mycobacterium cell wall composition: The present invention relates generally to a method of immunomodulating therapy and pharmaceutical compositions useful for same. More particularly, the present invention provides a method of ameliorating the effects of autoimmune conditions. Even more particularly, the present invention contemplates a method for preventing, delaying onset of or otherwise ameliorating the...

20060147474 - Detection of antibodies against chamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunoassay: A new recombinant form of the plasmid-encoded protein pgp3 from C. trachomatis, serotype D, was purified by ion exchange column chromatography and shown to be suitable for quantitative immunoassay on clinical samples in an ELISA format....

20060147475 - Ringworm vaccine: A ringworm vaccine is disclosed comprising antigen isolated from at least one dermatophyte and a suitable carrier. The “antigen” can include a single antigen from a dermatophyte or a plurality of antigens as long as at least one antigen is included which will produce a sufficient immune response to confer...

20060147476 - Immunogenic compositions and diagnostic and therapeutic uses thereof: The present invention relates generally to a method of eliciting or otherwise inducing an immune response to a microorganism and compositions for use therein. More particularly, the present invention relates to a method of inducing an immune response to a parasite utilising an immunogenic composition comprising a glycosylphosphatidylinositol (referred to...

20060147477 - Immunogenic compositions: The present invention relates fusion partners which act as immunological fusion partners, as expression enhancers, and preferably to fusion partners having both functions. In particular the fusion partners contain a so-called choline binding domain, for example fusions comprising LytA from Streptococcus pneumoniae, or the pneumococcal phage CP1 lysozyme (CPL1) wherein...

20060147478 - Protein involved in carcinoma: The present invention provides a polypeptide, PTK7, of use in the treatment and/or prophylaxis of carcinoma. Also provided are agents which interact with or modulate the expression or activity of the polypeptide, methods for the identification of such agents and the use of PTK7 in the diagnosis of carcinoma....

20060147479 - Angiogenic medical cyanoacrylate adhesive: Tissue adhesive comprising a cyanoacrylate in combination with an angiogenic factor such as butyric acid or a derivative or a precursor thereof....

20060147483 - Hydrogel string medical device: A hydrogel string that is useful as a medical device and a method for forming a hydrogel string that utilizes a delivery device in which gelation of a prepolymer is initiated to form a hydrogel, which is then extruded from the device as the hydrogel string....

20060147481 - Ketoprofen powder for oral use: A readily water-soluble ingestible form of ketoprofen is provided by the reaction of ketoprofen and any edible weak base to yeild a palatable, stable, safe pharamaceutical solution for mass medication of animals. Any edible weak base such as sodium bicarbonate may be used with ketoprofen in a ratio of 10...

20060147480 - Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant: The invention relates to the field of pharmaceutical formulations of follicle-stimulating hormone (FSH), luteinising hormone (LH), and mixtures of FSH and luteinising hormone (LH), and to methods of producing such formulations. The invention provides a liquid or freeze-dried formulation of FSH, or LH, or FSH and LH comprising a surfactant...

20060147482 - Oral liquid pharmaceutical composition of leukotriene antagonists: An oral liquid pharmaceutical composition of leukotriene antagonists is described and is used an anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agent. The composition is a buffer solution with the Montelukast or its pharmaceutically acceptable salt. The pH value of the buffer solution is between about 7 and 11. The buffer solution...

20060147484 - Urushiol-induced contact dermatitis composition, method of use, and method of manufacture: A composition for treating urushiol-induced contact dermatitis includes an aqueous solution of water, a first surfactant, and a second surfactant in proportions that bind a sufficient number of the water molecules that when this aqueous solution is mixed with granulated salt, the majority of the salt is not dissolved but...

20060147485 - Oil-in-water formulation of avermectins: Oil-in-water emulsion formulations (EW) of avermectins based on phthalates as organic solvent and the use of such formulations for the control of pests....

20060147486 - Biodegradable dual porous scaffold wrapped with semi-permeable membrane and tissue cell culture using thereof: Disclosed is a scaffold including a semi-permeable membrane on an outer surface thereof. The present invention also discloses a method of preparing a scaffold covered with a semi-permeable membrane, including loading one or more scaffolds into a mold with a predetermined form and size; and adding a semi-permeable agent and...

20060147487 - Smart textile vascular graft: The smart textile vascular graft is used with an electrical control unit. The vascular graft includes a tube structure formed of a textile material. At least one active fiber is incorporated in the textile material. The active fiber provides electrical coupling thereof to the electrical control unit to provide for...

20060147488 - Surgical implant comprising an anabolic and a corticosteroid: A surgical implant with a basic structure, preferably configured as an implant mesh, contains an anabolic steroid and a corticosteroid. The implant is preferably designed to release these active substances after implantation. It becomes incorporated rapidly and effectively, without any undesired scar contraction occurring....

20060147489 - Implantable medical device with beneficial agent concentration gradient: The implantable medical devices are configured to release at least one therapeutic agent from a matrix affixed to the implantable body with a release profile which is programmable to the agent and treatment. The matrix is formed such that the concentration of the therapeutic agent in the matrix varies as...

20060147491 - Biodegradable coating compositions including multiple layers: The invention provides devices for treatment of a patient, wherein at least a portion of the device is provided with a biodegradable coating composed of multiple coated layers of biodegradable material. The invention further provides methods of treatment utilizing the devices....

20060147492 - Medical implants and anti-scarring agents: Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent,...

20060147490 - New polymers and applications: The present invention provides a biodegradable, biocompatible polymer that is capable of forming particles (micelles), vesicles, surfaces and membranes, and other structures in which a biologically active agent, e.g. a drug, can be incorporated in such a way that its release to the host can be controlled to a high...

20060147497 - Administration form and kit for the oral administration of active substances, vitamins and/or nutrients and use thereof: An administration form for oral administration of active substances, vitamins and/or nutrients including a drinking straw (1) provided with a barrier device (3) which is impermeable to the active substance formulation, vitamin formulation and/or nutrient formulation (2) and which is permeable to air and to a transport liquid. The closing...

20060147495 - Amino acid-based nutritional formulation: A ready to feed nutritional formulation for consumption by persons with an inborn error of metabolism, the formulation comprising: a homogenised blend water, calcium and amino acid moieties in a profile appropriate to the inborn error, said amino acid moieties being selected from the group consisting of free amino acids,...

20060147494 - Bioactive compounds protection method and compositions containing the same: The present invention relates to means for protecting bioactive materials in mammalian food or feed formulations used to enhance the health status of mammals...

20060147496 - Methods of diagnosing small intestinal bacterial overgrowth (sibo) and sibo-related conditions: Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune...

20060147493 - Packaging and dispensing of rapid dissolve dosage form: An oral dosage delivery vehicle comprising an edible film including a uniformly distributed active ingredient, wherein said film comprises dosage units releasably joined by one or more weakened sections, which permit said dosage units to be detached from said film....

20060147498 - Composition material for transmucosal delivery: The invention refers to a composition material that is intended for rapid transmucosal delivery in the mouth of a biologically active substance when in contact with saliva. The composition material comprises at least one ionic carbohydrate, having at least one biologically active substance ionically bound thereto, and at least one...

20060147499 - Proteases: The invention relates to a novel class of serine proteases of peptidase family S2A or S1E that are stable in the presence of copper (Cu2+) and/or inhibited by copper only to a limited extent. Structural features of potential relevance for this effect are also disclosed. This class of proteases includes...

20060147500 - Use of isomalt (mixture of 1,6 gps and 1,1 gpm) as a prebiotic for the production of a medicament used for the treatment of intestinal diseases, among other things: The present invention relates to a novel use of a mixture of 6-O-α-D-glucopyranosyl-D-sorbitol and 1-O-α-D-glucopyranosyl-D-mannitol....

20060147501 - Collagen compositions and biomaterials: The invention relates to biomaterials and, in particular, biomaterials containing collagen....

20060147504 - Feminine anti-itch cloth: The present invention provides disposable cloths that are designed to reduce itching discomfort when wiped across the vulvar tissue. These disposable cloths are wetted with a composition that includes at least one anesthetic, protectant, buffer, and surfactant. The composition is substantially clear and preferably does not bring about a cooling...

20060147506 - Foam with germproof and mildew-proof effects: The present invention relates to foam with the germproof and mildew-proof effects. To produce such foam, Chinese herbaceous extracts are prepared by extracting from angelica-laxiflora, ranunculacese-clematis chinensis, tripterygium wilfordli hook, Atractylodes lancea(Thunb)DC, talc powder, alunite, Cnidium monnieri(L.)Cuss and hydnocarpus anthelmintica P. These extracts are then blended with plastic or rubber...

20060147507 - Hot flash treatment system: A composition comprising an alcohol and an aloe vera gel for topically treating hot flashes and methods for the storing, dispensing and application thereof....

20060147502 - Methods for controlling microbial pathogens on currency and mail: The present invention relates to methods for minimizing the presence of microbial pathogens on currency or on mail. More particularly, the presence of microbial pathogens may be minimized by introducing an antimicrobial product comprising a base substrate and a volatile and/or non-volatile antimicrobial agent into a money container comprising currency...

20060147503 - Oil absorbent wipe with high crumpability: There is provided an oil absorbing wipe material suitable for wiping a users' skin or hair and a method for their manufacture. The wipes comprise at least an oil absorbing porous coextruded film of a crystalline thermoplastic material with a solid diluant containing crumpable layer and a generally nontacky layer....

20060147505 - Water-dispersible wet wipe having mixed solvent wetting composition: A wet wipe contains fibrous material, a binder composition for binding the fibrous material into an integral web, and a wetting composition containing water, a salt, and at least about 10 wt % of an organic solvent. The binder composition contains an ionic copolymer. The wet wipe is not dispersible...

20060147508 - Concurrent enhancement of skin penetration of organic base active agents and organic hydroxy acid active agents as their ion-pair complexes: This invention relates to concurrent enhancement of skin penetration of certain organic nitrogen heterocyclic base active agents and certain organic acid active agents, especially organic hydroxy acids. This concurrent enhancement of skin penetration also provides enhanced bioavailability of both organic nitrogen heterocyclic base active agent and organic hydroxy acid active...

20060147509 - Composition for vaccination: The present invention provides novel compositions for transdermal delivery of at least one immunogen to an individual, which compositions comprise (a) said at least one immunogen (b) an occlusion vehicle and (c) an immunogen delivery system in the form of a PosIntro or a cationic ISCOM or comprising at least...

20060147510 - Method for treating non-neuropathic pain: A method including topically administering an effective amount of local anesthetic to a patient is disclosed. The method is effective for inducing analgesia for treating non-neuropathic pain. Non-neuropathic pain suitable for treatment according to the invention includes pain associated with sports injuries; sprains; strains; soft-tissue injury; repetitive motion injury; carpal...

20060147512 - Compositions and methods of use for treatment of mammalian diseases: This disclosure relates to a Composition having medicinal properties for use with mammalian diseases such as anti-cancer properties and methods of use, anti-viral properties and methods of use, anti-protozoan properties and methods of use, and anti-bacterial properties and methods of use in mammals. A chemical Composition for use as a...

20060147511 - Liposomal glucocorticoids: The invention relates to a liposomal formulation comprising water-soluble glucocorticoids, to the use of said formulation in the treatment of inflammatory diseases, and to a kit comprising said liposomal formulation, e.g. in the form of a pharmaceutical agent....

20060147514 - Method for introducing antisense oligonucleotides into eucaryotic cells: The present invention relates to a method for introducing one or more antisense oligonucleotides into one or more eucaryotic cells using one or more lipid formulations comprising one or more cationic lipids of Formula I and optionally at least one neutral lipid. In particular, the present invention relates to a...

20060147513 - Methods of forming targeted liposomes loaded with a therapeutic agent: The present invention provides for liposomes loaded with a therapeutic agent, which liposomes are targeted to a cell of interest by incubation with a targeting protein protein conjugated to a linker molecule comprising a hydrophobic domain, a hydrophilic polymer chain terminally attached to the hydrophobic domain, and a chemical group...

20060147515 - Bioactive dispersible formulation: A composition containing an effective amount of a water-insoluble bioactive agent and two surfactants having different HLB values, the difference between the HLB values of the two surfactants being greater than 5. This invention also relates to a method of prepare such a composition....

20060147516 - Taste masking system for alprazolam: The present invention relates to taste masking system, taste masked formulations, dosage forms made from those formulations and methods of making those formulations that involve dissolving or dispersing a pH dependant polymer and alprazolam in a solvent, granulating using that material or forming layers over a solid support therewith. This...

20060147517 - Taste masking system for non-plasticizing drugs: The present invention relates to taste masking system, taste masked formulations, dosage forms made from those formulations and methods of making those formulations that involve dissolving or dispersing a pH dependant polymer and a non-plasticizing active pharmaceutical ingredient in a solvent, granulating using that material or forming layers over a...

20060147518 - Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it: This invention relates to solid and stable dispersions of a hydrosoluble derivative of vinca alkaloids in at least one polyethyleneglycol with a molecular mass between 800 and 30 000....

20060147523 - Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof: A nutritional supplement composed of phytosterols, anti-oxidants, and other complexes, including essential fatty acids, amino acids, peptides, proline rich polypeptides and digestive enzymes is described. The nutritional supplement may be used by individuals suffering from or at risk of developing immune system diseases; breast cancer, colon and prostate cancer; HIV...

20060147525 - Lipophilic drug compositions: The invention is directed to biologically active lipophilic compositions comprising a biologically active covalently attached to, or encapsulated within, a lipid. Preferably, a biologically active agent is both covalently attached to a lipid and encapsulated within a lipid composition. Preferred lipid components include triglycerides and fatty acids. The resulting composition...

20060147524 - Melt-formulated, multi-particulate oral dosage form: A melt-formulated, multiparticulate, oral dosage form containing clavulanic acid and/or at least one physiologically acceptable salt thereof and at least one sucrose fatty acid ester and optionally further physiologically acceptable auxiliary substances; a process for producing such a dosage form, combination dosage forms with β-lactam antibiotics, and the pharmaceutical use...

20060147522 - Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them: The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed...

20060147519 - Process for the preparation of robust formulations of valacyclovir hydrochloride tablets: The invention relates to robust formulations of valacyclovir hydrochloride tablets. A robust tablet includes a hydrated form of valacyclovir hydrochloride having a water of hydration content of more than approximately 3% w/w and a particle size of less than approximately 355 μm....

20060147521 - Sustained release ranolazine formulations: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and...

20060147520 - Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation: Microparticles comprising iloprost are disclosed. In some embodiments, the microparticles are used to treat pulmonary hypertension. Devices comprising the microparticles are also disclosed. Combination therapies utilizing the microparticles are also provided....

20060147527 - Controlled release preparations comprising tramadol and topiramate: This invention relates to an oral pharmaceutical preparation, suitable for dosing every 24 hours, comprising a substrate, which substrate comprises a pharmaceutically effective amount of tramadol or a salt thereof and a pharmaceutically effective amount of topiramate and wherein said substrate may be coated with a controlled release coating; said...

20060147528 - Extended release, multiple unit dosage forms of phenytoin sodium and processes for their preparation: The present invention relates to oral extended release, multiple unit dosage forms of phenytoin sodium in which individual units comprising phenytoin sodium are coated with one or more film forming polymers. The individual units include between greater than 75% w/w and about 90% w/w of phenytoin sodium....

20060147526 - Pharmaceutical formulations comprising ß-2 adrenoreceptor agonists and xanthines: A pharmaceutical formulation comprising (i) a sustained release layer comprising at least one xanthine, and (ii) an immediate release layer comprising at least one β-2 adrenoreceptor agonist selected from the group consisting of long acting and short acting β-2 adrenoreceptor agonists....

20060147529 - Granulate comprising an oily substance, corresponding production method and tablet: The invention relates to a process for the preparation of granules comprising an oily substance. It relates also to granules for a pharmaceutical formulation and to a tablet as a product of further processing....

20060147530 - Sustained release compositions containing alfuzosin: The present invention relates to pharmaceutical compositions of alfuzosin or pharmaceutically acceptable salt, solvate, enantiomers or mixtures thereof, that release the active ingredient over an extended period of time. The pharmaceutical composition can be a sustained release oral dosage form that includes a single functional layer and, optionally, one or...

20060147531 - Tamsulosin core with a coating of polyvinylpyrrolidone and polyfinylacetate: The present invention is directed to a sustained/release pharmaceutical composition containing Tamsulosin and having a reduced food effect....

20060147532 - Microparticles prepared using an ionic liquid: Microparticles comprising at least one active agent embedded within a biocompatible, biodegradable polymeric matrix, wherein said microparticles are prepared with an ionic liquid....

20060147533 - Antimicrobial biomaterial for blood bags: An antimicrobial biomaterial including a polymer substrate and silver particles bound to at least a portion of a surface of the polymer substrate. The antimicrobial biomaterial is useful in various medical devices, particularly blood or blood component storage bags, that contact or contain human blood, blood components, and/or other bodily...

20060147534 - Methods of inhibiting or inducing bone formation: The present invention relates to a pharmaceutical composition containing a mixture of stable folding variants of recombinant bone morphogenic proteins (rBMPs) and its use in therapy, especially in the treatment of orthopaedic and dental patients. Specifically, the present invention relates to a pharmaceutical composition containing a mixture of stable folding...

20060147536 - Method for removing fluids containing dissolved or suspended carbohydrates, lipids, metals, salts, and/or toxins from biological systems: A means for reducing the levels of carbohydrates, lipids, metals, salts and/or toxins in biological systems thereby preventing or reducing weight gain, while reducing, for example, the incidence of atherosclerosis, hypertension, and toxic reactions, is provided. More specifically, the subject invention provides non-toxic, substantially non-degradable, optionally collapsible and/or expandable particles...

20060147535 - Methods for and compositions of anticancer medicaments: The present invention provides methods for and compositions of anticancer medicaments. These compositions are comprised of nanoparticles or microparticles produced by antisolvent technology. The particles can be used to treat cancerous tissues in humans or animals....

20060147538 - Nanocomposite drug delivery composition: The invention relates to a drug delivery composition comprising an active ingredient and a biologically inert material wherein the biologically inert material is a nanocomposite material. Preferably the biologically inert material is a polymer-clay nanocomposite comprising up to about 40% by weight of nano-sized (1-1000 nm) clay particles dispersed in...

20060147539 - Nanoparticles for protein drug delivery: The invention discloses the nanoparticles composed of chitosan, poly-γ-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery....

20060147540 - Non-hygroscopic and powdery amorphous pimecrolimus: An amorphous pimecrolimus and processes for providing an amorphous pimecrolimus are provided....

20060147541 - Pharmaceutical preparation for rectal administration: A pharmaceutical preparation for rectal administration by which a drug is retained in the affected region or the lower region of the rectum, where the drug is sustained-released is disclosed. The present invention is a pharmaceutical preparation for rectal administration comprising a coated drug-supported particle dispersed in a base, wherein...

20060147537 - Stabilized pharmaceutical product: The invention relates to the use of an adsorbent and a sealed package, for example an overwrap, to protect a pharmaceutical product in a solid state in the presence of a reducing sugar....

20060147543 - Method for controlling stability of nanofabricated polypeptide multilayer films, coatings, and microcapsules: Disclosed herein is a method of controlling the stability of multilayer polypeptide films. A method of controlling the stability of a film, comprises exposing the film to an oxidizing agent or a reducing agent, wherein the film comprises a plurality of layers, the layers comprising alternating oppositely charged polypeptides, wherein...

20060147542 - Solid preparation containing reduced coenzyme q10 and method for producing the same: The present invention has its object to provide a solid preparation containing reduced coenzyme Q10 with high stability by protecting reduced coenzyme Q10 against oxidization to oxidized coenzyme Q10 by molecular oxygen. The present invention provides a solid preparation containing reduced coenzyme Q10 which comprises a solid composition containing reduced...

20060147544 - Use of emu oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations: An animal-derived lipid is disclosed that is useful as a carrying agent for anti-microbial formulations. Pharmaceutical and other preparations including Emu Oil are also described as profoundly useful components in anti-bacterial, anti-fungal, and anti-viral treatments. This lipid material is extracted from the Emu (Dromais Novae-Hollandiae), an indigenous bird of Australia...

20060147545 - Volume maintaining osteoinductive/osteoconductive compositions: An osteoinductive/osteoconductive composition prepared from a quantity, of demineralized fibrous bone elements possessing an average surface area to volume ratio of about 100:1 to about 20:1, a quantity of mostly shaped regular non-fibrous bone elements possessing an average surface area to volume ratio of about 10:1 or less and a...

20060147546 - Compound consisting of precipitated silica and phosphate and use thereof as nutrient intake liquid support and as anticaking agent with nutrient intake: The invention concerns compounds, for use as liquid support and as anticaking agent, and, simultaneously, as nutrient additive in particular for animals, consisting of precipitated silica and phosphate selected among phosphates of elements of groups Ia or IIa of the periodic table of the elements and rare-earth phosphates, said compounds...

20060147547 - Bone enhancing composite: A bone-enhancing composite material comprising synthetic apatite and at least one supplementary bioactive agent selected from a biocompatible polymer and an anti-resorption agent added ab initio, methods of preparing said composite and uses thereof are provided. The physical and biological properties of the composite are controlled by the addition of...

20060147548 - Therapeutic delivery of carbon monoxide: Metal carbonyls are used in combination with at least one guanylate cyclase stimulant/stabilizer to deliver CO having biological activity, for example vasodilatation and inhibition of platelet aggregation. The two components may be administered simultaneously or sequentially. A particular described combination is tricarbonylchloro(glycinato)ruthenium(II) and the drug YC-1....

20060147549 - Methods and compositions for reducing population of plant pathogen: The present invention relates to methods for reducing the population of canker microbe (e.g., citrus canker microbe) or microbes and articles of manufacture that can be used in the method. The methods employ and the articles of manufacture include composition including metal antimicrobial agent, poly(hexamethyl biguanide), surfactant, and alcohol....

20060147550 - Immune system enhancement and stimulation formulation: The composition of ingredients enhances and stimulates the immune system. The composition includes beta glucan and coenzyme Q10 (Ubiquinone). Both of these components have the effect of preventing, reversing and treating tumors. In addition, secondary nutrients, including Vitamin C, Vitamin E, Selenium and Zinc, offer additional benefits when combined with...

20060147551 - Auxiliary agent to be used in cancer therapy by dielectric heating and cancer therapy method: There is provided an adjuvant capable of enlarging an ablation area and reducing ablation unevenness in a dielectric heating-assisted cancer treatment such as radiofrequency ablation used for treatment of hepatic cancer. The adjuvant includes a conductive substance such as a metal element (e.g., iron) and a pharmaceutically acceptable carrier of...

20060147552 - Use of iron for treating attention deficit hyperactivity disorder in children: The invention relates to the use of iron for preparing a medicament for the preventive and/or curative treatment of attention deficit hyperactivity disorder (ADHD) or at least one of the symptoms thereof, for a patient requiring such treatment....

20060147553 - Method and apparatus for treatment of respiratory infections by nitric oxide inhalation: Methods for suppressing, killing, and inhibiting pathogenic cells, such as microorganisms associated with a respiratory infection within the respiratory tract of an animal are described. Methods include the step of exposing the pathogenic cells to an effective amount of nitric oxide, such as through inhalation of nitric oxide gas....

20060147554 - Ayurvedic herbal soft drink: The invention provides a novel herbal soft drink comprising decoction of plants selected from Sida sps., Vitis vinifera, Withania somnifera, Boerhaavia diffusa and Tinospora cordifolia for the protection and prevention of health and in particular, but not exclusively with antioxidant, immunoenhancing, hepatoprotective, cardiotonic, diuretic, digestive, choleretic, nervine relaxant properties....

20060147557 - Composition for treating amyloidoses and/or oxidation damage in nervous system: The present invention provides a composition for treating amyloidoses and/or oxidation damage in nervous system comprising a therapeutically effective amount of the water extract of polygonum multiflorum. A method for treating amyloidoses and/or oxidation damage in nervous system of a subject is also provided....

20060147559 - Methods for altering the mineral content of foods: The present invention involves removing of particular ions, particularly ionic potassium, from juices via an electrodialysis system and replacing the removed ions with other nutrients or beneficial ions, such as, calcium....

20060147555 - Novel polyherbal preparation for the prevention of atherosclerosis and hyperlipidemia: A polyherbal preparation for the prevention of atherosclerosis and hyperlipidemia comprising a mixture of Commiphora mukul, Boswellia serrata, Semecarpus anacardium Strychnox nux vomica, Termenalia arjuna and Shankha Bhusma....

20060147560 - Pharmaceutical, nutraceutical, dietetic and nutritional compositions based on vegetable fibres: b) Opuntia ficus indica, c) microcrystalline cellulose present a high gastrointestinal swelling index, which induces an immediate feeling of fullness, release of cholecystokinins and slowing of gastric voiding that prolongs the feeling of fullness. Associating the complex of three vegetable fibres with a mixture of freeze-dried mucilages increases its gastrointestinal...

20060147556 - Process and apparatus for modifying plant extracts: Phytonutrients or other active materials can be extracted from plant material using a particular process which requires extracting juice from the plant material, followed by breaking open the plant cells to release the phytonutrients by subjecting the juice to high shear conditions, followed by concentrating the juice using a membrane...

20060147558 - Remedies: The present invention provides a composition for enhancing growth factor production, comprising a plant-derived enhancer for growth factor production; a therapeutic agent or prophylactic agent for a disease requiring enhancement of growth factor production and a food, beverage or feed for enhancing growth factor production, each comprising the above composition....

20060147561 - Herbal nutraceutical formulation for diabetics and process for preparing the same: The present invention relates to a herbal nutraceutical formulation for diabetics, and also relates to a process for the preparation of the formulation. The formulation comprises the base product of a microwave roasted seed powder mixture from selected genera of Glycine, Cicer, Phaseolus, Cyamompsis, Mucuna, Hordeum, Amaranthus and Fagopyrum, fortified...

20060147563 - Dietary supplement and related method: A dietary supplement including a unique combination of fruits, vegetables, herbs, and optionally vitamins, minerals and specialty ingredients. The supplement can include a fruit ingredient, a vegetable ingredient and an herbal ingredient, wherein the fruit ingredient is at least one of pomegranate and citrus bioflavonoids, wherein the vegetable ingredient is...

20060147562 - Insect repellent based on a mixture of essential oils: A natural and non-toxic composition is described which has surprisingly superior and super additive effectiveness over conventional insect repellents. In one embodiment, the composition is comprised of a mixture of essential oils, including lime oil, myrtle, citronella oil, eucalyptus oil and neem oil in a carrier oil. Alternatively, the neem...

20060147564 - Composition for preventing or treating allergic disease using black rice extract and its therapeutic use: The present invention relates to a composition for preventing or treating allergic diseases using black rice extract and its therapeutic use. More precisely, the present invention relates to a composition for preventing or treating allergic diseases comprising pelargonidin, cyanidin glycoside, or black rice extract including pelargonidin and cyanidin glycoside, which...

20060147565 - Purified amylase inhibitor and novel process for obtaining the same: The present invention provides a purified amylase inhibitor obtained by a superior process that includes extracting ground beans with supercritical carbon dioxide. The invention also provides a method for inducing weight loss in a mammal in need thereof comprising administering to the mammal, an effective amount of an amylase inhibitor...

20060147566 - Use of physiologically active fatty acids: The disclosed invention is directed to physiologically active compositions comprising (a) a physiologically active fatty acid, or a salt or ester thereof, and (b) extracts of Glycyrrhiza glabra or its active principles for preparing a medicament for the treatment of pruritus (itching). Component (a) may be used alone for the...

20060147567 - Methods of using grape seed extract to stimulate tyrosinase expression or melanin synthesis: The present invention relates to methods of increasing tyrosinase synthesis, expression, or activity in a cell comprising administering at least one grape seed extract to the cell. The grape seed extract may be obtained by any extraction process including solvent sequential fractionation and supercritical fluid extraction....

20060147568 - Blood pressure-lowering agent, vascular flexibility -improving agent and foods having these functions imparted thereto: According to the present invention, there is provided a blood pressure-lowering agent, a vascular flexibility-ameliorating agent and foods having these functions imparted thereto, which are comprising isohumulones or a hop extract and/or an isomerized hop extract as an active ingredient....

20060147569 - Anti-depression formulations: The present invention relates to the use of Chinese herbs Buguzhi and Fuling extracts in preparation formulations for the treatment of depression and related symptoms....